|
NCF1
|
Homo sapiens
|
7q11.23
|
marker
|
D7S1870
|
Disease risk
|
Negative
|
|
NCF1
|
Homo sapiens
|
7q11.23
|
marker
|
D7S2518
|
Disease risk
|
Negative
|
|
NCF2
|
Homo sapiens
|
1q25.3
|
SNP
|
rs796860
|
Disease risk
|
Negative
|
|
NCF2
|
Homo sapiens
|
1q25.3
|
SNP
|
rs2296164
|
Disease risk
|
Negative
|
|
NCF2
|
Homo sapiens
|
1q25.3
|
SNP
|
rs3818364
|
Disease risk
|
Negative
|
|
NCF2
|
Homo sapiens
|
1q25.3
|
SNP
|
rs789192
|
Disease risk
|
Negative
|
|
NCF2
|
Homo sapiens
|
1q25.3
|
SNP
|
rs2274065
|
Disease risk
|
Negative
|
|
NCF4
|
Homo sapiens
|
22q12.3
|
SNP
|
rs1883112
|
Disease risk
|
Negative
|
|
NCF4
|
Homo sapiens
|
22q12.3
|
SNP
|
rs741999
|
Disease risk
|
Negative
|
|
CYBA
|
Homo sapiens
|
16q24.2
|
SNP
|
rs4673
|
Disease risk
|
Negative
|
|
CYBA
|
Homo sapiens
|
16q24.2
|
SNP
|
rs2306422
|
Disease risk
|
Negative
|
|
CYBB
|
Homo sapiens
|
Xp21.1-p11.4
|
SNP
|
rs5963310
|
Disease risk
|
Negative
|
|
CYBB
|
Homo sapiens
|
Xp21.1-p11.4
|
SNP
|
rs9330580
|
Disease risk
|
Negative
|
|
GRIN1
|
Homo sapiens
|
9q34.3
|
clone
|
anti-LGI1
|
Disease risk
|
Negative
|
|
GRIN1
|
Homo sapiens
|
9q34.3
|
clone
|
NMOSD
|
Disease risk
|
Negative
|
|
IL25
|
Homo sapiens
|
14q11.2
|
polymorphisms
|
IL-25 exon1
|
Disease risk
|
Negative
|
|
IL25
|
Homo sapiens
|
14q11.2
|
polymorphisms
|
IL-25 exon2
|
Disease risk
|
Negative
|
|
QKI
|
Homo sapiens
|
6q26
|
polymorphisms
|
V5
|
Disease risk
|
Positive
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs12044852
|
Disease risk
|
Negative
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs2300747
|
Disease risk
|
Negative
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs1335532
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
rs221775A>G
|
Disease risk
|
Negative
|
|
IL2
|
Homo sapiens
|
4q27
|
polymorphisms
|
-475 AA
|
Disease risk
|
Negative
|
|
IL2
|
Homo sapiens
|
4q27
|
polymorphisms
|
-475 AT
|
Disease risk
|
Positive
|
|
IL2
|
Homo sapiens
|
4q27
|
polymorphisms
|
-475 TT
|
Disease risk
|
Negative
|
|
IL2
|
Homo sapiens
|
4q27
|
polymorphisms
|
-475 A
|
Disease risk
|
Positive
|
|
IL2
|
Homo sapiens
|
4q27
|
polymorphisms
|
-475 T
|
Disease risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
polymorphisms
|
locus A
|
Disease risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
polymorphisms
|
locus B
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
E3/E3
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
E3/E4
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
E3/E2
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
E2/E4
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
E2/E2
|
Disease risk
|
Negative
|
|
IL6
|
Homo sapiens
|
7p15.3
|
SNP
|
rs2069852
|
Disease risk
|
Negative
|
|
BCL2
|
Homo sapiens
|
18q21.33
|
SNP
|
rs2187163
|
Disease risk
|
Negative
|
|
NFKB1
|
Homo sapiens
|
4q24
|
SNP
|
rs7665090
|
Disease risk
|
Positive
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
genotype
|
+ +
|
Disease risk
|
Negative
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
genotype
|
+ -
|
Disease risk
|
Negative
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
genotype
|
- -
|
Disease risk
|
Negative
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
allel
|
+
|
Disease risk
|
Negative
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
allel
|
-
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs4935356
|
Disease risk
|
Positive
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3135390
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs4935354
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3177928
|
Disease risk
|
Positive
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs7194
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs7195
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs1131541
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
s7196
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs7197
|
Disease risk
|
Positive
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs1051336
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs111471704
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs1157343109
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
SNP
|
rs1041885
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722489
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs917751277
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs992067421
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs959264277
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs11597542
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs140860467
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs17149458
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722490
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs3118470
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs78556477
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs41294925
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722491
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs550805995
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722621
|
Disease risk
|
Negative
|
|
HMGB
|
Homo sapiens
|
13q12.3
|
SNP
|
DELINSCrs146076135
|
Disease risk
|
Negative
|
|
HMGB
|
Homo sapiens
|
13q12.3
|
SNP
|
DELINSTrs201945336
|
Disease risk
|
Negative
|
|
HMGB
|
Homo sapiens
|
13q12.3
|
SNP
|
rs111892138
|
Disease risk
|
Negative
|
|
HMGB
|
Homo sapiens
|
13q12.3
|
SNP
|
DELINSArs200308321
|
Disease risk
|
Negative
|
|
HMGB
|
Homo sapiens
|
13q12.3
|
SNP
|
DELINSGAAGrs149637108
|
Disease risk
|
Negative
|
|
HMGB
|
Homo sapiens
|
13q12.3
|
SNP
|
rs538493533
|
Disease risk
|
Negative
|
|
HMGB
|
Homo sapiens
|
13q12.3
|
SNP
|
rs577524260
|
Disease risk
|
Negative
|
|
HMGB
|
Homo sapiens
|
13q12.3
|
SNP
|
rs182881863
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1506
|
disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1507
|
disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1508
|
disease risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphism
|
HLA-A11
|
disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
polymorphism
|
HLA-A12
|
disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphism
|
HLA-A13
|
disease risk
|
Positive
|
|
ATXN2
|
Homo sapiens
|
12q24.12
|
polymorphism
|
the 22 repeat length allele
|
phenotypics risk
|
N/A
|
|
APOE
|
Homo sapiens
|
19q13.32
|
polymorphism
|
e2
|
phenotypics risk
|
N/A
|
|
LIF
|
Homo sapiens
|
22q12.2
|
SNP
|
SNP3951
|
disease risk
|
Negative
|
|
LIF
|
Homo sapiens
|
22q12.2
|
SNP
|
SNP2680
|
disease risk
|
Negative
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
polymorphism
|
exon1
|
disease risk
|
Negative
|
|
TLR7
|
Homo sapiens
|
Xp22.2
|
polymorphism
|
intron 6
|
disease risk
|
Negative
|
|
CCL5
|
Homo sapiens
|
17q12
|
polymorphism
|
RANTES-403G/A
|
disease risk
|
Positive
|
|
CCL5
|
Homo sapiens
|
17q12
|
polymorphism
|
RANTES-28G
|
phenotypics risk
|
Positive
|
|
CCL5
|
Homo sapiens
|
17q12
|
polymorphism
|
RANTES-28C/G
|
disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
polymorphism
|
TCRBV8
|
disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
polymorphism
|
TCRBV11
|
disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
polymorphism
|
TCRBC2
|
disease risk
|
Negative
|
|
TRA
|
Homo sapiens
|
14q11.2
|
polymorphism
|
TCRAC1
|
disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphism
|
TNF2
|
phenotypics risk
|
Negative
|
|
PTPRC
|
Homo sapiens
|
1q31.3-q32.1
|
polymorphism
|
C77G
|
disease risk
|
Negative
|
|
PTPRC
|
Homo sapiens
|
1q31.3-q32.1
|
polymorphism
|
C772T
|
disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
polymorphism
|
260-bp allele (allele 13)
|
treatment risk
|
Positive
|
|
MT-ND1
|
Homo sapiens
|
N/A
|
SNP
|
NDUFS5
|
phenotypics risk
|
Positive
|
|
MT-ND1
|
Homo sapiens
|
N/A
|
SNP
|
NDUFS7
|
phenotypics risk
|
Positive
|
|
MT-ND1
|
Homo sapiens
|
N/A
|
SNP
|
NDUFA7
|
phenotypics risk
|
Positive
|
|
TRA
|
Homo sapiens
|
14q11.2
|
polymorphism
|
Val
|
disease risk
|
Negative
|
|
TRA
|
Homo sapiens
|
14q11.2
|
polymorphism
|
Va6
|
disease risk
|
Negative
|
|
EVI5
|
Homo sapiens
|
1p22.1
|
SNP
|
rs79667032
|
disease risk
|
Positive
|
|
IGSF3
|
Homo sapiens
|
1p13.1
|
SNP
|
rs517857
|
disease risk
|
Positive
|
|
LINC02868
|
Homo sapiens
|
1p13.1
|
SNP
|
rs11583823
|
disease risk
|
Positive
|
|
RUNX3
|
Homo sapiens
|
1p36.11
|
SNP
|
rs335555
|
disease risk
|
Positive
|
|
TRPC3
|
Homo sapiens
|
4q27
|
SNP
|
rs55756717
|
disease risk
|
Positive
|
|
SIM1
|
Homo sapiens
|
6q16.3
|
SNP
|
rs924974
|
disease risk
|
Positive
|
|
OPCML
|
Homo sapiens
|
11q25
|
SNP
|
rs2659624
|
disease risk
|
Positive
|
|
LAIR2
|
Homo sapiens
|
19q13.42
|
SNP
|
rs2161471
|
disease risk
|
Positive
|
|
BIRC5
|
Homo sapiens
|
17q25.3
|
SNP
|
rs9904341
|
phenotypics risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
HLA-DRB1*15:01(+)*04:05()
|
disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
HLA-DRB1*15:01()*04:05(+)
|
disease risk
|
Positive
|
|
IFNA17
|
Homo sapiens
|
9p21.3
|
polymorphism
|
N/A
|
disease risk
|
Negative
|
|
TRA
|
Homo sapiens
|
14q11.2
|
polymorphism
|
N/A
|
disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
polymorphism
|
N/A
|
disease risk
|
Negative
|
|
TRG
|
Homo sapiens
|
7p14.1
|
polymorphism
|
N/A
|
disease risk
|
Negative
|
|
TRD
|
Homo sapiens
|
14q11.2
|
polymorphism
|
N/A
|
disease risk
|
Negative
|
|
OMG
|
Homo sapiens
|
17q11.2
|
mutation
|
N/A
|
disease risk
|
Negative
|
|
EVI2A
|
Homo sapiens
|
17q11.2
|
mutation
|
N/A
|
disease risk
|
Negative
|
|
EVI2A
|
Homo sapiens
|
17q11.2
|
mutation
|
N/A
|
disease risk
|
Negative
|
|
EVI2A
|
Homo sapiens
|
17q11.2
|
polymorphism
|
N/A
|
disease risk
|
Negative
|
|
PSMB9
|
Homo sapiens
|
6p21.32
|
SNP
|
N/A
|
N/A
|
Negative
|
|
PSMB8
|
Homo sapiens
|
6p21.32
|
SNP
|
N/A
|
N/A
|
Negative
|
|
ABCB9
|
Homo sapiens
|
12q24.31
|
SNP
|
N/A
|
N/A
|
Negative
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
SNP
|
N/A
|
N/A
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
SNP
|
Vβ5.2
|
disease risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
SNP
|
Vβ6.1
|
disease risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
gene rearrangement
|
N/A
|
disease risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
Haplotype assignments
|
N/A
|
disease risk
|
Positive
|
|
BTN1A1
|
Homo sapiens
|
6p22.2
|
alloantigens
|
BT 101
|
disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
alloantigens
|
HLA-B7
|
disease risk
|
Positive
|
|
IGH
|
Homo sapiens
|
14q32.33
|
polymorphism
|
IghC
|
N/A
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
mutation
|
M694V
|
Disease risk
|
Positive
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
mutation
|
V726A
|
Disease risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
mutation
|
E148Q
|
Disease risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
mutation
|
K695R
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
HLA-A*31:01
|
Disease risk
|
Positive
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs17824933
|
Disease risk
|
Positive
|
|
IRF8
|
Homo sapiens
|
16q24.1
|
SNP
|
rs17445836
|
Disease risk
|
Positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs4149584
|
Disease risk
|
Negative
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs1860545
|
Disease risk
|
Positive
|
|
TLR4
|
Homo sapiens
|
9q33.1
|
mutation
|
Asp299Gly
|
Phenotype risk
|
Negative
|
|
TLR4
|
Homo sapiens
|
9q33.1
|
genotype
|
+896 A/A
|
Phenotype risk
|
Negative
|
|
TLR4
|
Homo sapiens
|
9q33.1
|
genotype
|
+896 A/G
|
Phenotype risk
|
Negative
|
|
TLR4
|
Homo sapiens
|
9q33.1
|
genotype
|
+896 AG/G
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*01
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*03
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*04
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*07
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*08
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*09
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*10
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*11
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*12
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*14
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15
|
Phenotype risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*16
|
Phenotype risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ1
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ2
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ3
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ4
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ5.1
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ5.2
|
Disease risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ6
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ7
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ8
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ9
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ10
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ11
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ12
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ13
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ14
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ15
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ16
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ17
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ18
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ19
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ20
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ21
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ22
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ23
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
expansion
|
Vβ24
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR1
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR(2)15
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR3
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR4
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR5
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR6
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR7
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR8
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR9
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR10
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR11
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR12
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR13
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR14
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR103
|
Phenotype risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
genotype
|
A1
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
genotype
|
A2
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
genotype
|
A11
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
genotype
|
A24
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
genotype
|
A26
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
genotype
|
A39
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
genotype
|
A31
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
genotype
|
Aw33
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B7
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B13
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B14
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B17
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B27
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B35
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B37
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B38
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B39
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B44
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
Bw46
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
Bw48
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B51
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B52
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B54
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B55
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B56
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B59
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B60
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B61
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B62
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B67
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B70
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
B75
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
Bw4
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
genotype
|
Bw6
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
genotype
|
Cw1
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
genotype
|
Cw3
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
N/A
|
genotype
|
Cw9
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
genotype
|
Cw10
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
genotype
|
Cw4
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
genotype
|
Cw5
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
genotype
|
Cw6
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
genotype
|
Cw7
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
genotype
|
Cw11
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
genotype
|
Blank (double)'
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
genotype
|
Blank (single) d
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR1
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR2
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR4
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR5
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR6
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR7
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR8
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR9
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR10
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRw52
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRw53
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1501
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1502
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1601
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1602
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0501
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0502
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0503
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0601
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0602
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0603
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0604
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0301
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0302
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0303
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0401
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0402
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*?
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*0101
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*0201
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*0202
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*0301
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*0401
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*0402
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*0501
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*0601
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*0801
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*0901
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*1001
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*1101
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*1301
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*1401
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*1501
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*1601
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*1701
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*1801
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*1901
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs987107
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs987106
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs3194051
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs11567698
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs11567701
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs10461959
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs3777090
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs11567773
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs1494555
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs987107
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs987106
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs3194051
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs10058453
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6871748
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs13169780
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6870944
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs2303137
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
polymorphisms
|
Taq I (rs731236)
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
polymorphisms
|
Fok I (rs2228570)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
polymorphisms
|
Apa I(rs7975232)
|
Disease risk
|
Negative
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
allele
|
2
|
Disease risk
|
Positive
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
allele
|
3
|
Disease risk
|
Negative
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
allele
|
5
|
Disease risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allele
|
1.29 kb
|
Disease risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allele
|
1.27 kb
|
Disease risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allele
|
1.25 kb
|
Disease risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allele
|
1.23 kb
|
Disease risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allele
|
1.20kb
|
Disease risk
|
Negative
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
mutation
|
R92Q
|
Disease risk
|
Negative
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
mutation
|
R92Q
|
Phenotype risk
|
Negative
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
mutation
|
R92Q
|
Treatment risk
|
Negative
|
|
AGER
|
Homo sapiens
|
6p21.32
|
genotype
|
374 T/A
|
Disease risk
|
Positive
|
|
AGER
|
Homo sapiens
|
6p21.32
|
homozygote
|
AA
|
Disease risk
|
Positive
|
|
AGER
|
Homo sapiens
|
6p21.32
|
genotype
|
-479 T/C
|
Disease risk
|
Negative
|
|
AGER
|
Homo sapiens
|
6p21.32
|
genotype
|
G82S
|
Disease risk
|
Negative
|
|
TNFSF14
|
Homo sapiens
|
19p13.3
|
genotype
|
rs1077667AA
|
Disease risk
|
Negative
|
|
TNFSF14
|
Homo sapiens
|
19p13.3
|
genotype
|
rs1077667AG
|
Disease risk
|
Negative
|
|
TNFSF14
|
Homo sapiens
|
19p13.3
|
genotype
|
rs1077667GG
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
rs405509 [ 219 G/T]
|
Phenotype risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
rs440446 [113 C/G]
|
Phenotype risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
rs440446 [113 C/C]
|
Phenotype risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
rs440446 [113 G/G]
|
Phenotype risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
rs405509 [ 219 G/G]
|
Phenotype risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
rs405509 [ 219 T/T]
|
Phenotype risk
|
Negative
|
|
MMP3
|
Homo sapiens
|
11q22.2
|
polymorphisms
|
5A/6A
|
Disease risk
|
Negative
|
|
LINE-1
|
Homo sapiens
|
1p31.3
|
methylation
|
N/A
|
Disease risk
|
Positive
|
|
GC
|
Homo sapiens
|
4q13.3
|
SNP
|
rs7041
|
Disease risk
|
Negative
|
|
GC
|
Homo sapiens
|
4q13.3
|
SNP
|
rs4588
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs118204009
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs118204011
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs118204012
|
Disease risk
|
Negative
|
|
GC
|
Homo sapiens
|
4q13.3
|
phenotype
|
Gc1S/Gc1S
|
Disease risk
|
Negative
|
|
GC
|
Homo sapiens
|
4q13.3
|
phenotype
|
Gc1S/Gc2
|
Disease risk
|
Negative
|
|
GC
|
Homo sapiens
|
4q13.3
|
phenotype
|
Gc1S/Gc1F
|
Disease risk
|
Negative
|
|
GC
|
Homo sapiens
|
4q13.3
|
phenotype
|
Gc1F/Gc2
|
Disease risk
|
Negative
|
|
GC
|
Homo sapiens
|
4q13.3
|
phenotype
|
Gc2/Gc2
|
Disease risk
|
Negative
|
|
GC
|
Homo sapiens
|
4q13.3
|
phenotype
|
Gc1F/Gc1F
|
Disease risk
|
Negative
|
|
BDNF
|
Homo sapiens
|
11p14.1
|
polymorphisms
|
196 G/G
|
Disease risk
|
Negative
|
|
BDNF
|
Homo sapiens
|
11p14.1
|
polymorphisms
|
196 G/A
|
Disease risk
|
Positive
|
|
BDNF
|
Homo sapiens
|
11p14.1
|
polymorphisms
|
270 C/C
|
Disease risk
|
Positive
|
|
BDNF
|
Homo sapiens
|
11p14.1
|
polymorphisms
|
270 C/T
|
Disease risk
|
Negative
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs2801
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs2800
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs4240552
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs6440183
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs6440184
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs10709029
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs7625330
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs9828519
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs1900647
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs1900648
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs11919382
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs1122452
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs1562495
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs6440185
|
Disease risk
|
Positive
|
|
SLC9A9
|
Homo sapiens
|
3q24
|
SNP
|
rs4839655
|
Disease risk
|
Positive
|
|
ST8SIA1
|
Homo sapiens
|
12p12.1
|
SNP
|
rs704219
|
Disease risk
|
Positive
|
|
ST8SIA1
|
Homo sapiens
|
12p12.1
|
SNP
|
rs2041906
|
Disease risk
|
Positive
|
|
ST8SIA1
|
Homo sapiens
|
12p12.1
|
SNP
|
rs1558793
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR1
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR3
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR4
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR6
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR7.1
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR8
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR7.2/9
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR10
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR11
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR12
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DR15
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DR1
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DR3
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DR4
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DR7
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DR8
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DR11
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DR13
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DR15
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
allele
|
B7
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
allele
|
B8
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
allele
|
B12
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
allele
|
B15
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
allele
|
B27
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
allele
|
B35
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
allele
|
B40
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
allele
|
A1
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
allele
|
A2
|
Disease risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
allele
|
A3
|
Disease risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
allele
|
A9
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
allele
|
A10
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
allele
|
A11
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
allele
|
A19
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
rearrangement
|
N/A
|
Disease risk
|
Positive
|
|
ERVW-1
|
Homo sapiens
|
7q21.2
|
DNA copy number
|
N/A
|
Disease risk
|
Positive
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
5V(-523) CC
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
5V(-523) CT
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
5V(-523) TT
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
5V(-523) C
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
5V(-523) T
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
E1(33) CC
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
E1(33) TT
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
E1(33) CT
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
E1(33) C
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
E1(33) T
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(709)
|
Disease risk
|
Positive
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(709) 11
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(709) 12
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(709) 22
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
I3(709) 1
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
I3(709) 2
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(2580) CC
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(2580) CA
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(2580) AA
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
I3(2580) A
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
I3(2580) C
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
5V(-523) CC
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
5V(-523) CT
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
5V(-523) TT
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
5V(-523) C
|
Phenotype risk
|
Positive
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
5V(-523) T
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
E1(33) CC
|
Phenotype risk
|
Positive
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
E1(33) TT
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
E1(33) CT
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
E1(33) C
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
E1(33) T
|
Phenotype risk
|
Positive
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
E1(33)
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(709) 11
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(709) 12
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(709) 22
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
I3(709) 1
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
I3(709) 2
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(2580) CC
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(2580) CA
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
genotype
|
I3(2580) AA
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
I3(2580) A
|
Phenotype risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
I3(2580) C
|
Phenotype risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
haplotype
|
GCTGC
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
haplotype
|
GTCGC
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
haplotype
|
GCCCC
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
haplotype
|
ACTGC
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
haplotype
|
GCCGC
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
haplotype
|
GTTGC
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
haplotype
|
GTCGT
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
haplotype
|
Rare C
|
Disease risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
rearrangement
|
N/A
|
Disease risk
|
Positive
|
|
NOS3
|
Homo sapiens
|
7q36.1
|
SNP
|
rs2070744
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3135388
|
Disease risk
|
Positive
|
|
MT-TT
|
Homo sapiens
|
N/A
|
variation
|
G15257A
|
Disease risk
|
Positive
|
|
MT-TT
|
Homo sapiens
|
N/A
|
variation
|
G15812A
|
Disease risk
|
Negative
|
|
GAL
|
Homo sapiens
|
11q13.2
|
SNP
|
rs948854
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
TaqI(rs731236)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
ApaI(rs7975232)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
FokI(rs2228570)
|
Disease risk
|
Positive
|
|
HLA-DRB5
|
Homo sapiens
|
6p21.32
|
haplotype
|
DRB5*0101-DQA1*0102-DQB1*0602
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
haplotype
|
DRB1*1302-DQA1*0102-DQBl*0604
|
Disease risk
|
Positive
|
|
HLA-DRB5
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB5*0101
|
Disease risk
|
Negative
|
|
ID1
|
Homo sapiens
|
20q11.21
|
N/A
|
N/A
|
Disease risk
|
Positive
|
|
IGH
|
Homo sapiens
|
14q32.33
|
N/A
|
IGHV1
|
Disease risk
|
Positive
|
|
IGH
|
Homo sapiens
|
14q32.33
|
N/A
|
IGHV3
|
Disease risk
|
Positive
|
|
IGKV@
|
Homo sapiens
|
2p12
|
N/A
|
IGKV1
|
Disease risk
|
Positive
|
|
IGKV@
|
Homo sapiens
|
2p12
|
N/A
|
IGKV3
|
Disease risk
|
Positive
|
|
IGKV@
|
Homo sapiens
|
2p12
|
N/A
|
IGKV5
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
HLA-DRB1*15:01
|
Disease risk
|
Positive
|
|
CHRNA9
|
Homo sapiens
|
4p14
|
SNP
|
rs6812832
|
Disease risk
|
Negative
|
|
CHRNA9
|
Homo sapiens
|
4p14
|
SNP
|
rs7681304
|
Disease risk
|
Negative
|
|
CHRNA9
|
Homo sapiens
|
4p14
|
SNP
|
rs4861307
|
Disease risk
|
Positive
|
|
CHRNA7
|
Homo sapiens
|
15q13.3
|
SNP
|
rs11635209
|
Disease risk
|
Positive
|
|
CHRNA7
|
Homo sapiens
|
15q13.3
|
SNP
|
rs35114543
|
Disease risk
|
Negative
|
|
CHRNA7
|
Homo sapiens
|
15q13.3
|
SNP
|
rs2175886
|
Disease risk
|
Positive
|
|
CHRNA7
|
Homo sapiens
|
15q13.3
|
SNP
|
rs1604265
|
Disease risk
|
Negative
|
|
CHRNA7
|
Homo sapiens
|
15q13.3
|
SNP
|
rs8033518
|
Disease risk
|
Positive
|
|
CHRNA7
|
Homo sapiens
|
15q13.3
|
SNP
|
rs2133965
|
Disease risk
|
Negative
|
|
CHRNA7
|
Homo sapiens
|
15q13.3
|
SNP
|
rs6494212
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0101
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0102
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0103
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0201
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0301
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0401
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0501
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0601
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0201
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0301
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0302
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0402
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0501
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0502
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0503
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0601
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0602
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
*0603
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
genotype
|
E o4
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs3019561
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs3019562
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs3019548
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs2905506
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs11230548
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs17824933
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs11230555
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs916811
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs11230559
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs2237997
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs11230563
|
Disease risk
|
Positive
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs2074225
|
Disease risk
|
Positive
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs12360861
|
Disease risk
|
Negative
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs650258(5)
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs7041
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs4588
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs2282679
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs4646536
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs4646537
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs703842
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs8176345
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs8176350
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2228570* (Fok1)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs7975232 (Apa1)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs1544410 (Bsm1)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236 (Taq1)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs11568820 (Cdx2)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs10783219
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs11168287
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs11574024
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs11574026
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs11574077
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs11574085
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs11574114
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs12581281
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs1540339
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2189480
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2107301
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2228572
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2238135
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2238136
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2239179
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2239181
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2239182
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2239185
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2239186
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2853559
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs3782905
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs3819545
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs3890734
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs4237855
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs4328262
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs4516035
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs4760648
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs4760655
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs7136534
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs739837
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs757343
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs886441
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs987849
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2283342
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2254210
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs1555439
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs1570669
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs2181874
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs2209314
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs4809960
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs6022999
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs6097797
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs6097801
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs6127119
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs912505
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs927650
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs3787555
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs2244719
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs2296241
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs2426496
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs2585428
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs7041
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs705120
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs4588
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs2282679
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs2298850
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs1352845
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs12512631
|
Disease risk
|
Negative
|
|
STAT3
|
Homo sapiens
|
17q21.2
|
methylation
|
N/A
|
Disease risk
|
Positive
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
genotype
|
rs2248359 GG
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
genotype
|
rs2248359 GA
|
Disease risk
|
Positive
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
genotype
|
rs2248359 AA
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
allel
|
rs2248359 G
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
allel
|
rs2248359 A
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
genotype
|
rs703842 TT
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
genotype
|
rs703842 TC
|
Disease risk
|
Positive
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
genotype
|
rs703842 CC
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
allel
|
rs703842 T
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
allel
|
rs703842 C
|
Disease risk
|
Negative
|
|
NOS1
|
Homo sapiens
|
12q24.22
|
allel
|
N/A
|
Disease risk
|
Negative
|
|
NFKB2
|
Homo sapiens
|
10q24.32
|
allel
|
N/A
|
Disease risk
|
Negative
|
|
FADD
|
Homo sapiens
|
11q13.3
|
allel
|
N/A
|
Disease risk
|
Negative
|
|
GZMB
|
Homo sapiens
|
14q12
|
allel
|
N/A
|
Disease risk
|
Negative
|
|
ERBB3
|
Homo sapiens
|
12q13.2
|
allel
|
N/A
|
Disease risk
|
Negative
|
|
NGF
|
Homo sapiens
|
1p13.2
|
allel
|
N/A
|
Disease risk
|
Negative
|
|
PARP1
|
Homo sapiens
|
1q42.12
|
allel
|
N/A
|
Disease risk
|
Negative
|
|
GNB3
|
Homo sapiens
|
12p13.31
|
polymorphisms
|
C825T
|
Disease risk
|
Negative
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
mutation
|
d32
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A1
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A2
|
Disease risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A3
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A9
|
Disease risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A10
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A11
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
AW19
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
AW24
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A25
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A26
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A28
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A29
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
AW30
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
AW31
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
AW32
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
AW33
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B5
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B7
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B8
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B12
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B13
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B14
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B15
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
BW16
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B17
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B18
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
BW21
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
BW35
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B27
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
BW35
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B37
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
BW38
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
BW39
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B40
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR1
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR2
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR3
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR4
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR5
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRW6
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR7
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
A3-B7
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
A1-B8
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
A2-B12
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
B7-B8
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
A3-B7
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
A1-B8
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
A2-B12
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
B7-DR2
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
B8-DR3
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
B12-DR7
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
B35-DR 1
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
A3-B7-DR2
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
A1-B8-DR3
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
A2-B12-DR7
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR2-DR3
|
Disease risk
|
Positive
|
|
TNFSF10
|
Homo sapiens
|
3q26.31
|
SNP
|
rs4894559
|
Disease risk
|
Positive
|
|
TNFRSF10A
|
Homo sapiens
|
8p21.3
|
SNP
|
rs4872077
|
Disease risk
|
Positive
|
|
TNFRSF10B
|
Homo sapiens
|
8p21.3
|
SNP
|
rs1001793
|
Disease risk
|
Positive
|
|
TNFRSF10B
|
Homo sapiens
|
8p21.3
|
SNP
|
rs11779484
|
Disease risk
|
Negative
|
|
TNFRSF10B
|
Homo sapiens
|
8p21.3
|
SNP
|
rs4460370
|
Disease risk
|
Negative
|
|
TNFRSF10B
|
Homo sapiens
|
8p21.3
|
SNP
|
rs9314261
|
Disease risk
|
Negative
|
|
TNFRSF10B
|
Homo sapiens
|
8p21.3
|
SNP
|
rs3924519
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
haplotypes
|
Hap1
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
haplotypes
|
Hap2
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
haplotypes
|
Hap3
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
haplotypes
|
Hap4
|
Disease risk
|
Negative
|
|
LTA
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
TNF-β NcoI
|
Disease risk
|
Positive
|
|
TPH2
|
Homo sapiens
|
12q21.1
|
SNP
|
rs4570625– rs10506645 GC
|
Disease risk
|
Negative
|
|
TPH2
|
Homo sapiens
|
12q21.1
|
SNP
|
rs4570625– rs10506645 TT
|
Disease risk
|
Positive
|
|
TPH2
|
Homo sapiens
|
12q21.1
|
SNP
|
rs4570625– rs10506645 GT
|
Disease risk
|
Negative
|
|
TPH2
|
Homo sapiens
|
12q21.1
|
SNP
|
rs4570625– rs10506645 TC
|
Disease risk
|
Positive
|
|
MTNR1B
|
Homo sapiens
|
11q14.3
|
SNP
|
rs10830963– rs4753426 CT
|
Disease risk
|
Negative
|
|
MTNR1B
|
Homo sapiens
|
11q14.3
|
SNP
|
rs10830963– rs4753426 GC
|
Disease risk
|
Positive
|
|
MTNR1B
|
Homo sapiens
|
11q14.3
|
SNP
|
rs10830963– rs4753426 CC
|
Disease risk
|
Negative
|
|
MTNR1B
|
Homo sapiens
|
11q14.3
|
SNP
|
rs10830963– rs4753426 GT
|
Disease risk
|
Positive
|
|
RPS6KB1
|
Homo sapiens
|
17q23.1
|
SNP
|
rs180515
|
Disease risk
|
Positive
|
|
RPS6KB1
|
Homo sapiens
|
17q23.1
|
SNP
|
rs180515 AA
|
Disease risk
|
Positive
|
|
RPS6KB1
|
Homo sapiens
|
17q23.1
|
SNP
|
rs180515 AG
|
Disease risk
|
Negative
|
|
RPS6KB1
|
Homo sapiens
|
17q23.1
|
SNP
|
rs180515 GG
|
Disease risk
|
Positive
|
|
CD86
|
Homo sapiens
|
3q13.33
|
SNP
|
rs9282641
|
Disease risk
|
Positive
|
|
CD86
|
Homo sapiens
|
3q13.33
|
SNP
|
rs9282641 GG
|
Disease risk
|
Positive
|
|
CD86
|
Homo sapiens
|
3q13.33
|
SNP
|
rs9282641 AG
|
Disease risk
|
Positive
|
|
CD86
|
Homo sapiens
|
3q13.33
|
SNP
|
rs9282641 AA
|
Disease risk
|
Negative
|
|
HERV-K18
|
Homo sapiens
|
1q23.3
|
polymorphisms
|
SU
|
Disease risk
|
Negative
|
|
Galc
|
Homo sapiens
|
12 E; 12 49.83 cM
|
mutation
|
GALC +/-
|
Disease risk
|
Positive
|
|
NAT1
|
Homo sapiens
|
8p22
|
SNP
|
rs7388368
|
Disease risk
|
Positive
|
|
NAT1
|
Homo sapiens
|
8p22
|
SNP
|
rs4921877
|
Disease risk
|
Negative
|
|
NAT1
|
Homo sapiens
|
8p22
|
SNP
|
rs6586711
|
Disease risk
|
Negative
|
|
IFNG
|
Homo sapiens
|
12q15
|
marker
|
D12S1676
|
Disease risk
|
Negative
|
|
IFNG
|
Homo sapiens
|
12q15
|
marker
|
D12S375
|
Disease risk
|
Positive
|
|
IFNG
|
Homo sapiens
|
12q15
|
marker
|
D12S1680
|
Disease risk
|
Negative
|
|
IFNG
|
Homo sapiens
|
12q15
|
marker
|
D12S1052
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
genotype
|
+869 TT
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
genotype
|
+869 TC
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
genotype
|
+869 CC
|
Disease risk
|
Positive
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
allel
|
+869 C
|
Disease risk
|
Positive
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
allel
|
+869 T
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
genotype
|
+915 GG
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
genotype
|
+915 GC
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
genotype
|
+915 CC
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
allel
|
+915 G
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
allel
|
+915 C
|
Disease risk
|
Negative
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
genotype
|
rs3761548 CC
|
Disease risk
|
Negative
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
genotype
|
rs3761548 CA
|
Disease risk
|
Negative
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
genotype
|
rs3761548 AA
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
allel
|
rs3761548 C
|
Disease risk
|
Negative
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
allel
|
rs3761548 A
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
genotype
|
rs3761548 CC
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
genotype
|
rs3761548 CA
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
genotype
|
rs3761548 AA
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
allel
|
rs3761548 C
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
allel
|
rs3761548 A
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
allel
|
rs3761548 C
|
Disease risk
|
Negative
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
allel
|
rs3761548 A
|
Disease risk
|
Negative
|
|
CD45
|
Homo sapiens
|
1q31.3-q32.1
|
mutation
|
C77G
|
Disease risk
|
Positive
|
|
CTSS
|
Homo sapiens
|
1q21.3
|
SNP
|
rs2275235a
|
Phenotype risk
|
Positive
|
|
CTSS
|
Homo sapiens
|
1q21.3
|
SNP
|
rs1415148a
|
Phenotype risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
SNP
|
rs71878b
|
Phenotype risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
SNP
|
rs470929a
|
Phenotype risk
|
Positive
|
|
CD86
|
Homo sapiens
|
3q13.33
|
SNP
|
rs2001791a
|
Phenotype risk
|
Positive
|
|
CD86
|
Homo sapiens
|
3q13.33
|
SNP
|
1129055a
|
Phenotype risk
|
Positive
|
|
IL1R1
|
Homo sapiens
|
2q11.2-q12.1
|
SNP
|
rs956730a
|
Phenotype risk
|
Positive
|
|
FAS
|
Homo sapiens
|
10q23.31
|
SNP
|
rs982764a
|
Phenotype risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
SNP
|
rs71878c
|
Phenotype risk
|
Positive
|
|
IL12RB2
|
Homo sapiens
|
1p31.3
|
SNP
|
rs946685c
|
Phenotype risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR1
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR2
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR3
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR4
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR5
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRw6
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR7
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRw8
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRw9
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRw10
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRw1
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR1
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR2
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR3
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR4
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR5
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRw6
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR7
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRw8
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRw9
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRw10
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRw1
|
Phenotype risk
|
Negative
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
polymorphisms
|
VNTR
|
Disease risk
|
Negative
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
polymorphisms
|
-511
|
Disease risk
|
Negative
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
polymorphisms
|
+3,953
|
Disease risk
|
Negative
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
polymorphisms
|
VNTR
|
Phenotype risk
|
Negative
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
polymorphisms
|
-511
|
Phenotype risk
|
Negative
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
polymorphisms
|
+3,953
|
Phenotype risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
HLA-DRB115
|
Phenotype risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A2
|
Phenotype risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B7
|
Phenotype risk
|
Positive
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
polymorphism
|
A3061G
|
Phenotypic risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
polymorphism
|
A-269C
|
Phenotypic risk
|
Negative
|
|
MX1
|
Homo sapiens
|
21q22.3
|
SNP
|
rs2071430
|
Treatment risk
|
Negative
|
|
MX1
|
Homo sapiens
|
21q22.3
|
SNP
|
rs17000900
|
Treatment risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
SNP
|
rs2243250
|
Disease risk
|
Positive
|
|
ANKRD55
|
Homo sapiens
|
5q11.2
|
SNP
|
rs6859219
|
Disease risk
|
Positive
|
|
DHCR7
|
Homo sapiens
|
11q13.4
|
SNP
|
rs12785878
|
Disease risk
|
Negative
|
|
AFF3
|
Homo sapiens
|
2q11.2
|
SNP
|
rs11676922
|
Disease risk
|
Negative
|
|
CCR6
|
Homo sapiens
|
6q27
|
SNP
|
rs6859219
|
Disease risk
|
Negative
|
|
CYP2R1
|
Homo sapiens
|
11p15.2
|
SNP
|
rs10741657
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs706778
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
SNP
|
rs3024505
|
Disease risk
|
Negative
|
|
PRDM1
|
Homo sapiens
|
6q21
|
SNP
|
rs548234
|
Disease risk
|
Negative
|
|
PRDM1
|
Homo sapiens
|
6q21
|
SNP
|
rs7746082
|
Disease risk
|
Negative
|
|
PXK
|
Homo sapiens
|
3p14.3
|
SNP
|
rs13315591
|
Disease risk
|
Negative
|
|
SERPINE1
|
Homo sapiens
|
7q22.1
|
polymorphism
|
5G5G
|
Disease risk
|
Positive
|
|
SERPINE1
|
Homo sapiens
|
7q22.1
|
polymorphism
|
4G4G
|
Disease risk
|
Positive
|
|
CBLB
|
Homo sapiens
|
3q13.11
|
SNP
|
rs9657904
|
Disease risk
|
Positive
|
|
PRL
|
Homo sapiens
|
6p22.3
|
polymorphism
|
G-1149T
|
Disease risk
|
Negative
|
|
PRL
|
Homo sapiens
|
6p22.3
|
polymorphism
|
IVS3-C214T
|
Disease risk
|
Negative
|
|
PRL
|
Homo sapiens
|
6p22.3
|
polymorphism
|
IVS3-G1220A
|
Disease risk
|
Negative
|
|
PRL
|
Homo sapiens
|
6p22.3
|
polymorphism
|
IVS4-G2243A
|
Disease risk
|
Negative
|
|
PRL
|
Homo sapiens
|
6p22.3
|
polymorphism
|
G671A
|
Disease risk
|
Negative
|
|
PRLR
|
Homo sapiens
|
5p13.2
|
polymorphism
|
C-524G
|
Disease risk
|
Negative
|
|
PRLR
|
Homo sapiens
|
5p13.2
|
polymorphism
|
T-435C
|
Disease risk
|
Negative
|
|
PRLR
|
Homo sapiens
|
5p13.2
|
polymorphism
|
IVS9-G1158A
|
Disease risk
|
Negative
|
|
PRLR
|
Homo sapiens
|
5p13.2
|
polymorphism
|
IVS10-A1870T
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DR15
|
Phenotypic risk
|
Positive
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DR16
|
Phenotypic risk
|
Negative
|
|
IGHG1
|
Homo sapiens
|
14q32.33
|
polymorphism
|
IgG CG1
|
Disease risk
|
Negative
|
|
IGHG1
|
Homo sapiens
|
14q32.33
|
polymorphism
|
IgG CG2
|
Disease risk
|
Negative
|
|
IGHG1
|
Homo sapiens
|
14q32.33
|
polymorphism
|
IgG CG3
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLADRB1*04:01, *04:08, *16:01
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DRB1*03:01, *04:04, *11:04
|
Disease risk
|
Negative
|
|
IL1A
|
Homo sapiens
|
2q14.1
|
SNP
|
rs1800587
|
N/A
|
Negative
|
|
IL-1RN
|
Homo sapiens
|
2q14.1
|
SNP
|
rs 16944
|
N/A
|
Negative
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
SNP
|
rs 1143634
|
N/A
|
Positive
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
SNP
|
IL-1 RN variable number tandom repeat (VNTR)
|
N/A
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
polymorphism
|
-1722 T C
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
polymorphism
|
-1661 A G
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
polymorphism
|
-318 C T
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
polymorphism
|
+49 A G
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
TACA
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
TACG
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
TGCG
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
TGCA
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
TATA
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
CACA
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
TATG
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
TGCG
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
TGTG
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQB1*0302
|
Phenotypic risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1502
|
Phenotypic risk
|
Positive
|
|
PLA2G7
|
Homo sapiens
|
6p12.3
|
polymorphism
|
TT
|
Phenotypic risk
|
Negative
|
|
PLA2G7
|
Homo sapiens
|
6p12.3
|
polymorphism
|
GT
|
Phenotypic risk
|
Negative
|
|
PLA2G7
|
Homo sapiens
|
6p12.3
|
polymorphism
|
GG
|
Phenotypic risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DRB1*15
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQAl*0102
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQB1*0201
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQBl*O302
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQBl*0602
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQB1*0301
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQAl*0102
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQBl*0602
|
Disease risk
|
Negative
|
|
MIR146A
|
Homo sapiens
|
5q33.3
|
SNP
|
rs57095329
|
Disease risk
|
Negative
|
|
MIR146A
|
Homo sapiens
|
5q33.3
|
SNP
|
rs2910164
|
Disease risk
|
Positive
|
|
MIR146A
|
Homo sapiens
|
5q33.3
|
polymorphism
|
rs2910164 G>C
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DRB1*04:05
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DRB1*15:01
|
Disease risk
|
Positive
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
polymorphism
|
N/A
|
Disease risk
|
Positive
|
|
TGFB2
|
Homo sapiens
|
1q41
|
polymorphism
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQB1*0501
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQB1*0602
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQB1*0302
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*0502-*0504
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*0601
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*0603-*0605
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*02
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*0301
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*0303
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*0401-*0402
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1502
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*04
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*0101-*0102
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*1502
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*1601
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*0301
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*0401-*0408
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*11-*14
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*07-*08
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*0901
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
*1001
|
Disease risk
|
Negative
|
|
SP140
|
Homo sapiens
|
2q37.1
|
SNP
|
rs28445040
|
Disease risk
|
Positive
|
|
CBLB
|
Homo sapiens
|
3q13.11
|
SNP
|
rs12487066
|
Disease risk
|
Positive
|
|
CBLB
|
Homo sapiens
|
3q13.11
|
SNP
|
rs2028597
|
Disease risk
|
Negative
|
|
CBLB
|
Homo sapiens
|
3q13.11
|
SNP
|
rs9657904
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3135005
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
polymorphism
|
E2
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
polymorphism
|
E3
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
polymorphism
|
E4
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQBl*0201
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQBl*0301
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQBl*0302
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQBl*0501
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQBl*0502
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQBl*0601
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DQBl*0602
|
Disease risk
|
Negative
|
|
P2RX7
|
Homo sapiens
|
12q24.31
|
SNP
|
rs17525809
|
Disease risk
|
Positive
|
|
P2RX7
|
Homo sapiens
|
12q24.31
|
SNP
|
rs208294
|
Disease risk
|
Negative
|
|
P2RX7
|
Homo sapiens
|
12q24.31
|
SNP
|
rs1718119
|
Disease risk
|
Negative
|
|
P2RX7
|
Homo sapiens
|
12q24.31
|
polymorphism
|
TA
|
Disease risk
|
Negative
|
|
P2RX7
|
Homo sapiens
|
12q24.31
|
polymorphism
|
TG
|
Disease risk
|
Negative
|
|
P2RX7
|
Homo sapiens
|
12q24.31
|
polymorphism
|
CG
|
Disease risk
|
Positive
|
|
P2RX7
|
Homo sapiens
|
12q24.31
|
polymorphism
|
AACCTG
|
Disease risk
|
Positive
|
|
GRIK2
|
Homo sapiens
|
6q16.3
|
polymorphism
|
GCGc
|
Disease risk
|
Negative
|
|
GRIK2
|
Homo sapiens
|
6q16.3
|
polymorphism
|
CGGTGAT
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DRB1*15
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DRB1*04
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
polymorphism
|
VDRG
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1501
|
Disease risk
|
Positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*0501
|
Disease risk
|
Positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*0201
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*0202
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*0301
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*0401
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*0402
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*0501
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*0601
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*0901
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*1301
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*1401
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*1701
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DPB1*1901
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*0101
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1501
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1502
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1602
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*0303
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*0401
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*0405
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*0407
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*0410
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1101
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1201
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1202
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1301
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1302
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1401
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1403
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1405
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1406
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*0701
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*0802
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*0803
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*0901
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*1001
|
Disease risk
|
Negative
|
|
RGS1
|
Homo sapiens
|
1q31.2
|
SNP
|
rs2760524
|
Disease risk
|
Negative
|
|
KIF21B
|
Homo sapiens
|
1q32.1
|
SNP
|
rs12122721
|
Disease risk
|
Negative
|
|
TMEM39A
|
Homo sapiens
|
3q13.33
|
SNP
|
rs1132200
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Negative
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs12708716
|
Disease risk
|
Negative
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs6498169
|
Disease risk
|
Negative
|
|
IRF8
|
Homo sapiens
|
16q24.1
|
SNP
|
rs17445836
|
Disease risk
|
Negative
|
|
CD226
|
Homo sapiens
|
18q22.2
|
SNP
|
rs763361
|
Disease risk
|
Negative
|
|
TYK2
|
Homo sapiens
|
19p13.2
|
SNP
|
rs34536443
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs2394160
|
Disease risk
|
Positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs2854050
|
Disease risk
|
Positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3830041
|
Disease risk
|
Positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3129939
|
Disease risk
|
Positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs9271366
|
Disease risk
|
Positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs2187668
|
Disease risk
|
Positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs9277535
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DRB1*15
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
polymorphism
|
position 318 of the CTLA4 promoter
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
polymorphism
|
position 49 in exon 1
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphism
|
TNF*(-308)A
|
Disease risk
|
Positive
|
|
IFNG
|
Homo sapiens
|
12q15
|
polymorphism
|
TNF*(-308)A
|
Disease risk
|
Negative
|
|
IL6
|
Homo sapiens
|
7p15.3
|
polymorphism
|
TNF*(-308)A
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DR2(+), DC 2.2(+)
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
DR2(+), DC 2.2(-)
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DRB1*15:01
|
Disease risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphism
|
HLA-A*02:01
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphism
|
HLA-B*38:01
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphism
|
HLA-B*44:02
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphism
|
rs9277565 (T)d
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DRB1*03:01
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphism
|
HLA-B*55:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DRB1*13:03
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DRB1*08:01
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10R2
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10R3
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10R4
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10G7
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10G8
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10G9
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10G10
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10G11
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10G12
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10G13
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10G14
|
Disease risk
|
Positive
|
|
IL10
|
Homo sapiens
|
1q32.1
|
polymorphism
|
IL-10G15
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*01
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*03
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*04
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*07
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*08
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*09
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*010
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*11
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*14
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1501
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*16
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0201
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0202
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0301
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0302
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0303
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0402
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0501
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0502
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0503
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0601
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0602
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0603
|
Treatment risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0604
|
Treatment risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0101
|
Treatment risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0102
|
Treatment risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0103
|
Treatment risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0104
|
Treatment risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0201
|
Treatment risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0301
|
Treatment risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0303
|
Treatment risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0401
|
Treatment risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0501
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*03
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*04
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*07
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*08
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*09
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*10
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*11
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*12
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*14
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*16
|
Disease risk
|
Negative
|
|
FasL
|
Homo sapiens
|
1q24.3
|
allel
|
A
|
Disease risk
|
Negative
|
|
FasL
|
Homo sapiens
|
1q24.3
|
allel
|
B
|
Disease risk
|
Positive
|
|
IGH
|
Homo sapiens
|
14q32.33
|
SNP
|
rs11621145
|
Disease risk
|
Positive
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
mutation
|
E148Q
|
Disease risk
|
Positive
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
mutation
|
K695R
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
(-308)
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
(-238)
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
(-857)
|
Disease risk
|
Positive
|
|
PTPRC
|
Homo sapiens
|
1q31.3-q32.1
|
mutation
|
C->G mutation in position 77 of exon 4
|
Disease risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
rearrangement
|
N/A
|
Disease risk
|
Positive
|
|
SPON1
|
Homo sapiens
|
11p15.2
|
SNP
|
rs7104613T
|
Phenotypic risk
|
Positive
|
|
SEMA3A
|
Homo sapiens
|
7q21.11
|
SNP
|
rs740948A
|
Phenotypic risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
A
|
Disease risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
B
|
Disease risk
|
Positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs6074022
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
allel
|
A
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
polymorphisms
|
C_3290614_10(A/T)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
polymorphisms
|
C_8716062_10(C/T)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
polymorphisms
|
C_12060044_1_(A/G)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
polymorphisms
|
C_2880811_10(C/T)
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
genotype
|
n/n
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
genotype
|
n/i
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
genotype
|
i/i
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
allel
|
n
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
allel
|
i
|
Disease risk
|
Negative
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
polymorphisms
|
A1/A1
|
Phenotypic risk
|
Positive
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
polymorphisms
|
A1/A2
|
Phenotypic risk
|
Positive
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
polymorphisms
|
A2/A2
|
Phenotypic risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*03
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*04
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*07
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*08
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*09
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*010
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*11
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*14
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*12
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*16
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1502
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1501
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1503
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR2
|
Disease risk
|
Positive
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
polymorphisms
|
(-511 C/T)
|
Disease risk
|
Negative
|
|
IL2
|
Homo sapiens
|
4q27
|
polymorphisms
|
(-475 A/T)
|
Disease risk
|
Negative
|
|
IL2
|
Homo sapiens
|
4q27
|
polymorphisms
|
(-631 G/A)
|
Disease risk
|
Negative
|
|
IL6
|
Homo sapiens
|
7p15.3
|
polymorphisms
|
(-634 C/G)
|
Disease risk
|
Positive
|
|
PON1
|
Homo sapiens
|
7q21.3
|
polymorphisms
|
(M55L)
|
Disease risk
|
Negative
|
|
PON1
|
Homo sapiens
|
7q21.3
|
polymorphisms
|
(Q192R)
|
Disease risk
|
Positive
|
|
UCP2
|
Homo sapiens
|
11q13.4
|
polymorphisms
|
(-866 G/A)
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR2
|
Disease risk
|
Negative
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
polymorphisms
|
(-511 C/T)
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
(-308 A/G)
|
Disease risk
|
Positive
|
|
APOA1
|
Homo sapiens
|
11q23.3
|
allel
|
A
|
Phenotypic risk
|
Positive
|
|
APOA1
|
Homo sapiens
|
11q23.3
|
polymorphisms
|
APOA1 –75G/A
|
Phenotypic risk
|
Positive
|
|
LRP2
|
Homo sapiens
|
2q31.1
|
allel
|
rs12988804*T
|
Phenotypic risk
|
Positive
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
polymorphisms
|
rs6195(AA)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
polymorphisms
|
rs6195(AG)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
allel
|
rs6195(A)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
allel
|
rs6195(G)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
polymorphisms
|
rs6196(TT)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
polymorphisms
|
rs6196(TC)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
polymorphisms
|
rs6196(CC)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
allel
|
rs6196(T)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
allel
|
rs6196(C)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
polymorphisms
|
rs6188(GG)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
polymorphisms
|
rs6188(GT)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
polymorphisms
|
rs6188(TT)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
allel
|
rs6188(G)
|
Phenotypic risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
allel
|
rs6188(T)
|
Phenotypic risk
|
Negative
|
|
ATG5
|
Homo sapiens
|
6q21
|
polymorphisms
|
rs2245214(GG/GC/CC)
|
Disease risk
|
Negative
|
|
ATG5
|
Homo sapiens
|
6q21
|
allel
|
rs2245214(C/G)
|
Disease risk
|
Negative
|
|
ATG5
|
Homo sapiens
|
6q21
|
polymorphisms
|
rs548234(TT/CC/TC)
|
Disease risk
|
Negative
|
|
ATG5
|
Homo sapiens
|
6q21
|
allel
|
rs548234(T/C)
|
Disease risk
|
Negative
|
|
ATG5
|
Homo sapiens
|
6q21
|
polymorphisms
|
rs573775(TT/TC/CC)
|
Disease risk
|
Negative
|
|
ATG5
|
Homo sapiens
|
6q21
|
allel
|
rs573775(T/C)
|
Disease risk
|
Negative
|
|
ATG5
|
Homo sapiens
|
6q21
|
polymorphisms
|
rs6568431(AA/AC/CC)
|
Disease risk
|
Negative
|
|
ATG5
|
Homo sapiens
|
6q21
|
allel
|
rs6568431(A/C)
|
Disease risk
|
Negative
|
|
ATG5
|
Homo sapiens
|
6q21
|
polymorphisms
|
rs6937876(GG/GA/AA)
|
Disease risk
|
Negative
|
|
ATG5
|
Homo sapiens
|
6q21
|
allel
|
rs6937876(G/A)
|
Disease risk
|
Negative
|
|
ATG5
|
Homo sapiens
|
6q21
|
polymorphisms
|
DRB1*01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*03
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*04
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*07
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*08
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*09
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*010
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*11
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*12
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*14
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*16
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*02
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*03
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*04
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*05
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*06
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*04-03
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*03-02
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*07-02
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*03-06
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*15-06
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*01-05
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*03-03
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*11-03
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*04-03
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*03-02
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*07-02
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*03-06
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*15-06
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*01-05
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*03-03
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR-DQ*11-03
|
Disease risk
|
Negative
|
|
LTA
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
TNF-b*1
|
Disease risk
|
Negative
|
|
LTA
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
TNF-b*2
|
Disease risk
|
Positive
|
|
LTA
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
TNF-b*1/*1
|
Disease risk
|
Negative
|
|
LTA
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
TNF-b*1/*2
|
Disease risk
|
Negative
|
|
LTA
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
TNF-b*2/*2
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1501
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1502
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1602
|
Disease risk
|
Negative
|
|
HLA-DRB5
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB5*0101
|
Disease risk
|
Negative
|
|
HLA-DRB5
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB5*0102
|
Disease risk
|
Negative
|
|
HLA-DRB5
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB5*new
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0101
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0102
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0103
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0501
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0502
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0601
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0602
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0603
|
Disease risk
|
Negative
|
|
IL-1RL1
|
Homo sapiens
|
2q12.1
|
SNP
|
rs10204137
|
Disease risk
|
Positive
|
|
IL33
|
Homo sapiens
|
9p24.1
|
SNP
|
rs1342326(TT)
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
TNFa9
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15(2)
|
Disease risk
|
Positive
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
genotype
|
(CCR5d32,DRB1*04)
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
(CCR5d32,DRB1*04)
|
Disease risk
|
Positive
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
genotype
|
(-509 TGFb1*C, DRB1*18(3),CTLA4*G)
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
genotype
|
(-509 TGFb1*C, DRB1*18(3),CTLA4*G)
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
(-509 TGFb1*C, DRB1*18(3),CTLA4*G)
|
Disease risk
|
Positive
|
|
LTA
|
Homo sapiens
|
6p21.33
|
genotype
|
(-238TNF*B1, -308TNF*A2,CTLA4*G)
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
genotype
|
(-238TNF*B1, -308TNF*A2,CTLA4*G)
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
genotype
|
(-238TNF*B1, -308TNF*A2,CTLA4*G)
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
allel
|
rs1799964/C
|
Phenotypic risk
|
Positive
|
|
LTA
|
Homo sapiens
|
6p21.33
|
allel
|
rs769178/T
|
Phenotypic risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs2189480/T
|
Phenotypic risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs3782905/C
|
Phenotypic risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs4890785/T
|
Phenotypic risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
allel
|
rs7412/T
|
Phenotypic risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs1540339/T
|
Phenotypic risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs2239186/G
|
Phenotypic risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs2238136/T
|
Phenotypic risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs8096433/A
|
Phenotypic risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs17660901/G
|
Phenotypic risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs2189480/T
|
Phenotypic risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs8096433/A
|
Phenotypic risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
allel
|
rs6897932/A
|
Phenotypic risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
allel
|
rs800629/A
|
Phenotypic risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
allel
|
rs3093671/A
|
Phenotypic risk
|
Negative
|
|
LTA
|
Homo sapiens
|
6p21.33
|
allel
|
rs769177/T
|
Phenotypic risk
|
Negative
|
|
LTA
|
Homo sapiens
|
6p21.33
|
allel
|
rs909253/A
|
Phenotypic risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allel
|
rs3135388/T
|
Phenotypic risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
allel
|
rs17133575/G
|
Phenotypic risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
allel
|
rs17243/G
|
Phenotypic risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
allel
|
rs2104286/C
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs7975128/A
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs2248098/A
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs2239182/T
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs2107301/A
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs2239179/C
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs3819545/G
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs2228570/T
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs2254210/A
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs2853564/G
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs4760648/T
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs11168287/G
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs4328262/G
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs4237855/G
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs7136534/T
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs7299460/A
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs4760658/G
|
Phenotypic risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
allel
|
rs4516035/C
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs17026/C
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs470724/T
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs470550/T
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs9676113/G
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs11661054/A
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs11661755/A
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs9675994/T
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs8090438/T
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs8094402/G
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs12456341/G
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs17576751/T
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs3794848/A
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs4890875/G
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs595997/G
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs2974260/T
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs2051344/A
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs470681/C
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs12967023/A
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs4890788/T
|
Phenotypic risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
allel
|
rs7232502/A
|
Phenotypic risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
allel
|
rs429358/C
|
Phenotypic risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
allel
|
rs7412/T
|
Phenotypic risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1*1501-DQA1*0102-DQB1* 0602 (DR15)
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1*1501-DQA1*0102-DQB1* 0602 (DR15)
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1*1501-DQA1*0102-DQB1* 0602 (DR15)
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1*1501-DQA1*0102-DQB1* 0602 (DR15)
|
Phenotypic risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1*1501-DQA1*0102-DQB1* 0602 (DR15)
|
Phenotypic risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1*1501-DQA1*0102-DQB1* 0602 (DR15)
|
Phenotypic risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1*15 + TGFB1*T + CCR5*d
|
Disease risk
|
Positive
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
genotype
|
DRB1*15 + TGFB1*T + CCR5*d
|
Disease risk
|
Positive
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
genotype
|
DRB1*15 + TGFB1*T + CCR5*d
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1*15 + TGFB1*T + CCR5*d + IFNAR1*G
|
Disease risk
|
Positive
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
genotype
|
DRB1*15 + TGFB1*T + CCR5*d + IFNAR1*G
|
Disease risk
|
Positive
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
genotype
|
DRB1*15 + TGFB1*T + CCR5*d + IFNAR1*G
|
Disease risk
|
Positive
|
|
IFNAR1
|
Homo sapiens
|
21q22.11
|
genotype
|
DRB1*15 + TGFB1*T + CCR5*d + IFNAR1*G
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
Chr 6p21
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
Chr 3q13
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
Chr 2q14
|
Phenotypic risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
Chr 19p13
|
Phenotypic risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
Chr 4p16
|
Phenotypic risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*03
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*04
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*07
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*08
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*09
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*010
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*11
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*12
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*14
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*16
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15
|
Phenotypic risk
|
Negative
|
|
ERVW-1
|
Homo sapiens
|
7q21.2
|
CNV
|
MSRV
|
Phenotypic risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*04
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*07
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*08
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*09
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*010
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*11
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*12
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*14
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*16
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*17
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1501
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0102
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0602
|
Disease risk
|
Negative
|
|
KIF5A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs1678542
|
N/A
|
Positive
|
|
KIF5A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs2888334
|
N/A
|
Positive
|
|
KIF5A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs775249
|
N/A
|
Negative
|
|
KIF5A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs1678536
|
N/A
|
Positive
|
|
KIF5A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs7313599
|
N/A
|
Positive
|
|
PIP4K2C
|
Homo sapiens
|
12q13.3
|
SNP
|
rs1078109
|
N/A
|
Negative
|
|
ARHGEF25
|
Homo sapiens
|
12q13.3
|
SNP
|
rs7305391
|
N/A
|
Negative
|
|
ARHGEF25
|
Homo sapiens
|
12q13.3
|
SNP
|
rs1564374
|
N/A
|
Positive
|
|
OS9
|
Homo sapiens
|
12q13.3-q14.1
|
SNP
|
rs3825078
|
N/A
|
Positive
|
|
OS9
|
Homo sapiens
|
12q13.3-q14.1
|
SNP
|
rs701006
|
N/A
|
Positive
|
|
AGAP2
|
Homo sapiens
|
12q14.1
|
SNP
|
rs2301551
|
N/A
|
Negative
|
|
AGAP2
|
Homo sapiens
|
12q14.1
|
SNP
|
rs12307841
|
N/A
|
Negative
|
|
AGAP2
|
Homo sapiens
|
12q14.1
|
SNP
|
rs12368653
|
N/A
|
Positive
|
|
MARCHF9
|
Homo sapiens
|
12q14.1
|
SNP
|
rs1048691
|
N/A
|
Negative
|
|
TSFM
|
Homo sapiens
|
12q14.1
|
SNP
|
rs6581155
|
N/A
|
Positive
|
|
SELP
|
Homo sapiens
|
1q24.2
|
SNP
|
rs6133
|
Disease risk
|
Negative
|
|
SELL
|
Homo sapiens
|
1q24.2
|
SNP
|
rs4987310
|
Disease risk
|
Negative
|
|
SELE
|
Homo sapiens
|
1q24.2
|
SNP
|
rs5368
|
Disease risk
|
Negative
|
|
CD24
|
Homo sapiens
|
6q21
|
allele
|
CD24 V/V
|
Disease risk
|
Positive
|
|
MCAT
|
Homo sapiens
|
22q13.2
|
allele
|
K*
|
Disease risk
|
Positive
|
|
MCAT
|
Homo sapiens
|
22q13.2
|
allele
|
J*
|
Disease risk
|
Negative
|
|
IL-12B
|
Homo sapiens
|
5q33.3
|
SNP
|
rs3212227
|
Disease risk
|
Negative
|
|
IL-23R
|
Homo sapiens
|
1p31.3
|
SNP
|
rs2201841
|
Disease risk
|
Negative
|
|
IL-23R
|
Homo sapiens
|
1p31.3
|
SNP
|
rs10889677
|
Disease risk
|
Negative
|
|
IL-23R
|
Homo sapiens
|
1p31.3
|
SNP
|
rs7517847
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
DNA methylation
|
N/A
|
N/A
|
Positive
|
|
ACKR3
|
Homo sapiens
|
2q37.3
|
DNA methylation
|
N/A
|
N/A
|
Positive
|
|
GSTP1
|
Homo sapiens
|
11q13.2
|
allele
|
lle
|
Disease risk
|
Negative
|
|
GSTP1
|
Homo sapiens
|
11q13.2
|
allele
|
Val
|
Disease risk
|
Negative
|
|
OGG1
|
Homo sapiens
|
3p25.3
|
allele
|
Ser
|
Disease risk
|
Positive
|
|
OGG1
|
Homo sapiens
|
3p25.3
|
allele
|
Cys
|
Disease risk
|
Negative
|
|
XRCC1
|
Homo sapiens
|
19q13.31
|
allele
|
Arg
|
Disease risk
|
Negative
|
|
XRCC1
|
Homo sapiens
|
19q13.31
|
allele
|
Gln
|
Disease risk
|
Negative
|
|
GSTP1
|
Homo sapiens
|
11q13.2
|
genotype
|
Ile/Ile
|
Disease risk
|
Negative
|
|
GSTP1
|
Homo sapiens
|
11q13.2
|
genotype
|
Ile/Val
|
Disease risk
|
Negative
|
|
GSTP1
|
Homo sapiens
|
11q13.2
|
genotype
|
Val/Val
|
Disease risk
|
Negative
|
|
GSTP1
|
Homo sapiens
|
11q13.2
|
genotype
|
Ile/Val +Val/Val
|
Disease risk
|
Negative
|
|
OGG1
|
Homo sapiens
|
3p25.3
|
genotype
|
Ser/Ser
|
Disease risk
|
Negative
|
|
OGG1
|
Homo sapiens
|
3p25.3
|
genotype
|
Ser/Cys
|
Disease risk
|
Positive
|
|
OGG1
|
Homo sapiens
|
3p25.3
|
genotype
|
Cys/Cys
|
Disease risk
|
Positive
|
|
OGG1
|
Homo sapiens
|
3p25.3
|
genotype
|
Ser/Cys + Cys/Cys
|
Disease risk
|
Negative
|
|
XRCC1
|
Homo sapiens
|
19q13.31
|
genotype
|
Arg/Arg
|
Disease risk
|
Negative
|
|
XRCC1
|
Homo sapiens
|
19q13.31
|
genotype
|
Arg/Gln
|
Disease risk
|
Negative
|
|
XRCC1
|
Homo sapiens
|
19q13.31
|
genotype
|
Gln/Gln
|
Disease risk
|
Negative
|
|
XRCC1
|
Homo sapiens
|
19q13.31
|
genotype
|
Arg/Gln + Gln/Gln
|
Disease risk
|
Positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB10501
|
Phenotypic risk
|
Positive
|
|
TAP1
|
Homo sapiens
|
6p21.32
|
allele
|
Ile
|
Disease risk
|
Negative
|
|
TAP1
|
Homo sapiens
|
6p21.32
|
allele
|
Val
|
Disease risk
|
Negative
|
|
TAP1
|
Homo sapiens
|
6p21.32
|
allele
|
Asp
|
Disease risk
|
Negative
|
|
TAP1
|
Homo sapiens
|
6p21.32
|
allele
|
Gly
|
Disease risk
|
Negative
|
|
TAP1
|
Homo sapiens
|
6p21.32
|
genotype
|
Ile/Ile
|
Disease risk
|
Negative
|
|
TAP1
|
Homo sapiens
|
6p21.32
|
genotype
|
Ile/Val
|
Disease risk
|
Negative
|
|
TAP1
|
Homo sapiens
|
6p21.32
|
genotype
|
Val/Val
|
Disease risk
|
Negative
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
allele
|
Ile
|
Disease risk
|
Negative
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
allele
|
Val
|
Disease risk
|
Negative
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
allele
|
Asp
|
Disease risk
|
Negative
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
allele
|
Gly
|
Disease risk
|
Negative
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
genotype
|
Ile/Ile
|
Disease risk
|
Negative
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
genotype
|
Ile/Val
|
Disease risk
|
Negative
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
genotype
|
Val/Val
|
Disease risk
|
Negative
|
|
CNR1
|
Homo sapiens
|
6q15
|
SNP
|
RS1049353(GG/GA/AA)
|
Disease risk
|
Negative
|
|
CNR1
|
Homo sapiens
|
6q15
|
SNP
|
RS806377(GG/GA/AA)
|
Disease risk
|
Negative
|
|
CNR1
|
Homo sapiens
|
6q15
|
SNP
|
RS806380(TT/TC/CC)
|
Disease risk
|
Negative
|
|
KLRB1
|
Homo sapiens
|
12p13.31
|
SNP
|
rs4763655
|
Disease risk
|
Positive
|
|
GSTT1
|
Homo sapiens
|
22q11.23
|
genotype
|
M1/T1
|
Disease risk
|
Positive
|
|
GSTM1
|
Homo sapiens
|
1p13.3
|
genotype
|
M1/T1
|
Disease risk
|
Positive
|
|
GSTT1
|
Homo sapiens
|
22q11.23
|
genotype
|
M1/T1
|
Phenotypic risk
|
Positive
|
|
GSTM1
|
Homo sapiens
|
1p13.3
|
genotype
|
M1/T1
|
Phenotypic risk
|
Positive
|
|
GSTT1
|
Homo sapiens
|
22q11.23
|
genotype
|
M1/T1
|
Phenotypic risk
|
Negative
|
|
GSTM1
|
Homo sapiens
|
1p13.3
|
genotype
|
M1/T1
|
Phenotypic risk
|
Negative
|
|
ARHGAP45
|
Homo sapiens
|
19p13.3
|
polymorphisms
|
HA-1 1500/504(CA,CA/TG,TG)
|
Disease risk
|
Negative
|
|
ARHGAP45
|
Homo sapiens
|
19p13.3
|
polymorphisms
|
HA-1 865(T,T/A,A)
|
Disease risk
|
Negative
|
|
ARHGAP45
|
Homo sapiens
|
19p13.3
|
polymorphisms
|
HA-1 1403(G,G/A,A)
|
Disease risk
|
Negative
|
|
ABCA7
|
Homo sapiens
|
19p13.3
|
polymorphisms
|
ABCA7 955(A, A/G, G)
|
Disease risk
|
Negative
|
|
ABCA7
|
Homo sapiens
|
19p13.3
|
polymorphisms
|
ABCA7 4580(C, C/G, G)
|
Disease risk
|
Negative
|
|
CIITA
|
Homo sapiens
|
16p13.13
|
SNP
|
rs3087456
|
Disease risk
|
Negative
|
|
CIITA
|
Homo sapiens
|
16p13.13
|
SNP
|
rs4774
|
Disease risk
|
Positive
|
|
PTPN22
|
Homo sapiens
|
1p13.2
|
polymorphisms
|
620W
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
E148Q
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
P369S
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
F479L
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
M680I (G/C)
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
I692 DEL
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
M694V
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
M694I
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
K695R
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
V726A
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
A744S
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
R761H
|
Phenotypic risk
|
Negative
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
polymorphisms
|
M680I (G/A)
|
Phenotypic risk
|
Negative
|
|
HPRT1
|
Homo sapiens
|
Xq26.2-q26.3
|
mutant frequency
|
N/A
|
Phenotypic risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15:01
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15:02
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*14:04
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13:02
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*12:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*11:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*10:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*08:03:02
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*07:01:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*04:03:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*04:01:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*03:01:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*01:01:01
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*02:01
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*03:01
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*03:02
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*03:03
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*04:01
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*05:01
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*06:01
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*06:02
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*06:09
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×01:01-DQB1×05:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×03:01-DQB1×02:02
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×04:03-DQB1×03:02
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×07:01-DQB1×02:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×07:01-DQB1×03:03
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×08:03-DQB1×03:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×10:01-DQB1×05:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×11:01-DQB1×03:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×13:02-DQB1×06:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×13:01-DQB1×06:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×14:04-DQB1×05:03
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×15:01 a-DQB1×05:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1×15:01a-DQB1×06:02
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932(CC)
|
Disease risk
|
Positive
|
|
PTPN22
|
Homo sapiens
|
1p13.2
|
SNP
|
1858 SNP
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs155141
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs1449263
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs3770138
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs3770136
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs3770132
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs155106
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs1038034
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs2305586
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs3770115
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs3816521
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs3770111
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs6714061
|
Disease risk
|
Negative
|
|
ITGA4
|
Homo sapiens
|
2q31.3
|
SNP
|
Rs4667319
|
Disease risk
|
Negative
|
|
SCN10A
|
Homo sapiens
|
3p22.2
|
SNP
|
rs6801957
|
Phenotypic risk
|
Positive
|
|
SCN10A
|
Homo sapiens
|
3p22.2
|
SNP
|
rs6795970
|
Phenotypic risk
|
Positive
|
|
CYBB
|
Homo sapiens
|
Xp21.1-p11.4
|
SNP
|
rs72619425
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15:01
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*03:01
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*04:05
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*15:03
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*11:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*04:01:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*16:02
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*14:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*09:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*08:04
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*11:02
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*07:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13:03
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*01:02
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*03:02
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*10:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*13:02
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*12:01
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*01:01
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*02e
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*03:01
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*03:02
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*03:03
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*04:02
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*05:01
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*05:02
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*05:03
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*06:02
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*06:03
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*06:04
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*06:09
|
Disease risk
|
Negative
|
|
ST8SIA1
|
Homo sapiens
|
12p12.1
|
SNP
|
rs704219
|
Disease risk
|
Negative
|
|
ST8SIA1
|
Homo sapiens
|
12p12.1
|
SNP
|
rs2041906
|
Disease risk
|
Negative
|
|
ST8SIA1
|
Homo sapiens
|
12p12.1
|
SNP
|
rs1558793
|
Disease risk
|
Negative
|
|
ST8SIA1
|
Homo sapiens
|
12p12.1
|
SNP
|
rs4762896
|
Disease risk
|
Negative
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs4810485*T
|
Disease risk
|
Positive
|
|
CD86
|
Homo sapiens
|
3q13.33
|
SNP
|
rs9282641*G
|
Disease risk
|
Positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs4810485*T
|
Disease risk
|
Positive
|
|
GAL
|
Homo sapiens
|
11q13.2
|
allele
|
rs948854(G)
|
Disease risk
|
Positive
|
|
GAL
|
Homo sapiens
|
11q13.2
|
allele
|
rs948854(G)
|
Phenotypic risk
|
Positive
|
|
GAL
|
Homo sapiens
|
11q13.2
|
SNP
|
rs948854
|
Phenotypic risk
|
Positive
|
|
PRNP
|
Homo sapiens
|
20p13
|
SNP
|
Prnp129 M/V
|
Disease risk
|
Negative
|
|
PRNP
|
Homo sapiens
|
20p13
|
SNP
|
Prnp129 M/V
|
Disease risk
|
Negative
|
|
VEGFA
|
Homo sapiens
|
6p21.1
|
genotype
|
rs1413711(T/T)
|
Disease risk
|
Positive
|
|
VEGFA
|
Homo sapiens
|
6p21.1
|
genotype
|
rs1413711(T/C)
|
Disease risk
|
Positive
|
|
VEGFA
|
Homo sapiens
|
6p21.1
|
genotype
|
rs1413711(C/C)
|
Disease risk
|
Positive
|
|
TIMP3
|
Homo sapiens
|
22q12.3
|
genotype
|
rs9621532(A/A)
|
Disease risk
|
Negative
|
|
TIMP3
|
Homo sapiens
|
22q12.3
|
genotype
|
rs9621532(C/C)
|
Disease risk
|
Negative
|
|
TIMP3
|
Homo sapiens
|
22q12.3
|
genotype
|
rs9621532(A/C)
|
Disease risk
|
Negative
|
|
IL6
|
Homo sapiens
|
7p15.3
|
genotype
|
rs1800796(C/G)
|
Disease risk
|
Negative
|
|
IL6
|
Homo sapiens
|
7p15.3
|
genotype
|
rs1800796(G/G)
|
Disease risk
|
Negative
|
|
IL6
|
Homo sapiens
|
7p15.3
|
genotype
|
rs1800796(C/C)
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0101
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0102
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0103
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0301
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0401
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0402
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0403
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0404
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0405
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0407
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0701
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0801
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0901
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1001
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1101
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1103
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1104
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1201
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1301
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1302
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1303
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1401
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1501
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1502
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1601
|
Disease risk
|
Negative
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
missense
|
C677T
|
Disease risk
|
Negative
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
missense
|
A1298C
|
Disease risk
|
Positive
|
|
SPP1
|
Homo sapiens
|
4q22.1
|
polymorphisms
|
5891C/T
|
Phenotypic risk
|
Positive
|
|
SPP1
|
Homo sapiens
|
4q22.1
|
polymorphisms
|
7052T/C
|
Phenotypic risk
|
Negative
|
|
SPP1
|
Homo sapiens
|
4q22.1
|
polymorphisms
|
1687A/G
|
Phenotypic risk
|
Negative
|
|
SPP1
|
Homo sapiens
|
4q22.1
|
polymorphisms
|
381T/C
|
Phenotypic risk
|
Negative
|
|
SPP1
|
Homo sapiens
|
4q22.1
|
polymorphisms
|
94 deletion/G
|
Phenotypic risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0101
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0102
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0103
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1501
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1502
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1601
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1602
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0301
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0303
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0401
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0402
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0403
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0404
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0405
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0406
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0407
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0408
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1101
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1102
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1103
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1104
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1201
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1301
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1302
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1303
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1305
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1405
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1402
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0701
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0801
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0804
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*0901
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1001
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0101
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0102
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0103
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0104
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0201
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0301
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0302
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0303
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0401
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0501
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0503
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0501
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0502
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0503
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0609
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0602
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0603
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0604
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0605
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0606
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0201
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0301
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0302
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0303
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0402
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1501
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DRB1*1501
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQA1*0201
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DQB1*0602
|
Disease risk
|
Positive
|
|
HLA-DPA1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPA1*0103
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DPB1*04
|
Disease risk
|
Negative
|
|
ERVW-1
|
Homo sapiens
|
7q21.2
|
CNV
|
N/A
|
Disease risk
|
Positive
|
|
NFASC
|
Homo sapiens
|
1q32.1
|
SNP
|
rs12368653
|
Disease risk
|
Positive
|
|
NFASC
|
Homo sapiens
|
1q32.1
|
SNP
|
rs703842
|
Disease risk
|
Positive
|
|
PDLIM7
|
Homo sapiens
|
5q35.3
|
genotype
|
N/A
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
polymorphisms
|
Cw1
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
polymorphisms
|
Cw2
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
polymorphisms
|
Cw3
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
polymorphisms
|
Cw4
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
polymorphisms
|
Cw5
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
polymorphisms
|
Cw6
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
polymorphisms
|
Cw7
|
Disease risk
|
Negative
|
|
HLA-C
|
Homo sapiens
|
N/A
|
polymorphisms
|
Cw8
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR1
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR2
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR3
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR4
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR5
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR6
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
DR7
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A1
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A2
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A3
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A11
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A23
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A24
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A25
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A26
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A28
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A29
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A30+31
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
A32
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
polymorphisms
|
Aw33
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B5
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B7
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B8
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B12
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B13
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B14
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B15
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B17
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B18
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B21
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
Bw22
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B27
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B35
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B37
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B38
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B39
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B40
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B41
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
B47
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
Bw53
|
Disease risk
|
Negative
|
|
IGH
|
Homo sapiens
|
14q32.33
|
rearrangement
|
N/A
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722495
|
Phenotypic risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Phenotypic risk
|
Positive
|
|
TRIM5
|
Homo sapiens
|
11p15.4
|
SNP
|
rs3802981
|
Disease risk
|
Positive
|
|
HERV-Fc1
|
Homo sapiens
|
Xq21.33
|
SNP
|
rs391745
|
Disease risk
|
Positive
|
|
FAS
|
Homo sapiens
|
10q23.31
|
SNP
|
rs2234767
|
Disease risk
|
Positive
|
|
DDT
|
Homo sapiens
|
22q11.23
|
SNP
|
rs755622
|
Disease risk
|
Positive
|
|
CBLB
|
Homo sapiens
|
3q13.11
|
SNP
|
rs9657904
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
variable number of tandem repeat polymorphism
|
Disease risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
allele
|
Vβ1I(25kb)
|
Disease risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
allele
|
Cβ
|
Disease risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
allele
|
Vβ1I
|
Disease risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
allele
|
HLA-A3
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
allele
|
HLA-B7
|
Disease risk
|
Positive
|
|
IL10
|
Homo sapiens
|
1q32.1
|
N/A
|
IL-10G7-11
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
allele
|
IL-10G13-15
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
allele
|
IL-10G12
|
Disease risk
|
Positive
|
|
IL10
|
Homo sapiens
|
1q32.1
|
allele
|
IL-10R2-4
|
Disease risk
|
Negative
|
|
HAVCR2
|
Homo sapiens
|
5q33.3
|
SNP
|
rs10515746
|
Disease risk
|
Positive
|
|
HAVCR2
|
Homo sapiens
|
5q33.3
|
SNP
|
rs10053538
|
Disease risk
|
Positive
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs2221903
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs2055979
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs2055979
|
Phenotypic risk
|
Positive
|
|
IL16
|
Homo sapiens
|
15q25.1
|
SNP
|
rs4072111
|
Disease risk
|
Positive
|
|
IL16
|
Homo sapiens
|
15q25.1
|
SNP
|
rs11556218
|
Disease risk
|
Positive
|
|
NINJ2
|
Homo sapiens
|
12p13.33
|
SNP
|
rs7298096
|
Treatment risk
|
Positive
|
|
SLC6A4
|
Homo sapiens
|
17q11.2
|
polymorphisms
|
5-HTTLPR, rs35521, and STin2VNTR
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Negative
|
|
IL25
|
Homo sapiens
|
14q11.2
|
polymorphisms
|
c424C/A
|
Disease risk
|
Negative
|
|
POLG
|
Homo sapiens
|
15q26.1
|
POLG CAG repeat length
|
N/A
|
Disease risk
|
Negative
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
polymorphisms
|
1562 C/T
|
Disease risk
|
Positive
|
|
TBX21
|
Homo sapiens
|
17q21.32
|
polymorphisms
|
1514T > C
|
Disease risk
|
Positive
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs17824933
|
Disease risk
|
Positive
|
|
TMEM39A
|
Homo sapiens
|
3q13.33
|
SNP
|
rs1132200
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Positive
|
|
IL10
|
Homo sapiens
|
1q32.1
|
SNP
|
rs1800871, rs1800872, and rs1800896
|
Disease risk
|
Negative
|
|
NOS3
|
Homo sapiens
|
7q36.1
|
SNP
|
rs2070744
|
Disease risk
|
Positive
|
|
NOS3
|
Homo sapiens
|
7q36.1
|
SNP
|
rs1799983
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
SNP
|
rs3761547, rs3761548
|
Disease risk
|
Negative
|
|
GATA3
|
Homo sapiens
|
10p14
|
SNP
|
rs3824662
|
Disease risk
|
Negative
|
|
PDCD1
|
Homo sapiens
|
2q37.3
|
SNP
|
rs36084323
|
Disease risk
|
Negative
|
|
PDCD1
|
Homo sapiens
|
2q37.3
|
SNP
|
rs11568821
|
Disease risk
|
Positive
|
|
PDCD1
|
Homo sapiens
|
2q37.3
|
SNP
|
rs2227981
|
Disease risk
|
Positive
|
|
AQP4
|
Homo sapiens
|
18q11.2
|
SNP
|
rs16942851, rs1058424, rs335929, rs335931, rs162007, rs3763043
|
Disease risk
|
Negative
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
allele
|
Δ32
|
Disease risk
|
Negative
|
|
IL1A
|
Homo sapiens
|
2q14.1
|
SNP
|
rs1800587
|
Disease risk
|
Negative
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
SNP
|
rs16944
|
Disease risk
|
Positive
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
SNP
|
rs1143634
|
Disease risk
|
Negative
|
|
IL1R1
|
Homo sapiens
|
2q11.2-q12.1
|
SNP
|
rs2234650
|
Disease risk
|
Positive
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
SNP
|
rs315952
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
SNP
|
rs2232369
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2225870
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs1544410
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236
|
Disease risk
|
Positive
|
|
FCRL5
|
Homo sapiens
|
1q23.1
|
SNP
|
rs2012199
|
Disease risk
|
Positive
|
|
FCRL5
|
Homo sapiens
|
1q23.1
|
SNP
|
rs6679793
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs7718919
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs11567685
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Positive
|
|
HSPA1A
|
Homo sapiens
|
6p21.33
|
SNP
|
rs1061581
|
Disease risk
|
Negative
|
|
IL7
|
Homo sapiens
|
8q21.13
|
SNP
|
rs1520333
|
Disease risk
|
Positive
|
|
AIRE
|
Homo sapiens
|
21q22.3
|
SNP
|
rs1800520
|
Disease risk
|
Positive
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
polymorphisms
|
MMP-9 -1562 C/T
|
Disease risk
|
Positive
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
polymorphisms
|
MMP-9 -1562 C/T
|
Disease risk
|
Positive
|
|
CD226
|
Homo sapiens
|
18q22.2
|
SNP
|
rs763361
|
Disease risk
|
Negative
|
|
DNMT3B
|
Homo sapiens
|
20q11.21
|
SNP
|
rs1569686
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphisms
|
N/A
|
Disease risk
|
Positive
|
|
HFE
|
Homo sapiens
|
6p22.2
|
polymorphisms
|
C282Y
|
Disease risk
|
Negative
|
|
HFE
|
Homo sapiens
|
6p22.2
|
polymorphisms
|
H63D
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphisms
|
from DR1 to DR18
|
Disease risk
|
Positive
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
SNP
|
rs3918242
|
Disease risk
|
Positive
|
|
IFNG
|
Homo sapiens
|
12q15
|
polymorphisms
|
at position +874
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
HLA-DRB1*15 allele(DRB1*01,DRB1*03,DRB1*04)
|
Treatment risk
|
Positive
|
|
IL10
|
Homo sapiens
|
1q32.1
|
SNP
|
IL-10 -1082 G/G and IL-10 -819 C/C
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
HLA-DRB1*15
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
SNP
|
SNP469,SNP457,SNP992,APOE,SNP952,SNP873,SNP888,SNP988
|
Disease risk
|
Positive
|
|
PTPRC
|
Homo sapiens
|
1q31.3-q32.1
|
SNP
|
exon 4 (C→G nucleotide transition in position 77)
|
Disease risk
|
Positive
|
|
IFNG
|
Homo sapiens
|
12q15
|
SNP
|
IFN-γ intron III (+2118 site A/G and +3586 site G/ACT).
|
Disease risk
|
Positive
|
|
IKZF3
|
Homo sapiens
|
17q12-q21.1
|
SNP
|
rs907091
|
Disease risk
|
Positive
|
|
CD69
|
Homo sapiens
|
12p13.31
|
SNP
|
rs11052877
|
Disease risk
|
Negative
|
|
IQGAP1
|
Homo sapiens
|
15q26.1
|
SNP
|
rs11609
|
Disease risk
|
Positive
|
|
IL18
|
Homo sapiens
|
11q23.1
|
SNP
|
IL-18 -137C/G and -607C/A
|
Disease risk
|
Positive
|
|
IL32
|
Homo sapiens
|
16p13.3
|
SNP
|
rs45499297
|
Disease risk
|
Positive
|
|
IL2
|
Homo sapiens
|
4q27
|
SNP
|
631 and 475 IL-2 promoter polymorphisms
|
Disease risk
|
Negative
|
|
MIF
|
Homo sapiens
|
22q11.23
|
SNP
|
rs755622
|
Disease risk
|
Negative
|
|
FAS
|
Homo sapiens
|
10q23.31
|
SNP
|
a band at 189 bp (allele G) or a band at 233 bp (allele A)
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
HLA-DRB1*15+/-
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
SNP
|
HLA-A*02+/-
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
SNP
|
HLA-B*07+/-
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
Exon 10 C/T
|
Disease risk
|
Positive
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
two promoter region microsatellites, (CCTTT)n and (TAAA)n, the original exon 10 C/T SNP, and an additional SNP within exon16, C/T (S569L)
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
CTLA-4-318, CTLA-4+49
|
Disease risk
|
Negative
|
|
CD28
|
Homo sapiens
|
2q33.2
|
SNP
|
CD28-I3+17
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
HLA-DRB1*1501, DRB1*04, DQB1*02,DQB1*0302, DQB1*0602
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
polymorphisms
|
N/A
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
polymorphisms
|
N/A
|
Disease risk
|
Negative
|
|
CYP27A1
|
Homo sapiens
|
2q35
|
polymorphisms
|
N/A
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3135388
|
Disease risk
|
Positive
|
|
DIPK1A
|
Homo sapiens
|
1p22.1
|
SNP
|
rs7536563
|
Disease risk
|
Positive
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs725613, rs12708716
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286, rs35285258
|
Disease risk
|
Positive
|
|
RPL5
|
Homo sapiens
|
1p22.1
|
SNP
|
rs10735781 rs6680578 rs6604026
|
Disease risk
|
Positive
|
|
KANK1
|
Homo sapiens
|
9p24.3
|
SNP
|
rs10975200
|
Disease risk
|
Positive
|
|
MBOAT2
|
Homo sapiens
|
2p25.1
|
SNP
|
rs11109670
|
Disease risk
|
Positive
|
|
TBC1D2
|
Homo sapiens
|
9q22.33
|
SNP
|
rs16914086
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
*1501,*0301,*0701,*1104,*0102
|
Phenotypic risk
|
Positive
|
|
C4A
|
Homo sapiens
|
6p21.33
|
allele
|
C4AQ0(null allele at the C4A locus)
|
Disease risk
|
Positive
|
|
NFKBIA
|
Homo sapiens
|
14q13.2
|
SNP
|
rs3138053
|
Disease risk
|
Positive
|
|
NFKBIA
|
Homo sapiens
|
14q13.2
|
SNP
|
rs2233406
|
Disease risk
|
Positive
|
|
NFKBIA
|
Homo sapiens
|
14q13.2
|
SNP
|
rs2233408
|
Disease risk
|
Negative
|
|
IL6
|
Homo sapiens
|
7p15.3
|
allele
|
A1,A2,A3,A4,A5,A6,A7,A8d,A9
|
Disease risk
|
Negative
|
|
IL6
|
Homo sapiens
|
7p15.3
|
allele
|
A1,A2,A3,A4,A5,A6,A7,A8d,A9
|
Phenotypic risk
|
Positive
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
allele
|
TNFa allele,TNFb allele,TNFa, b combination
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs7041, rs4588
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs7041, rs4588
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs7041, rs4588
|
Disease risk
|
Positive
|
|
ERG
|
Homo sapiens
|
21q22.2
|
polymorphism
|
PvuII
|
Disease risk
|
Positive
|
|
ERG
|
Homo sapiens
|
21q22.2
|
polymorphism
|
Xba
|
Disease risk
|
Negative
|
|
CD24
|
Homo sapiens
|
6q21
|
SNP
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
haplotype
|
HLA-DRB1*15:01 haplotype
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
polymorphism
|
TaqI, ApaI
|
Disease risk
|
Negative
|
|
STK11
|
Homo sapiens
|
19p13.3
|
SNP
|
rs9282860
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
SNP
|
N/A
|
Phenotypic risk
|
Positive
|
|
IL27
|
Homo sapiens
|
16p12.1-p11.2
|
polymorphism
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Phenotypic risk
|
Positive
|
|
HLA-DPA1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DPw4
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
HLA-DR2
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
N/A
|
Disease risk
|
Negative
|
|
LILRA3
|
Homo sapiens
|
19q13.4
|
Deletion
|
6.7-kbp
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
HLA-DRB1*1501
|
Disease risk
|
Positive
|
|
PVR
|
Homo sapiens
|
19q13.31
|
polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
allele
|
N/A
|
Disease risk
|
Negative
|
|
TARDBP
|
Homo sapiens
|
1p36.22
|
mutation
|
Ala382Thr
|
Disease risk
|
Negative
|
|
C9orf72
|
Homo sapiens
|
9p21.2
|
expansion
|
N/A
|
Disease risk
|
Negative
|
|
IL7
|
Homo sapiens
|
8q21.13
|
SNP
|
rs1520333
|
Disease risk
|
Positive
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs1414273
|
Disease risk
|
Negative
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs1800693
|
Disease risk
|
Negative
|
|
EVI5
|
Homo sapiens
|
1p22.1
|
SNP
|
rs11808092
|
Disease risk
|
Positive
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
SNP
|
rs1801131
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs9271366
|
Disease risk
|
Positive
|
|
B2m
|
Homo sapiens
|
2 E5; 2 60.55 cM
|
Deletion
|
class I-deficient (β2m/)
|
Disease risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
DNA length polymorphism
|
RraI, EcoR
|
Disease risk
|
Negative
|
|
TNFRSF6B
|
Homo sapiens
|
20q13.33
|
SNP
|
rs4809330(*)A
|
Disease risk
|
Positive
|
|
TNFRSF14
|
Homo sapiens
|
1p36.32
|
SNP
|
rs6684865(*)A
|
Disease risk
|
Positive
|
|
MOG
|
Homo sapiens
|
6p22.1
|
restriction fragment length polymorphism (RFLP)
|
1.9 kb Taq 1
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
A49G
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs13188960
|
Disease risk
|
Positive
|
|
LAG3
|
Homo sapiens
|
12p13.31
|
SNP
|
rs2365095
|
Disease risk
|
Positive
|
|
IGH
|
Homo sapiens
|
14q32.33
|
CNV
|
VH4-34 genecopy number
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
genotype
|
DRB1*15
|
Phenotypic risk
|
Positive
|
|
MC1R
|
Homo sapiens
|
16q24.3
|
the red hair color (RHC) variant
|
Arg151Cys, Arg160Trp, Asp294His
|
Disease risk
|
Positive
|
|
KLC1
|
Homo sapiens
|
14q32.33
|
SNP
|
rs8702
|
Disease risk
|
Positive
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
Deletion
|
Δ32 deletion allele
|
Treatment risk
|
Negative
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
Deletion
|
Δ32 deletion allele
|
Phenotypic risk
|
Positive
|
|
LAG3
|
Homo sapiens
|
12p13.31
|
SNP
|
rs870849
|
Disease risk
|
Negative
|
|
CD4
|
Homo sapiens
|
12p13.31
|
SNP
|
rs1922452
|
Disease risk
|
Negative
|
|
CD4
|
Homo sapiens
|
12p13.31
|
SNP
|
rs951818
|
Disease risk
|
Negative
|
|
IL1A
|
Homo sapiens
|
2q14.1
|
polymorphism
|
IL-1 α(-889 T/C)
|
Disease risk
|
Positive
|
|
IL1R1
|
Homo sapiens
|
2q11.2-q12.1
|
polymorphism
|
IL-1R (pst1 1970 C/T)
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphism
|
TNFF-α (-308 G/A and -238G/A)
|
Disease risk
|
Positive
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
polymorphism
|
IL-1β (-511 C/T and +3962 C/T)
|
Disease risk
|
Positive
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
polymorphism
|
IL-1Ra (mspal 11100 T/C)
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
504 C (GCA haplotype)
|
Disease risk
|
Positive
|
|
EIF2B5
|
Homo sapiens
|
3q27.1
|
SNP
|
rs843358
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphism
|
TNF-α 376
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
SNP
|
rs1800629
|
Disease risk
|
Positive
|
|
GSK3B
|
Homo sapiens
|
3q13.33
|
SNP
|
rs334558
|
Disease risk
|
Positive
|
|
TNFSF10
|
Homo sapiens
|
3q26.31
|
polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
FTO
|
Homo sapiens
|
16q12.2
|
SNP
|
rs9939609
|
Disease risk
|
Negative
|
|
FTO
|
Homo sapiens
|
16q12.2
|
SNP
|
rs9939609
|
Phenotypic risk
|
Positive
|
|
GSTP1
|
Homo sapiens
|
11q13.2
|
polymorphism
|
A313 G
|
Disease risk
|
Negative
|
|
NQO1
|
Homo sapiens
|
16q22.1
|
polymorphism
|
C609 T
|
Disease risk
|
Positive
|
|
GSTP1
|
Homo sapiens
|
11q13.2
|
polymorphism
|
A313 G
|
Phenotypic risk
|
Positive
|
|
MT-ND1
|
Homo sapiens
|
N/A
|
polymorphism
|
Nt 4216 T>C
|
Disease risk
|
Positive
|
|
MT-ND2
|
Homo sapiens
|
N/A
|
polymorphism
|
Nt 5153 A>G
|
Disease risk
|
Positive
|
|
MT-ND3
|
Homo sapiens
|
N/A
|
polymorphism
|
Nt 10142 C>T
|
Disease risk
|
Positive
|
|
MT-ND4
|
Homo sapiens
|
N/A
|
polymorphism
|
Nt 11353 T>C, Nt 11935 T>C, Nt 12062 C>T
|
Disease risk
|
Positive
|
|
MT-ND5
|
Homo sapiens
|
N/A
|
polymorphism
|
Nt 13042 G>A, Nt 13708 G>A
|
Disease risk
|
Positive
|
|
MT-ND6
|
Homo sapiens
|
N/A
|
polymorphism
|
Nt 14179 G>A
|
Disease risk
|
Positive
|
|
TRA
|
Homo sapiens
|
14q11.2
|
polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
polymorphism
|
N363S, ER22/23EK, BclIG
|
Disease risk
|
Positive
|
|
PRNP
|
Homo sapiens
|
20p13
|
polymorphism
|
129Val
|
Disease risk
|
Negative
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
polymorphism
|
1377
|
Disease risk
|
Positive
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
polymorphism
|
TLR9-1486
|
Disease risk
|
Negative
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
polymorphism
|
TLR9 2848
|
Disease risk
|
Positive
|
|
IFIH1
|
Homo sapiens
|
2q24.2
|
SNP
|
rs2111485, rs1990760, rs3747517, rs13023380
|
Disease risk
|
Negative
|
|
RIGI
|
Homo sapiens
|
9p21.1
|
SNP
|
rs12555727, rs10813825, rs6476363, rs659527, rs626214
|
Disease risk
|
Negative
|
|
DHX58
|
Homo sapiens
|
17q21.2
|
SNP
|
rs2074158
|
Disease risk
|
Negative
|
|
MAVS
|
Homo sapiens
|
20p13
|
SNP
|
rs4815617, rs7262903, rs17857295, rs45437096, rs16989000
|
Disease risk
|
Negative
|
|
IGHV4-39
|
Homo sapiens
|
14q32.33
|
Deletion
|
IGHV4-39
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
HAMP
|
Homo sapiens
|
19q13.12
|
SNP
|
rs10421768
|
Phenotypic risk
|
Positive
|
|
TF
|
Homo sapiens
|
3q22.1
|
SNP
|
rs1049296
|
Phenotypic risk
|
Positive
|
|
TF
|
Homo sapiens
|
3q22.1
|
SNP
|
rs3811647
|
Phenotypic risk
|
Positive
|
|
TFR2
|
Homo sapiens
|
7q22.1
|
SNP
|
rs7385804
|
Phenotypic risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
haplotype
|
Hap 1, Hap 2, Hap 4
|
Treatment risk
|
Positive
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
allele
|
CCR5 Delta32
|
Disease risk
|
Negative
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
polymorphism
|
promoter -2459
|
Disease risk
|
Negative
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
allele
|
CCR5 Delta32
|
Treatment risk
|
Negative
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
polymorphism
|
promoter -2459
|
Treatment risk
|
Negative
|
|
IL17A
|
Homo sapiens
|
6p12.2
|
SNP
|
rs2275913
|
Disease risk
|
Negative
|
|
IL17F
|
Homo sapiens
|
6p12.2
|
SNP
|
rs763780
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DRB1*0301
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
allele
|
HLA-B*52
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2228570 (Fok1)
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236 (Taq1)
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Phenotypic risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722489
|
Phenotypic risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs7090512
|
Phenotypic risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722489
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphism
|
TNF-α -308
|
Disease risk
|
Negative
|
|
LTA
|
Homo sapiens
|
6p21.33
|
allele
|
TNF-β +252
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
allele
|
IL-4 (-590)
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DRB11501
|
Disease risk
|
Positive
|
|
GFI1
|
Homo sapiens
|
1p22.1
|
SNP
|
rs11804321
|
Disease risk
|
Positive
|
|
CIITA
|
Homo sapiens
|
16p13.13
|
haplotype
|
168A→G
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DRB1*15
|
Disease risk
|
Negative
|
|
CD86
|
Homo sapiens
|
3q13.33
|
SNP
|
rs928264
|
Disease risk
|
Negative
|
|
PTAFR
|
Homo sapiens
|
1p35.3
|
polymorphism
|
A224D
|
Disease risk
|
Positive
|
|
GAS5
|
Homo sapiens
|
1q25.1
|
SNP
|
rs2067079
|
Disease risk
|
Positive
|
|
GAS5
|
Homo sapiens
|
1q25.1
|
SNP
|
rs6790
|
Disease risk
|
Negative
|
|
CBLB
|
Homo sapiens
|
3q13.11
|
SNP
|
rs12487066
|
Treatment risk
|
Negative
|
|
GRIA3
|
Homo sapiens
|
Xq25
|
SNP
|
rs12557782
|
Treatment risk
|
Positive
|
|
CTSS
|
Homo sapiens
|
1q21.3
|
SNP
|
rs1136774
|
Treatment risk
|
Positive
|
|
OAS1
|
Homo sapiens
|
12q24.13
|
SNP
|
rs10774671
|
Treatment risk
|
Negative
|
|
TNFRSF10A
|
Homo sapiens
|
8p21.3
|
SNP
|
rs20576
|
Treatment risk
|
Negative
|
|
IFI16
|
Homo sapiens
|
1q23.1
|
CNV
|
rs1772408
|
Disease risk
|
Negative
|
|
IFI16
|
Homo sapiens
|
1q23.1
|
CNV
|
rs62621173
|
Disease risk
|
Negative
|
|
IFI16
|
Homo sapiens
|
1q23.1
|
CNV
|
rs1772408
|
Disease risk
|
Negative
|
|
IFI16
|
Homo sapiens
|
1q23.1
|
CNV
|
rs62621173
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphism
|
TNF1/l ,TNF1 /2 ,TNF2/2
|
Disease risk
|
Negative
|
|
SYN3
|
Homo sapiens
|
22q12.3
|
SNP
|
g–196 (G > A)
|
Disease risk
|
Negative
|
|
SYN3
|
Homo sapiens
|
22q12.3
|
SNP
|
g–631 (C > G)
|
Disease risk
|
Positive
|
|
SYN3
|
Homo sapiens
|
22q12.3
|
haplotype
|
C631 haplotype
|
Disease risk
|
Positive
|
|
SYN3
|
Homo sapiens
|
22q12.3
|
haplotype
|
A196 haplotype
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DRB1*0901
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DRB1*1501
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
allele
|
DPB1*0501
|
Disease risk
|
Negative
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
polymorphism, allele
|
N/A
|
Disease risk
|
Negative
|
|
Val158Met
|
Homo sapiens
|
22q11.21
|
polymorphism
|
rs4680 Val158Met (Val/Val, Val/Met,and Met/Met)
|
Disease risk
|
Negative
|
|
Val158Met
|
Homo sapiens
|
22q11.21
|
polymorphism
|
rs4680 Val158Met (Val/Val, Val/Met,and Met/Met)
|
Phenotypic risk
|
Positive
|
|
IL1A
|
Homo sapiens
|
2q14.1
|
polymorphism
|
-889 C/T
|
Disease risk
|
Negative
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
polymorphism
|
-511 C/T
|
Disease risk
|
Negative
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
SNP
|
rs3761548
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
SNP
|
rs2232365
|
Disease risk
|
Positive
|
|
CNTF
|
Homo sapiens
|
11q12.1
|
SNP
|
the G-to-A CNTF null mutation at position -6 of the second exon(CNTF -/-)
|
Disease risk
|
Negative
|
|
IL2
|
Homo sapiens
|
4q27
|
allele
|
IL2 -330 GT , TT ,GG
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DRBl*I501,DRBS*0I01,DQAl*OlO2,DQB1*0602
|
Disease risk
|
Positive
|
|
NOS1
|
Homo sapiens
|
12q24.22
|
allele
|
N/A
|
Disease risk
|
Negative
|
|
NINJ2
|
Homo sapiens
|
12p13.33
|
SNP
|
rs11833579
|
Disease risk
|
Negative
|
|
NINJ2
|
Homo sapiens
|
12p13.33
|
SNP
|
rs3809263
|
Disease risk
|
Positive
|
|
PECAM1
|
Homo sapiens
|
17q23.3
|
allele
|
Amplicon length (bp):P1 (119),P2 (121),P3 (123),P4 (125),P5 (127),P6 (129),P7 (131)
|
Disease risk
|
Negative
|
|
MPO
|
Homo sapiens
|
17q22
|
allele
|
N/A
|
Disease risk
|
Negative
|
|
MPO
|
Homo sapiens
|
17q22
|
SNP
|
G/G, G/A and A/A
|
Disease risk
|
Negative
|
|
PRKAR1A
|
Homo sapiens
|
17q24.2
|
allele
|
N/A
|
Disease risk
|
Negative
|
|
SYN3
|
Homo sapiens
|
22q12.3
|
SNP
|
rs133946
|
Disease risk
|
Negative
|
|
SYN3
|
Homo sapiens
|
22q12.3
|
SNP
|
rs133945
|
Disease risk
|
Negative
|
|
APOC2
|
Homo sapiens
|
19q13.32
|
allele
|
(TG)n(AG)m allele
|
Disease risk
|
Positive
|
|
TNFSF10
|
Homo sapiens
|
3q26.31
|
SNP
|
1595C/T
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
allele
|
HLA-DQB1*0602
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
HLA-DRB1*15 +/-
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
residue 86 polymorphism
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3135388
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Phenotypic risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Phenotypic risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
polymorphism
|
N/A
|
Disease risk ,Phenotypic risk
|
Positive
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
allele
|
A2+,A2-
|
Disease risk
|
Positive
|
|
PNMT
|
Homo sapiens
|
17q12
|
polymorphism
|
G (-387)/A (-387) and G (-182)/A (-182)
|
Disease risk
|
Positive
|
|
NOTCH4
|
Homo sapiens
|
6p21.32
|
SNP
|
rs422951
|
Disease risk
|
Positive
|
|
HLA-DQA2
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3997849
|
Disease risk
|
Positive
|
|
CFB
|
Homo sapiens
|
6p21.33
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
STAT3
|
Homo sapiens
|
17q21.2
|
SNP
|
rs3809758/rs744166/rs1026916/rs12948909
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722489
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Negative
|
|
CCL2
|
Homo sapiens
|
17q12
|
SNP
|
-2138A>T
|
Disease risk
|
Positive
|
|
CCL11
|
Homo sapiens
|
17q12
|
SNP
|
-488C>A
|
Disease risk
|
Positive
|
|
IL6
|
Homo sapiens
|
7p15.3
|
polymorphism
|
C allele present or absent
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
allele
|
N/A
|
Disease risk
|
Negative
|
|
SERPINA1
|
Homo sapiens
|
14q32.13
|
allele
|
M3
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DRB1*1501
|
Phenotypic risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
DRB1*1501-positive and -negative
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
allele
|
HLA B*44
|
Disease risk
|
Positive
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
CD40
|
Homo sapiens
|
20q13.12
|
polymorphism
|
C/T
|
Disease risk
|
Negative
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs725613
|
Disease risk
|
Positive
|
|
IFNL3
|
Homo sapiens
|
19q13.2
|
SNP
|
rs8099917
|
Treatment risk
|
Negative
|
|
IFNL3
|
Homo sapiens
|
19q13.2
|
SNP
|
rs12979860
|
Treatment risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
HLA-DRB1*04:05 or *15:01
|
Phenotypic risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele-haplotype
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele-haplotype
|
N/A
|
Phenotypic risk
|
Positive
|
|
HLA-DRB2
|
Homo sapiens
|
6p21.3
|
allele-haplotype
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DRB3
|
Homo sapiens
|
6p21.3
|
allele-haplotype
|
N/A
|
Phenotypic risk
|
Positive
|
|
HLA-DRB4
|
Homo sapiens
|
6p21.3
|
allele-haplotype
|
N/A
|
Phenotypic risk
|
Positive
|
|
HLA-DRB6
|
Homo sapiens
|
6p21.32
|
allele-haplotype
|
N/A
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
methylation
|
N/A
|
Disease risk
|
Positive
|
|
IFNAR1
|
Homo sapiens
|
21q22.11
|
SNP
|
rs2850015
|
Treatment risk
|
Positive
|
|
A2M
|
Homo sapiens
|
12p13.31
|
Deletion
|
Exon 18Del
|
Disease risk
|
Negative
|
|
A2M
|
Homo sapiens
|
12p13.31
|
polymorphism
|
Val 1000 Iso
|
Disease risk
|
Negative
|
|
LRP6
|
Homo sapiens
|
12p13.2
|
polymorphism
|
A216V
|
Disease risk
|
Negative
|
|
CNR1
|
Homo sapiens
|
6q15
|
allele
|
short AAT , long AAT
|
Phenotypic risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
allele
|
N/A
|
Disease risk ; Phenotypic risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
allele
|
N/A
|
Disease risk ; Phenotypic risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Phenotypic risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
DNA methylation at CpG dinucleotides
|
N/A
|
Phenotypic risk
|
Negative
|
|
HLA-DRB5
|
Homo sapiens
|
6p21.32
|
DNA methylation at CpG dinucleotides
|
N/A
|
Phenotypic risk
|
Negative
|
|
NCF1
|
Homo sapiens
|
7q11.23
|
Deletion
|
dinucleotide deletion (ΔGT) in exon 2
|
Disease risk
|
Negative
|
|
NCF1
|
Homo sapiens
|
7q11.23
|
Deletion
|
dinucleotide deletion (ΔGT) in exon 2
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs2055979
|
Disease risk
|
Positive
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
polymorphism
|
1562 C/T
|
Disease risk
|
Positive
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
polymorphism
|
1562 C/T
|
Phenotypic risk
|
Negative
|
|
LEP
|
Homo sapiens
|
7q32.1
|
SNP
|
rs2167270 or 19G > A
|
Disease risk
|
Positive
|
|
LEP
|
Homo sapiens
|
7q32.1
|
SNP
|
rs7799039 or -2,548G > A
|
Disease risk
|
Positive
|
|
LEP
|
Homo sapiens
|
7q32.1
|
SNP
|
rs2167270 or 19G > A
|
Phenotypic risk
|
Negative
|
|
LEP
|
Homo sapiens
|
7q32.1
|
SNP
|
rs7799039 or -2,548G > A
|
Phenotypic risk
|
Negative
|
|
ADIPOQ
|
Homo sapiens
|
3q27.3
|
SNP
|
rs1501299 or +276G > T
|
Disease risk
|
Positive
|
|
ADIPOQ
|
Homo sapiens
|
3q27.3
|
SNP
|
rs266729 or -11,377C > G
|
Disease risk
|
Positive
|
|
ADIPOQ
|
Homo sapiens
|
3q27.3
|
SNP
|
rs1501299 or +276G > T
|
Phenotypic risk
|
Positive
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
IL6
|
Homo sapiens
|
7p15.3
|
SNP
|
rs1818879
|
Phenotypic risk
|
Positive
|
|
IFNG
|
Homo sapiens
|
12q15
|
SNP
|
874A/T
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
SNP
|
308A/G
|
Disease risk
|
Positive
|
|
KIF5A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs703842
|
Phenotypic risk
|
Positive
|
|
KIF5A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs12368653
|
Phenotypic risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
allele
|
epsilon4 Allele positive / negative
|
Disease risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
SNP
|
N/A
|
Treatment risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
allele
|
–308 in the TNFα promotor
|
Disease risk
|
Negative
|
|
CFH
|
Homo sapiens
|
1q31.3
|
allele-haplotype
|
Tyr402
|
Disease risk
|
Negative
|
|
IFNLR1
|
Homo sapiens
|
1p36.11
|
SNP
|
rs4649203
|
Disease risk
|
Negative
|
|
MIF
|
Homo sapiens
|
22q11.23
|
SNP
|
173 G/C
|
Phenotypic risk
|
Positive
|
|
DDT
|
Homo sapiens
|
22q11.23
|
polymorphism
|
rs5844572(794 CATT5–8)
|
Phenotypic risk
|
Positive
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs12044852
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Positive
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs6498169
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722489
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Positive
|
|
CBLB
|
Homo sapiens
|
3q13.11
|
SNP
|
rs12487066
|
Disease risk
|
Positive
|
|
CNTF
|
Homo sapiens
|
11q12.1
|
mutation
|
N/A
|
Phenotypic risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphism
|
TNFα–308
|
Phenotypic risk
|
Negative
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
Insertion
|
14bp
|
Phenotypic risk
|
Positive
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
Deletion
|
14bp
|
Phenotypic risk
|
Positive
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
polymorphism
|
+3142C>G
|
Phenotypic risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
CXCL12
|
Homo sapiens
|
10q11.21
|
polymorphism
|
SDF-13'a
|
Disease risk
|
Positive
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs7206912,rs6498168,rs9934231,rs6498169,rs8060411
|
Disease risk
|
Positive
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs12708716 , rs12923849
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Positive
|
|
LEP
|
Homo sapiens
|
7q32.1
|
SNP
|
rs11761556,rs2167270,rs7799039
|
Disease risk
|
Negative
|
|
LEPR
|
Homo sapiens
|
1p31.3
|
SNP
|
rs1137100,rs1137101,rs8179183
|
Disease risk
|
Negative
|
|
GHRL
|
Homo sapiens
|
3p25.3
|
SNP
|
rs696217,rs1629816,rs4684677
|
Disease risk
|
Negative
|
|
GHSR
|
Homo sapiens
|
3q26.31
|
SNP
|
rs519384,rs509035,rs5772169
|
Disease risk
|
Negative
|
|
SPP1
|
Homo sapiens
|
4q22.1
|
SNP
|
rs1126616
|
Disease risk
|
Negative
|
|
IRF1
|
Homo sapiens
|
5q31.1
|
allele
|
GT repeat alleles
|
Disease risk
|
Negative
|
|
NRG1
|
Homo sapiens
|
8p12
|
SNP
|
rs6994992
|
Disease risk
|
Negative
|
|
NRG1
|
Homo sapiens
|
8p12
|
SNP
|
rs7014762
|
Disease risk
|
Negative
|
|
NRG1
|
Homo sapiens
|
8p12
|
SNP
|
rs6994992
|
Phenotypic risk
|
Positive
|
|
NRG1
|
Homo sapiens
|
8p12
|
SNP
|
rs7014762
|
Phenotypic risk
|
Positive
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs725613, rs2041670, rs2080272, rs998592
|
Disease risk
|
Positive
|
|
HNMT
|
Homo sapiens
|
2q22.1
|
polymorphism
|
Thr/Ile
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs7975232
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236
|
Disease risk
|
Negative
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
allele
|
N/A
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Treatment risk
|
Negative
|
|
PTPN6
|
Homo sapiens
|
12p13.31
|
methylation
|
N/A
|
Disease risk
|
Positive
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
polymorphism
|
C677T
|
Disease risk
|
Positive
|
|
SLFN12
|
Homo sapiens
|
17q12
|
methylation
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
methylation-mediated SNP
|
rs9267649
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
CT60
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
49A/G
|
Disease risk
|
Negative
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
SNP
|
rs1611715
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
polymorphism
|
N/A
|
Treatment risk
|
Negative
|
|
CCL20
|
Homo sapiens
|
2q36.3
|
SNP
|
rs6749704
|
Disease risk
|
Positive
|
|
IL17F
|
Homo sapiens
|
6p12.2
|
SNP
|
rs763780
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
polymorphism
|
376a
|
Disease risk
|
Negative
|
|
ARSA
|
Homo sapiens
|
22q13.33
|
polymorphism
|
ASA-PD (N350S and 1524+95A-G)
|
Phenotypic risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Phenotypic risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
allele
|
N/A
|
Phenotypic risk
|
Negative
|
|
IL6
|
Homo sapiens
|
7p15.3
|
SNP
|
rs1800796
|
Disease risk
|
Positive
|
|
TAGAP
|
Homo sapiens
|
6q25.3
|
SNP
|
rs1738074,rs3127214
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
haplotype
|
N/A
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722489,rs2104286
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
SNP
|
—308 polymorphism
|
Phenotypic risk
|
Negative
|
|
NECTIN2
|
Homo sapiens
|
19q13.32
|
SNP
|
rs394221
|
Disease risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
haplotype
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
haplotype
|
N/A
|
Disease risk
|
Positive
|
|
IL6
|
Homo sapiens
|
7p15.3
|
polymorphisms
|
N/A
|
Phenotypic risk
|
Negative
|
|
IGHM
|
Homo sapiens
|
14q32.33
|
haplotypes
|
N/A
|
Disease risk
|
Negative
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs2762943
|
Disease risk
|
up-regulation
|
|
SIRT1
|
Homo sapiens
|
10q21.3
|
SNP
|
rs3758391
|
Disease risk
|
N/A
|
|
SIRT1
|
Homo sapiens
|
10q21.3
|
SNP
|
rs7895833
|
Disease risk
|
N/A
|
|
IL4
|
Homo sapiens
|
5q31.1
|
gene are in strong linkage disequilibrium
|
rs2070874
|
Disease risk
|
protective
|
|
MPO
|
Homo sapiens
|
17q22
|
myeloperoxidase promoter polymorphism
|
position 1856–2629 of MPO
|
N/A
|
N/A
|
|
IL10
|
Homo sapiens
|
1q32.1
|
diallelic polymorphism
|
position –1082 in the IL10 promotor
|
N/A
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
Polymorphism of the CTLA-4 gene
|
dinucleotide microsatelite (AT)
|
N/A
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
multiallelic polymorphisms
|
DRB1*1501
|
Disease risk
|
MS susceptibility is conferred by HLA class II alleles
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
multiallelic polymorphisms
|
DQA1*0102
|
Disease risk
|
MS susceptibility is conferred by HLA class II alleles
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
multiallelic polymorphisms
|
DQB1*0602
|
Disease risk
|
MS susceptibility is conferred by HLA class II alleles
|
|
TNF
|
Homo sapiens
|
6p21.33
|
gene polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
NOTCH4
|
Homo sapiens
|
6p21.32
|
SNP
|
rs422951
|
Disease risk
|
negative
|
|
KCNA3
|
Homo sapiens
|
1p13.3
|
SNP
|
rs2821557
|
Disease risk
|
positive
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
SNP
|
rs6189/6190
|
Disease risk
|
positive
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
SNP
|
rs56149945
|
Disease risk
|
positive
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
SNP
|
rs41423247
|
Disease risk
|
positive
|
|
GAS5
|
Homo sapiens
|
1q25.1
|
SNP
|
rs55829688
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
HLA-DRB1*15:01
|
Disease risk
|
not related
|
|
GAPVD1
|
Homo sapiens
|
9q33.3
|
SNP
|
rs2291858
|
Disease risk
|
negative
|
|
LINGO1
|
Homo sapiens
|
15q24.3
|
SNP
|
rs11856808
|
Disease risk
|
not related
|
|
LINGO1
|
Homo sapiens
|
15q24.3
|
SNP
|
rs9652490
|
Disease risk
|
not related
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
HLA-DRB1*15:01
|
Disease risk
|
positive
|
|
IL4
|
Homo sapiens
|
5q31.1
|
SNP
|
VNTR and +33 C/T
|
Disease risk
|
positive
|
|
IL4
|
Homo sapiens
|
5q31.1
|
SNP
|
Q551*R
|
Disease risk
|
positive
|
|
PDCD1
|
Homo sapiens
|
2q37.3
|
intronic polymorphism
|
7146G/A
|
Disease risk
|
positive
|
|
IL13
|
Homo sapiens
|
5q31.1
|
promoter polymorphism
|
IL-131024TT
|
Disease risk
|
no association
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
HLA-DRB1*15:01
|
Disease risk
|
positive
|
|
IL23R
|
Homo sapiens
|
1p31.3
|
SNP
|
rs10127763 rs6656929 rs10489630 rs1004819 rs790633 rs7517847 rs10489629 rs7528924 rs12070470 rs12030948 rs11465804 rs4655530 rs10789229 rs11209026 rs1343151 rs6693831 rs10889677 rs2863209 rs11209030 rs11209032 rs6660226 rs1495965 rs7539817 rs10889680 rs12
|
Disease risk
|
N/A
|
|
TYK2
|
Homo sapiens
|
19p13.2
|
SNP
|
rs34536443
|
Disease risk
|
negative
|
|
NLRP3
|
Homo sapiens
|
1q44
|
SNP
|
rs35829419
|
Disease risk
|
negative
|
|
IL22
|
Homo sapiens
|
12q15
|
gene polymorphism
|
N/A
|
Disease risk
|
positive
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
SNP
|
rs2276631
|
Disease risk
|
positive
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
SNP
|
rs3731865
|
Disease risk
|
N/A
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
SNP
|
rs3731864
|
Disease risk
|
N/A
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
SNP
|
rs17221959
|
Disease risk
|
N/A
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
SNP
|
rs2695342
|
Disease risk
|
N/A
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
SNP
|
rs2279015
|
Disease risk
|
N/A
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
SNP
|
rs17235409
|
Disease risk
|
N/A
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
SNP
|
rs17235416
|
Disease risk
|
N/A
|
|
MOG
|
Homo sapiens
|
6p22.1
|
aminoacid substitution
|
a G→A transition occurring in exon 3 of the human MOG gene.
|
Disease risk
|
no association
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs1544410(BsmI)ã€rs7975232(ApaI)ã€rs731236(TaqI)ã€rs10735810(FokI)ã€rs11568820(Cdx-2)
|
Disease risk
|
N/A
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs703426ã€rs10877012
|
Disease risk
|
N/A
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs2296241
|
Disease risk
|
N/A
|
|
CYP2R1
|
Homo sapiens
|
11p15.2
|
SNP
|
rs10500804, rs12794714
|
Disease risk
|
N/A
|
|
DBP
|
Homo sapiens
|
19q13.33
|
SNP
|
rs7041ã€rs4588
|
Disease risk
|
N/A
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs12288280
|
Disease risk
|
positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs767455
|
Disease risk
|
positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs1800693
|
Disease risk
|
positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs4149577
|
Disease risk
|
positive
|
|
IRF8
|
Homo sapiens
|
16q24.1
|
SNP
|
rs767455
|
Disease risk
|
N/A
|
|
STAT4
|
Homo sapiens
|
2q32.2-q32.3
|
SNP
|
rs7574865
|
Disease risk
|
positive
|
|
MIR146A
|
Homo sapiens
|
5q33.3
|
SNP
|
rs2910164
|
Disease risk
|
positive
|
|
KIF5A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs1678542
|
Disease risk
|
positive
|
|
SH2B3
|
Homo sapiens
|
12q24.12
|
SNP
|
rs3184504
|
Disease risk
|
positive
|
|
CD226
|
Homo sapiens
|
18q22.2
|
SNP
|
rs763361
|
Disease risk
|
positive
|
|
IFNAR1
|
Homo sapiens
|
21q22.11
|
SNP
|
rs# 2243590,rs# 2252931,rs# 2243600
|
Disease risk
|
N/A
|
|
IFNAR2
|
Homo sapiens
|
21q22.11
|
SNP
|
rs# 2300370,rs# 2248412,rs# 2834154,rs# 2154430,rs# 2236756,rs# 2284549,rs# 2284551,rs# 2834163,rs #2236757,rs #2236758
|
Disease risk
|
N/A
|
|
STAT1
|
Homo sapiens
|
2q32.2
|
SNP
|
rs# 2066802,rs# 1547550
|
Disease risk
|
positive
|
|
STAT2
|
Homo sapiens
|
12q13.3
|
SNP
|
rs# 2066818,rs# 2066819,rs# 2020854,rs# 2066811
|
Disease risk
|
N/A
|
|
IRF1
|
Homo sapiens
|
5q31.1
|
SNP
|
rs# 2070721
|
Disease risk
|
positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
ApaI(rs7975232)
|
Disease risk
|
negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
BsmI(rs1544410)
|
Disease risk
|
positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
TaqI(rs731236)
|
Disease risk
|
negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
FokI(rs222870)
|
Disease risk
|
positive
|
|
ZC3HAV1
|
Homo sapiens
|
7q34
|
SNP
|
rs3735007
|
Disease risk
|
positive
|
|
IL2
|
Homo sapiens
|
4q27
|
allele
|
IL-2 330 T/HLA-DRB1*1501
|
Disease risk
|
positive
|
|
HOTAIR
|
Homo sapiens
|
12q13.13
|
SNP
|
rs920778
|
Disease risk
|
Positive
|
|
CDKN2B-AS1
|
Homo sapiens
|
9p21.3
|
SNP
|
rs10757278
|
Disease risk
|
Positive
|
|
CDKN2B-AS1
|
Homo sapiens
|
9p21.3
|
SNP
|
rs1333045
|
Disease risk
|
Positive
|
|
LAMP2
|
Homo sapiens
|
Xq24
|
SNP
|
rs1194422515; rs42895; rs41300191; rs42886
|
Disease risk
|
Positive
|
|
AVPR2
|
Homo sapiens
|
Xq28
|
SNP
|
Affx-89,012,620; Affx89,008,152; Affx89,010,658
|
Disease risk
|
Positive
|
|
MTMR8
|
Homo sapiens
|
Xq11.2
|
SNP
|
rs766668643
|
Disease risk
|
Positive
|
|
F8
|
Homo sapiens
|
Xq28
|
SNP
|
rs369414658
|
Disease risk
|
Positive
|
|
PORCN
|
Homo sapiens
|
Xp11.23
|
SNP
|
rs1556974235
|
Disease risk
|
Positive
|
|
ELF4
|
Homo sapiens
|
Xq26.1
|
SNP
|
rs373568641
|
Disease risk
|
Positive
|
|
NSDHL
|
Homo sapiens
|
Xq28
|
SNP
|
rs797045835
|
Disease risk
|
Positive
|
|
HS6ST2
|
Homo sapiens
|
Xq26.2
|
SNP
|
rs950792996
|
Disease risk
|
Positive
|
|
RBM10
|
Homo sapiens
|
Xp11.3
|
SNP
|
rs139585263
|
Disease risk
|
Positive
|
|
AR
|
Homo sapiens
|
Xq12
|
SNP
|
rs367604031
|
Disease risk
|
Positive
|
|
TAFAZZIN
|
Homo sapiens
|
Xq28
|
SNP
|
rs387907218; Affx89,017,095
|
Disease risk
|
Positive
|
|
RIBC1
|
Homo sapiens
|
Xp11.22
|
SNP
|
rs782346908
|
Disease risk
|
Positive
|
|
BCOR
|
Homo sapiens
|
Xp11.4
|
SNP
|
rs199676230
|
Disease risk
|
Positive
|
|
DKC1
|
Homo sapiens
|
Xq28
|
SNP
|
rs121912302
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
G511525 and D6S1666
|
Disease risk
|
Positive
|
|
ACE
|
Homo sapiens
|
17q23.3
|
Gene polymorphisms
|
ACE I/D
|
Disease risk
|
Negative
|
|
ACE
|
Homo sapiens
|
17q23.3
|
Gene polymorphisms
|
ATG M235T
|
Disease risk
|
Negative
|
|
ACE
|
Homo sapiens
|
17q23.3
|
Gene polymorphisms
|
ATG (6)A/G
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
SNP
|
rs7412 (C/T)
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
SNP
|
rs429358 (C/T)
|
Disease risk
|
Positive
|
|
FUT1
|
Homo sapiens
|
19q13.33
|
alleles
|
N/A
|
Disease risk
|
Positive
|
|
FUT2
|
Homo sapiens
|
19q13.33
|
alleles
|
N/A
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs1570538
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722489
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs10795791
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs4147359
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs7090530
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs41295061
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs35285258
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
promoter polymorphism
|
TNF-376A
|
Disease risk
|
Positive
|
|
MOG
|
Homo sapiens
|
6p22.1
|
Gene polymorphisms
|
N/A
|
Disease risk
|
Positive
|
|
KIR3DL1
|
Homo sapiens
|
19q13.42
|
SNP
|
N/A
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
SNP
|
HLA-Bw4
|
Disease risk
|
Positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs1883832CT
|
Disease risk
|
Negative
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs1883832CC
|
Disease risk
|
Negative
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs1883832TT
|
Disease risk
|
Negative
|
|
ASAP2
|
Homo sapiens
|
2p25.1; 2p24
|
SNP
|
rs1109670
|
Disease risk
|
Negative
|
|
PDZRN4
|
Homo sapiens
|
12q12
|
SNP
|
rs1458175
|
Disease risk
|
Negative
|
|
CSMD1
|
Homo sapiens
|
8p23.2
|
SNP
|
rs1529316
|
Disease risk
|
Negative
|
|
CSMD1
|
Homo sapiens
|
8p23.2
|
SNP
|
rs2049306
|
Disease risk
|
Negative
|
|
TBC1D2
|
Homo sapiens
|
9q22.33
|
SNP
|
rs16914086
|
Disease risk
|
Negative
|
|
SH3GL2
|
Homo sapiens
|
9p22.2
|
SNP
|
rs1755289
|
Disease risk
|
Negative
|
|
ZIC1
|
Homo sapiens
|
3q24
|
SNP
|
rs1841770
|
Disease risk
|
Negative
|
|
EN1
|
Homo sapiens
|
2q14.2
|
SNP
|
rs651477
|
Disease risk
|
Negative
|
|
TRIB2
|
Homo sapiens
|
2p24.3
|
SNP
|
rs7607490
|
Disease risk
|
Negative
|
|
TMEM74B
|
Homo sapiens
|
20p13
|
SNP
|
rs397020
|
Disease risk
|
Negative
|
|
SLC25A36
|
Homo sapiens
|
3q23
|
SNP
|
rs908821
|
Disease risk
|
Negative
|
|
TENM3-AS1
|
Homo sapiens
|
4q34.3
|
SNP
|
rs7672826
|
Disease risk
|
Negative
|
|
GPC5
|
Homo sapiens
|
13q31.3
|
SNP
|
rs9523762
|
Disease risk
|
Positive
|
|
SH2D2A
|
Homo sapiens
|
1q23.1
|
SNP
|
rs2768766
|
Disease risk
|
Positive
|
|
SH2D2A
|
Homo sapiens
|
1q23.1
|
SNP
|
rs909200
|
Disease risk
|
Positive
|
|
SH2D2A
|
Homo sapiens
|
1q23.1
|
SNP
|
rs926103
|
Disease risk
|
Positive
|
|
SH2D2A
|
Homo sapiens
|
1q23.1
|
SNP
|
rs1800600
|
Disease risk
|
Positive
|
|
SH2D2A
|
Homo sapiens
|
1q23.1
|
SNP
|
GA repeat polymorphism
|
Disease risk
|
Positive
|
|
SH2D2A
|
Homo sapiens
|
1q23.1
|
SNP
|
rs2768764
|
Disease risk
|
Positive
|
|
IL23R
|
Homo sapiens
|
1p31.3
|
SNP
|
rs7517847
|
Disease risk
|
Negative
|
|
IL23R
|
Homo sapiens
|
1p31.3
|
SNP
|
rs11209026
|
Disease risk
|
Positive
|
|
IL12B
|
Homo sapiens
|
5q33.3
|
SNP
|
rs6887695
|
Disease risk
|
Negative
|
|
IL12B
|
Homo sapiens
|
5q33.3
|
SNP
|
rs3212227
|
Disease risk
|
Negative
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
promoter polymorphism
|
MMP-9 PM ≥22 CA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
HLA-DRB1*15
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
HLA-DRB1*04
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV2S1
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV3S1
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV6S5
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV8S1
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV8S2
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV8S3
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV10S1
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV12S2
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV15S1
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV16S1
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV21S4
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV24S1
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV25S1
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Gene Polymorphism
|
BV26S1
|
Disease risk
|
Negative
|
|
NPY
|
Homo sapiens
|
7p15.3
|
SNP
|
rs16139
|
Disease risk
|
Positive
|
|
NPY
|
Homo sapiens
|
7p15.3
|
SNP
|
rs16147
|
Disease risk
|
Positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs1800693
|
Disease risk
|
Positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs4149584
|
Disease risk
|
Positive
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
SNP
|
-500 C/T ï¼›rs16944
|
Disease risk
|
Positive
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
SNP
|
+3954 C/T ;rs1143634
|
Disease risk
|
Positive
|
|
IL1A
|
Homo sapiens
|
2q14.1
|
SNP
|
-889 C/T; rs1800587
|
Disease risk
|
Positive
|
|
IL1A
|
Homo sapiens
|
2q14.1
|
SNP
|
+4845 G/T; rs17561
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs11567685
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs1494555
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs987106
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs3194051
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722489
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs11256369
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs7076103
|
Disease risk
|
Positive
|
|
IFNG
|
Homo sapiens
|
12q15
|
gene Polymorphism
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
gene Polymorphism
|
N/A
|
Disease risk
|
Positive
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs13151961
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs6822844
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs925549
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs17879298
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs907715
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs4833837
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs13143866
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs17005929
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs17005931
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs12505138
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs4326027
|
Disease risk
|
Negative
|
|
IL21
|
Homo sapiens
|
4q27
|
SNP
|
rs6840978
|
Disease risk
|
Negative
|
|
CRYAB
|
Homo sapiens
|
11q23.1
|
gene Polymorphism
|
-C249G
|
Disease risk
|
Negative
|
|
CRYAB
|
Homo sapiens
|
11q23.1
|
gene Polymorphism
|
-C650G
|
Disease risk
|
Positive
|
|
CRYAB
|
Homo sapiens
|
11q23.1
|
gene Polymorphism
|
-A652G
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
alleles
|
N/A
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
alleles
|
N/A
|
Disease risk
|
Positive
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
alleles
|
N/A
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
alleles
|
N/A
|
Disease risk
|
Positive
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
alleles
|
N/A
|
Disease risk
|
Positive
|
|
PLAT
|
Homo sapiens
|
8p11.21
|
insertion/deletion (I/D) genetic polymorphism
|
TPA DD/PAI-1 4G4G
|
Disease risk
|
Positive
|
|
SERPINE1
|
Homo sapiens
|
7q22.1
|
insertion/deletion (I/D) genetic polymorphism
|
TPA DD/PAI-1 4G4G
|
Disease risk
|
Positive
|
|
IFNG
|
Homo sapiens
|
12q15
|
allele
|
I1(761)*CA12
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
haplotypic diversity
|
HLA-DRB1*1501
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
haplotypic diversity
|
HLA-DQB1*0602
|
Disease risk
|
Positive
|
|
PRF1
|
Homo sapiens
|
10q22.1
|
mutations
|
N/A
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
1577 GG
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
+6230
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
+10242
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
+10717
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
+12310
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
-658
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
gene polymorphism
|
-491 A/T
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
exon 1 dimorphism
|
( + 49)A/G
|
Phenotypic risk
|
Positive
|
|
HSPA4
|
Homo sapiens
|
5q31.1
|
gene polymorphism
|
hsp70 -2 (+1267 A/G)
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
intragenic restriction fragment length polymorphisms
|
N/A
|
Disease risk
|
Positive
|
|
ENPEP
|
Homo sapiens
|
4q25
|
intragenic restriction fragment length polymorphisms
|
N/A
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722489
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs987107
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
T244
|
Disease risk
|
Positive
|
|
IL4
|
Homo sapiens
|
5q31.1
|
gene polymorphisms
|
C/C, T/C, and T/T genotypes of the -590 region of IL-4
|
Disease risk
|
Positive
|
|
ACE
|
Homo sapiens
|
17q23.3
|
insertion/deletion gene polymorphism
|
N/A
|
Disease risk
|
Positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
allele
|
DRB1*1501
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
allele
|
DPB1*0301
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
allele
|
DPB1*0501
|
Disease risk
|
Negative
|
|
IFNG
|
Homo sapiens
|
12q15
|
allelic
|
located in the first intron of the interferon-gamma gene
|
Phenotypic risk
|
Positive
|
|
HSPA1B
|
Homo sapiens
|
6p21.33
|
SNP
|
rs1061581
|
Disease risk
|
Positive
|
|
GRIN2A
|
Homo sapiens
|
16p13.2
|
SNP
|
rs3859123
|
Phenotypic risk
|
Positive
|
|
GRIN2A
|
Homo sapiens
|
16p13.2
|
SNP
|
rs9927924
|
Phenotypic risk
|
Positive
|
|
GRIN2A
|
Homo sapiens
|
16p13.2
|
SNP
|
rs6497658
|
Phenotypic risk
|
Positive
|
|
GRIN2A
|
Homo sapiens
|
16p13.2
|
SNP
|
rs13338243
|
Phenotypic risk
|
Positive
|
|
GRIN2A
|
Homo sapiens
|
16p13.2
|
SNP
|
rs1070484
|
Phenotypic risk
|
Positive
|
|
GRIN2A
|
Homo sapiens
|
16p13.2
|
SNP
|
rs3104703
|
Phenotypic risk
|
Positive
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
gene variants
|
N/A
|
Treatment risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
SNP
|
rs3135932
|
Disease risk
|
Positive
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
insertion/ deletion
|
N/A
|
Disease risk
|
Positive
|
|
IFNG
|
Homo sapiens
|
12q15
|
SNP
|
rs2069727
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
gene polymorphisms
|
一308Gï¼A
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
gene polymorphisms
|
N/A
|
Disease risk
|
Positive
|
|
ZFAT
|
Homo sapiens
|
8q24.22
|
SNP
|
rs733254
|
Disease risk
|
Positive
|
|
ZFAT
|
Homo sapiens
|
8q24.22
|
SNP
|
rs12557782
|
Disease risk
|
Positive
|
|
ZFAT
|
Homo sapiens
|
8q24.22
|
SNP
|
rs2229857
|
Disease risk
|
Positive
|
|
ZFAT
|
Homo sapiens
|
8q24.22
|
SNP
|
rs9527281
|
Disease risk
|
Positive
|
|
ZFAT
|
Homo sapiens
|
8q24.22
|
SNP
|
rs11787532
|
Disease risk
|
Positive
|
|
ZFAT
|
Homo sapiens
|
8q24.22
|
SNP
|
rs7308076
|
Disease risk
|
Positive
|
|
ZFAT
|
Homo sapiens
|
8q24.22
|
SNP
|
rs2248202
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
gene polymorphisms
|
A (/ 238 allele
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
gene polymorphisms
|
GGhaplotypes
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
gene polymorphisms
|
GAhaplotypes
|
Disease risk
|
Positive
|
|
IL2
|
Homo sapiens
|
4q27
|
gene polymorphisms
|
GG (/ 330 genotype
|
Disease risk
|
Positive
|
|
IL6
|
Homo sapiens
|
7p15.3
|
gene polymorphisms
|
C (/ 174 allele
|
Disease risk
|
Positive
|
|
IL6
|
Homo sapiens
|
7p15.3
|
gene polymorphisms
|
CGhaplotypes
|
Disease risk
|
Positive
|
|
IL6
|
Homo sapiens
|
7p15.3
|
gene polymorphisms
|
GGhaplotypes
|
Disease risk
|
Positive
|
|
IL6
|
Homo sapiens
|
7p15.3
|
gene polymorphisms
|
GGgenotypes
|
Disease risk
|
Positive
|
|
IL6
|
Homo sapiens
|
7p15.3
|
gene polymorphisms
|
CGgenotypes
|
Disease risk
|
Positive
|
|
CCL20
|
Homo sapiens
|
2q36.3
|
SNP
|
rs6749704
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2228570
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs1544410
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236
|
Disease risk
|
Positive
|
|
TNFSF10
|
Homo sapiens
|
3q26.31
|
SNP
|
rs6763816
|
Disease risk
|
Positive
|
|
TNFSF10
|
Homo sapiens
|
3q26.31
|
SNP
|
rs11545817
|
Disease risk
|
Positive
|
|
TNFSF10
|
Homo sapiens
|
3q26.31
|
SNP
|
rs1047275
|
Disease risk
|
Positive
|
|
TNFSF10
|
Homo sapiens
|
3q26.31
|
SNP
|
rs16845759
|
Disease risk
|
Positive
|
|
TNFSF10
|
Homo sapiens
|
3q26.31
|
SNP
|
rs7011559
|
Disease risk
|
Positive
|
|
TNFSF10
|
Homo sapiens
|
3q26.31
|
SNP
|
rs4491934
|
Disease risk
|
Positive
|
|
TNFSF10
|
Homo sapiens
|
3q26.31
|
SNP
|
rs1131579
|
Disease risk
|
Positive
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
SNP
|
rs116729895
|
Disease risk
|
N/A
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
SNP
|
rs3775296
|
Disease risk
|
N/A
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
SNP
|
rs377529
|
Disease risk
|
N/A
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
SNP
|
rs3775290
|
Disease risk
|
N/A
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
SNP
|
rs3775291
|
Disease risk
|
Positive
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
SNP
|
rs376735334
|
Disease risk
|
N/A
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
SNP
|
rs73873710
|
Disease risk
|
N/A
|
|
SOCS1
|
Homo sapiens
|
16p13.13
|
SNP
|
rs243324
|
Disease risk
|
Positive
|
|
ANKRD55
|
Homo sapiens
|
5q11.2
|
SNP
|
rs6859219
|
Disease risk
|
Positive
|
|
IL22RA2
|
Homo sapiens
|
6q23.3
|
SNP
|
rs276474
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Positive
|
|
HMOX2
|
Homo sapiens
|
16p13.3
|
SNP
|
rs1051308AA
|
Disease risk
|
Positive
|
|
HMOX2
|
Homo sapiens
|
16p13.3
|
SNP
|
rs1051308A
|
Disease risk
|
Positive
|
|
HMOX1
|
Homo sapiens
|
22q12.3
|
SNP
|
rs2071746A
|
Disease risk
|
Positive
|
|
VAV1
|
Homo sapiens
|
19p13.3
|
SNP
|
rs2546133-rs2617822
|
Disease risk
|
Positive
|
|
CCL22
|
Homo sapiens
|
16q21
|
SNP
|
rs223889
|
Disease risk
|
Positive
|
|
CCL22
|
Homo sapiens
|
16q21
|
SNP
|
rs4359426
|
Disease risk
|
Positive
|
|
CCL17
|
Homo sapiens
|
16q21
|
SNP
|
rs223828
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
HLA-DQB1*06:02ã€rs9273342
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
HLA-A*2:01ã€rs28844821
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
HLA-DPB1*03:01ã€DPB1-2939-33046757-intron1
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
HLA-DRB1*13:03:01ã€rs75589097
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
HLA-DQB1*02:01ã€DQB1-6203-32628182-intron 5
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
HLA-DRB1*15:01ã€rs9269243
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
r6929950
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
HLA-DRB1*15:01ã€rs9269243
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
HLA-A*02:01ã€rs12153924
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
HLA-B*53:01ã€rs115219755
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
rs760145
|
Disease risk
|
Positive
|
|
FCRL3
|
Homo sapiens
|
1q23.1
|
A functional promoter polymorphism
|
-169 T/C
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs7093069
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722598
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
rs3087243
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
rs231775
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
rs5742906
|
Disease risk
|
Negative
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs1883832
|
Disease risk
|
Negative
|
|
PADI4
|
Homo sapiens
|
1p36.13
|
SNP
|
rs1748033
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB1*1501
|
Disease risk
|
Positive
|
|
HLA-DRB5
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB5*0101
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Gene polymorphisms
|
112C/R
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Gene polymorphisms
|
158R/C
|
Disease risk
|
Positive
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
Gene polymorphisms
|
–511T/C
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3135388
|
Disease risk
|
Positive
|
|
EVI5
|
Homo sapiens
|
1p22.1
|
SNP
|
rs10735781
|
Disease risk
|
Positive
|
|
EVI5
|
Homo sapiens
|
1p22.1
|
SNP
|
rs6680578
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs689732
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722489
|
Disease risk
|
Negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Negative
|
|
EVI5
|
Homo sapiens
|
1p22.1
|
SNP
|
rs10735781
|
Disease risk
|
Positive
|
|
EVI5
|
Homo sapiens
|
1p22.1
|
SNP
|
rs6680578
|
Disease risk
|
Positive
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs1335532
|
Disease risk
|
Positive
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs2300747
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Alleles
|
ε4ã€Îµ3/ε4
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Alleles
|
ε2/ε3
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Alleles
|
ε3/ε3
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
TNF-alpha - 238 G-->A
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
TNF-alpha - 308 G-->A
|
Disease risk
|
Negative
|
|
IL10
|
Homo sapiens
|
1q32.1
|
Gene polymorphisms
|
L-10 - 1082
|
Disease risk
|
Positive
|
|
TAP1
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
TAP1 - 1069
|
Disease risk
|
Negative
|
|
TAP1
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
TAP1 - 1982
|
Disease risk
|
Negative
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
TAP2 - 1231
|
Disease risk
|
Negative
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
TAP2 - 2089
|
Disease risk
|
Negative
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
TAP2 - 2155
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
TNF - 376
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
TNF - 238
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
TNF - 308
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
TNF - 238
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
TNF - 308
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Alleles
|
a11
|
Disease risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
Gene polymorphisms
|
a tetranucleotide (TGGA)n repeat polymorphism 5'
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Gene polymorphisms
|
E4 - ε2
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Gene polymorphisms
|
E4 - ε3
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Gene polymorphisms
|
E4 - ε4
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB1*14 -
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB1*11 -
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB1*01 -
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB1*10 -
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB1*15 -
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB1*17 -
|
Disease risk
|
Positive
|
|
CIITA
|
Homo sapiens
|
16p13.13
|
SNP
|
rs4774
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB1*15:01
|
Disease risk
|
Positive
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
SNP
|
rs3918242
|
Disease risk
|
Positive
|
|
PRRC2A
|
Homo sapiens
|
6p21.33
|
SNP
|
rs2242659
|
Disease risk
|
Positive
|
|
PRRC2A
|
Homo sapiens
|
6p21.33
|
SNP
|
rs2844470
|
Disease risk
|
Positive
|
|
PRRC2A
|
Homo sapiens
|
6p21.33
|
SNP
|
rs2736157
|
Disease risk
|
Positive
|
|
PRRC2A
|
Homo sapiens
|
6p21.33
|
SNP
|
rs2736171
|
Disease risk
|
Positive
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs2300747
|
Disease risk
|
Positive
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs12044852
|
Disease risk
|
Positive
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs929230
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs1544410
|
Disease risk
|
Positive
|
|
AGER
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
p.82G>S
|
Disease risk
|
Positive
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs2301369
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs8078340
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs9282799
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs2779248
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs3730013
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs3794764
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs3729508
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs1137933
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs4796052
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs2248814
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs2297518
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs1060826
|
Disease risk
|
Negative
|
|
NOS2
|
Homo sapiens
|
17q11.2
|
SNP
|
rs8081248
|
Disease risk
|
Negative
|
|
VEGFA
|
Homo sapiens
|
6p21.1
|
SNP
|
rs3025039
|
Disease risk
|
Positive
|
|
KDR
|
Homo sapiens
|
4q12
|
SNP
|
rs2071559
|
Disease risk
|
Negative
|
|
IL17F
|
Homo sapiens
|
6p12.2
|
SNP
|
rs763780
|
Disease risk
|
Positive
|
|
IL17A
|
Homo sapiens
|
6p12.2
|
SNP
|
rs2275913
|
Disease risk
|
Negative
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
SNP
|
rs1801133
|
Disease risk
|
Negative
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
SNP
|
rs1801131
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
Gene polymorphisms
|
ApaI
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
Gene polymorphisms
|
BsmI
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
Gene polymorphisms
|
TaqI
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
Gene polymorphisms
|
BsmI BB(AA)
|
Disease risk
|
Positive
|
|
FAS
|
Homo sapiens
|
10q23.31
|
SNP
|
rs2234978
|
Disease risk
|
Positive
|
|
KCNIP1
|
Homo sapiens
|
5q35.1
|
SNP
|
rs11957313
|
Disease risk
|
Positive
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs8056098
|
Disease risk
|
Positive
|
|
MOG
|
Homo sapiens
|
6p22.1
|
SNP
|
rs3130253
|
Disease risk
|
Positive
|
|
NCAN
|
Homo sapiens
|
19p13.11
|
SNP
|
rs1064395
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
rs5742909
|
Disease risk
|
Positive
|
|
FAS
|
Homo sapiens
|
10q23.31
|
SNP
|
rs2234978
|
Disease risk
|
Positive
|
|
PLXNA3
|
Homo sapiens
|
Xq28
|
SNP
|
rs5945430
|
Disease risk
|
Positive
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs2300747 A>G
|
Disease risk
|
Negative
|
|
CD226
|
Homo sapiens
|
18q22.2
|
SNP
|
rs763361 C>T
|
Disease risk
|
Positive
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
SNP
|
rs1611715 A>C
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
rs2647040
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
SNP
|
rs3135021
|
Disease risk
|
Positive
|
|
TYK2
|
Homo sapiens
|
19p13.2
|
SNP
|
rs34536443
|
Disease risk
|
Positive
|
|
CYP2R1
|
Homo sapiens
|
11p15.2
|
SNP
|
rs10766197
|
Disease risk
|
Positive
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs10877012
|
Disease risk
|
Negative
|
|
GAS5
|
Homo sapiens
|
1q25.1
|
SNP
|
rs2067079
|
Disease risk
|
Positive
|
|
MIR137
|
Homo sapiens
|
1p21.3
|
SNP
|
rs1625579
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB1*1503
|
Disease risk
|
Positive
|
|
HLA-DRB5
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB5*null
|
Disease risk
|
Positive
|
|
AGER
|
Homo sapiens
|
6p21.32
|
SNP
|
rs1035798
|
Disease risk
|
Positive
|
|
AGER
|
Homo sapiens
|
6p21.32
|
SNP
|
rs2070600
|
Disease risk
|
Positive
|
|
TBATAp
|
Homo sapiens
|
10q22.1
|
SNP
|
rs2791196
|
Disease risk
|
Positive
|
|
TBATAp
|
Homo sapiens
|
10q22.1
|
SNP
|
rs2791196
|
Disease risk
|
Positive
|
|
TBATAp
|
Homo sapiens
|
10q22.1
|
SNP
|
rs12221473
|
Disease risk
|
Positive
|
|
HIF1A
|
Homo sapiens
|
14q23.2
|
SNP
|
rs11549465
|
Disease risk
|
Negative
|
|
VEGFA
|
Homo sapiens
|
6p21.1
|
SNP
|
rs699947
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
DRB1*1501
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
exon 10 nt 1668*T-->G
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
exon 6 nt 676*T-->G
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
exon 6 nt 783*G-->A
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
exon 10 nt 1663*G-->A
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
exon 10 nt 1690*T-->C
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Gene polymorphisms
|
ε4
|
Disease risk
|
Positive
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
Gene polymorphisms
|
allele 2 of the Taq1
|
Disease risk
|
Negative
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
Gene polymorphisms
|
allele 2 of VNTR locus
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs4646536
|
Disease risk
|
Positive
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs10877012
|
Disease risk
|
Positive
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs10877015
|
Disease risk
|
Positive
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs703842
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
rs3087243
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
TNF - 238
|
Disease risk
|
Positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs1883832
|
Disease risk
|
Positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs6074022
|
Disease risk
|
Positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs1535045
|
Disease risk
|
Negative
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs11086998
|
Disease risk
|
Negative
|
|
HAVCR1
|
Homo sapiens
|
5q33.3
|
SNP
|
rs7702920
|
Disease risk
|
Negative
|
|
HAVCR1
|
Homo sapiens
|
5q33.3
|
SNP
|
rs41297577
|
Disease risk
|
Negative
|
|
HAVCR1
|
Homo sapiens
|
5q33.3
|
SNP
|
rs41297579
|
Disease risk
|
Negative
|
|
HAVCR1
|
Homo sapiens
|
5q33.3
|
SNP
|
rs9313422
|
Disease risk
|
Negative
|
|
HAVCR1
|
Homo sapiens
|
5q33.3
|
SNP
|
rs34333511
|
Disease risk
|
Negative
|
|
HAVCR1
|
Homo sapiens
|
5q33.3
|
SNP
|
rs1553316
|
Disease risk
|
Negative
|
|
HAVCR1
|
Homo sapiens
|
5q33.3
|
SNP
|
rs12522248
|
Disease risk
|
Negative
|
|
HAVCR1
|
Homo sapiens
|
5q33.3
|
SNP
|
rs1553318
|
Disease risk
|
Negative
|
|
HAVCR1
|
Homo sapiens
|
5q33.3
|
SNP
|
rs2279804
|
Disease risk
|
Negative
|
|
HAVCR1
|
Homo sapiens
|
5q33.3
|
SNP
|
rs2277025
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs11574010
|
Disease risk
|
Positive
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs10735810
|
Disease risk
|
Negative
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
SNP
|
rs731236
|
Disease risk
|
Negative
|
|
ICAM1
|
Homo sapiens
|
19p13.2
|
Gene polymorphisms
|
ICAM1 AA
|
Disease risk
|
Positive
|
|
ICAM1
|
Homo sapiens
|
19p13.2
|
Gene polymorphisms
|
ICAM1 AA
|
Disease risk
|
Positive
|
|
IFNAR1
|
Homo sapiens
|
21q22.11
|
SNP
|
ref.27
|
Treatment risk
|
Negative
|
|
IFNAR1
|
Homo sapiens
|
21q22.11
|
SNP
|
rs1041429
|
Treatment risk
|
Negative
|
|
IFNAR1
|
Homo sapiens
|
21q22.11
|
SNP
|
rs1012334
|
Treatment risk
|
Negative
|
|
IFNAR1
|
Homo sapiens
|
21q22.11
|
SNP
|
rs1012335
|
Treatment risk
|
Negative
|
|
IFNAR1
|
Homo sapiens
|
21q22.11
|
SNP
|
rs2257167
|
Treatment risk
|
Negative
|
|
IFNAR2
|
Homo sapiens
|
21q22.11
|
SNP
|
rs3153
|
Treatment risk
|
Negative
|
|
IFNAR2
|
Homo sapiens
|
21q22.11
|
SNP
|
rs1051393
|
Treatment risk
|
Negative
|
|
IFNAR2
|
Homo sapiens
|
21q22.11
|
SNP
|
rs1131668
|
Treatment risk
|
Negative
|
|
CASP9
|
Homo sapiens
|
1p36.21
|
Gene polymorphisms
|
CASP9 G/G
|
Disease risk
|
Positive
|
|
RORA
|
Homo sapiens
|
15q22.2
|
SNP
|
rs4774388
|
Treatment risk
|
Positive
|
|
RORA
|
Homo sapiens
|
15q22.2
|
SNP
|
rs11639084
|
Treatment risk
|
Positive
|
|
DBP
|
Homo sapiens
|
19q13.33
|
Gene polymorphisms
|
codon 416
|
Disease risk
|
Negative
|
|
DBP
|
Homo sapiens
|
19q13.33
|
Gene polymorphisms
|
codon 420
|
Disease risk
|
Negative
|
|
IL4R
|
Homo sapiens
|
16p12.1
|
Gene polymorphisms
|
R551
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
DRB1*1501
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
TNF-alpha -308 G/A
|
Disease risk
|
Positive
|
|
CYP27B1
|
Homo sapiens
|
12q14.1
|
Gene polymorphisms
|
genotype bb
|
Disease risk
|
Positive
|
|
NGF
|
Homo sapiens
|
1p13.2
|
SNP
|
rs6330
|
Disease risk
|
Positive
|
|
NGF
|
Homo sapiens
|
1p13.2
|
SNP
|
rs11102930
|
Disease risk
|
Positive
|
|
NGF
|
Homo sapiens
|
1p13.2
|
SNP
|
rs7523831
|
Disease risk
|
Negative
|
|
NGF
|
Homo sapiens
|
1p13.2
|
SNP
|
rs11102915
|
Disease risk
|
Negative
|
|
NGF
|
Homo sapiens
|
1p13.2
|
SNP
|
rs6327
|
Disease risk
|
Negative
|
|
NGF
|
Homo sapiens
|
1p13.2
|
SNP
|
rs2239622
|
Disease risk
|
Negative
|
|
NGF
|
Homo sapiens
|
1p13.2
|
SNP
|
rs910330
|
Disease risk
|
Negative
|
|
NGF
|
Homo sapiens
|
1p13.2
|
SNP
|
rs3811014
|
Disease risk
|
Negative
|
|
NGF
|
Homo sapiens
|
1p13.2
|
SNP
|
rs17540656
|
Disease risk
|
Negative
|
|
NGF
|
Homo sapiens
|
1p13.2
|
SNP
|
rs6673867
|
Disease risk
|
Negative
|
|
CD24
|
Homo sapiens
|
6q21
|
SNP
|
CD24V/V
|
Disease risk
|
Positive
|
|
CD24
|
Homo sapiens
|
6q21
|
SNP
|
CD24A/V
|
Disease risk
|
Positive
|
|
CD24
|
Homo sapiens
|
6q21
|
SNP
|
CD24A/A
|
Disease risk
|
Positive
|
|
ACE
|
Homo sapiens
|
17q23.3
|
SNP
|
DD genotype
|
Disease risk
|
Positive
|
|
STMN1
|
Homo sapiens
|
1p36.11
|
SNP
|
rs182455
|
Disease risk
|
Negative
|
|
NR3C1
|
Homo sapiens
|
5q31.3
|
Gene polymorphisms
|
Haplotype 6 (TthIIII, ER2223EK, and 9beta-G
|
Disease risk
|
Positive
|
|
TNFAIP3
|
Homo sapiens
|
6q23.3
|
SNP
|
rs10499194
|
Disease risk
|
Positive
|
|
TNFAIP3
|
Homo sapiens
|
6q23.3
|
SNP
|
rs6920220
|
Disease risk
|
Positive
|
|
TNFAIP3
|
Homo sapiens
|
6q23.3
|
SNP
|
rs5029939
|
Disease risk
|
Positive
|
|
TNFAIP3
|
Homo sapiens
|
6q23.3
|
SNP
|
rs6922466
|
Disease risk
|
Positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs1800693
|
Disease risk
|
Positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs4149584
|
Disease risk
|
Positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs4149577
|
Disease risk
|
Positive
|
|
PHGDH
|
Homo sapiens
|
1p12
|
SNP
|
rs666930
|
Disease risk
|
Positive
|
|
IRF8
|
Homo sapiens
|
16q24.1
|
SNP
|
rs35929052
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
SNP
|
rs3761548
|
Disease risk
|
Positive
|
|
HFE
|
Homo sapiens
|
6p22.2
|
Gene polymorphisms
|
C282Y
|
Disease risk
|
Negative
|
|
HFE
|
Homo sapiens
|
6p22.2
|
Gene polymorphisms
|
H63D
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
DRB1*03
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
DRB1*15
|
Disease risk
|
Positive
|
|
HLA-DRB3
|
Homo sapiens
|
6p21.3
|
Gene polymorphisms
|
DRB3
|
Disease risk
|
Positive
|
|
HLA-DRB5
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
DRB5*0101
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
HLA-A*0301
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Gene polymorphisms
|
HLA-A*0201
|
Disease risk
|
Positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs1883832
|
Disease risk
|
Positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs1535045
|
Disease risk
|
Positive
|
|
KIF1B
|
Homo sapiens
|
1p36.22
|
SNP
|
rs3135388
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2228570
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs1544410
|
Disease risk
|
Positive
|
|
PON1
|
Homo sapiens
|
7q21.3
|
SNP
|
rs662
|
Disease risk
|
Negative
|
|
PON1
|
Homo sapiens
|
7q21.3
|
SNP
|
rs854560
|
Disease risk
|
Negative
|
|
PON1
|
Homo sapiens
|
7q21.3
|
SNP
|
rs705381
|
Disease risk
|
Negative
|
|
PON2
|
Homo sapiens
|
7q21.3
|
SNP
|
rs6954345
|
Disease risk
|
Negative
|
|
AGER
|
Homo sapiens
|
6p21.32
|
SNP
|
rs1800624
|
Disease risk
|
Negative
|
|
AGER
|
Homo sapiens
|
6p21.32
|
SNP
|
rs1800625
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
Gene polymorphisms
|
FokI
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
Gene polymorphisms
|
BsmI
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
Gene polymorphisms
|
TaqI
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
Gene polymorphisms
|
ApaI
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
Gene polymorphisms
|
-318 C/T
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
Gene polymorphisms
|
intergenic CT60 SNPs
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
Gene polymorphisms
|
+49 A/G
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
Gene polymorphisms
|
3' UTR (AT(n))
|
Disease risk
|
Positive
|
|
ESR1
|
Homo sapiens
|
6q25.1-q25.2
|
Gene polymorphisms
|
PvuII
|
Disease risk
|
Negative
|
|
ESR1
|
Homo sapiens
|
6q25.1-q25.2
|
Gene polymorphisms
|
XbaI
|
Disease risk
|
Negative
|
|
OAS1
|
Homo sapiens
|
12q24.13
|
SNP
|
rs10774671
|
Disease risk
|
Positive
|
|
OAS1
|
Homo sapiens
|
12q24.13
|
SNP
|
rs3741981
|
Disease risk
|
Positive
|
|
KIF1B
|
Homo sapiens
|
1p36.22
|
SNP
|
rs10492972
|
Disease risk
|
Negative
|
|
CYP7A1
|
Homo sapiens
|
8q12.1
|
SNP
|
rs3808607
|
Disease risk
|
Negative
|
|
CYP7A1
|
Homo sapiens
|
8q12.1
|
SNP
|
rs3824260
|
Disease risk
|
Negative
|
|
CYP7A1
|
Homo sapiens
|
8q12.1
|
SNP
|
-208G>C
|
Disease risk
|
Negative
|
|
NFKB1
|
Homo sapiens
|
4q24
|
Gene polymorphisms
|
-94 ins/del ATTG promoter polymorphism
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs10735810
|
Disease risk
|
Positive
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
Gene mutations
|
M694V
|
Disease risk
|
Positive
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
Gene mutations
|
M680I
|
Disease risk
|
Positive
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
Gene mutations
|
V726A
|
Disease risk
|
Positive
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
Gene mutations
|
E148Q
|
Disease risk
|
Positive
|
|
MEFV
|
Homo sapiens
|
16p13.3
|
Gene mutations
|
P369S
|
Disease risk
|
Positive
|
|
NFKBIL1
|
Homo sapiens
|
6p21.33
|
Gene polymorphisms
|
exon 4
|
Disease risk
|
Negative
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
SNP
|
—725C>G>T
|
Disease risk
|
Positive
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
SNP
|
—716>G>T
|
Disease risk
|
Negative
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
indel
|
N/A
|
Disease risk
|
Positive
|
|
IL2
|
Homo sapiens
|
4q27
|
polymorphisms
|
The positionβ384 in the promoter region
|
Disease risk
|
Negative
|
|
IL2
|
Homo sapiens
|
4q27
|
polymorphisms
|
The position +114 in the first exon
|
Disease risk
|
Negative
|
|
TLR9
|
Homo sapiens
|
3p21.2
|
SNP
|
rs5743836
|
Disease risk
|
Negative
|
|
TRIOBP
|
Homo sapiens
|
22q13.1
|
SNP
|
rs201693690
|
Disease risk
|
Positive
|
|
FCGR2A
|
Homo sapiens
|
1q23.3
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CXCL8
|
Homo sapiens
|
4q13.3
|
SNP
|
rs2227306
|
Disease risk
|
Positive
|
|
BDNF
|
Homo sapiens
|
11p14.1
|
SNP
|
rs6265
|
Treatment risk
|
Positive
|
|
IL23A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs11209026
|
Disease risk
|
Negative
|
|
IL23A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs1004819
|
Disease risk
|
Negative
|
|
STAT4
|
Homo sapiens
|
2q32.2-q32.3
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs4149584
|
Disease risk
|
Positive
|
|
AQP4
|
Homo sapiens
|
18q11.2
|
SNP
|
NA
|
Disease risk
|
Negative
|
|
CNR1
|
Homo sapiens
|
6q15
|
Allele
|
NA
|
Treatment risk
|
Positive
|
|
CD14
|
Homo sapiens
|
5q31.3
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IL18
|
Homo sapiens
|
11q23.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IL-27
|
Homo sapiens
|
16p12.1-p11.2
|
snp
|
rs 153109
|
Disease risk
|
Positive
|
|
IL-27
|
Homo sapiens
|
16p12.1-p11.2
|
snp
|
rs 181206
|
Disease risk
|
Positive
|
|
IL23A
|
Homo sapiens
|
12q13.3
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
SNP
|
(rs1799964
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
SNP
|
rs9267649
|
Disease risk
|
Positive
|
|
CYP24A1
|
Homo sapiens
|
20q13.2
|
SNP
|
rs2248359
|
Disease risk
|
Positive
|
|
CD24
|
Homo sapiens
|
6q21
|
SNP
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Alleles
|
NA
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Alleles
|
NA
|
Disease risk
|
Positive
|
|
MPO
|
Homo sapiens
|
17q22
|
SNP
|
NA
|
Disease risk
|
Positive
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
restriction fragments length polymorphisms (RFLP)
|
NA
|
Disease risk
|
Positive
|
|
ESR1
|
Homo sapiens
|
6q25.1-q25.2
|
Alleles
|
NA
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
Alleles
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Alleles
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
Alleles
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQB2
|
Homo sapiens
|
6p21.32
|
Alleles
|
NA
|
Disease risk
|
Positive
|
|
INPP4B
|
Homo sapiens
|
4q31.21
|
SNP
|
rs13102150
|
Disease risk
|
Positive
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
Alleles
|
NA
|
Disease risk
|
Positive
|
|
EIF2B1
|
Homo sapiens
|
12q24.31
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
EIF2B5
|
Homo sapiens
|
3q27.1
|
SNP
|
rs2971410
|
Disease risk
|
Negative
|
|
EIF2B5
|
Homo sapiens
|
3q27.1
|
SNP
|
rs2893756
|
Disease risk
|
Negative
|
|
PTPRC
|
Homo sapiens
|
1q31.3-q32.1
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
SYN3
|
Homo sapiens
|
22q12.3
|
SNP
|
rs133946
|
Disease risk
|
Negative
|
|
SYN3
|
Homo sapiens
|
22q12.3
|
SNP
|
rs133945
|
Disease risk
|
Negative
|
|
CYP2D6
|
Homo sapiens
|
22q13.2
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
Mbp
|
Homo sapiens
|
18q23
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
CCL2
|
Homo sapiens
|
17q12
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
VMP1
|
Homo sapiens
|
17q23.1
|
SNP
|
RS8070345
|
Phenotypic risk
|
Positive
|
|
VMP1
|
Homo sapiens
|
17q23.1
|
SNP
|
RS8070345
|
Disease risk
|
Negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
MMP2
|
Homo sapiens
|
16q12.2
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IL-2R
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs1544410
|
Disease risk
|
Negative
|
|
ESR1
|
Homo sapiens
|
6q25.1-q25.2
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
CD1A
|
Homo sapiens
|
1q23.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CD1E
|
Homo sapiens
|
1q23.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
TAGAP
|
Homo sapiens
|
6q25.3
|
SNP
|
rs1738074
|
Disease risk
|
Positive
|
|
BDNF
|
Homo sapiens
|
11p14.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3135388
|
Phenotypic risk
|
Positive
|
|
CIITA
|
Homo sapiens
|
16p13.13
|
SNP
|
rs4774C
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
STAT3
|
Homo sapiens
|
17q21.2
|
SNP
|
rs744166
|
Disease risk
|
Positive
|
|
STAT3
|
Homo sapiens
|
17q21.2
|
SNP
|
rs2293152
|
Disease risk
|
Negative
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
Rs4149584
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs10877013
|
Disease risk
|
Positive
|
|
CD14
|
Homo sapiens
|
5q31.3
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
CD14
|
Homo sapiens
|
5q31.3
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
NOTCH4
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CXCL16
|
Homo sapiens
|
17p13.2
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IFIH1
|
Homo sapiens
|
2q24.2
|
SNP
|
rs1990760
|
Disease risk
|
Positive
|
|
GPC5
|
Homo sapiens
|
13q31.3
|
SNP
|
rs10492503
|
Disease risk
|
Positive
|
|
CD58
|
Homo sapiens
|
1p13.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IRF8
|
Homo sapiens
|
16q24.1
|
SNP
|
rs17445836
|
Disease risk
|
Positive
|
|
IL23A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs2066808
|
Disease risk
|
Positive
|
|
IL23A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs2371494
|
Disease risk
|
Positive
|
|
IL23A
|
Homo sapiens
|
12q13.3
|
SNP
|
rs11575248
|
Disease risk
|
Positive
|
|
IL23R
|
Homo sapiens
|
1p31.3
|
SNP
|
rs1884444
|
Disease risk
|
Positive
|
|
IL10
|
Homo sapiens
|
1q32.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
TYK2
|
Homo sapiens
|
19p13.2
|
SNP
|
rs55762744
|
Disease risk
|
Positive
|
|
IFIH1
|
Homo sapiens
|
2q24.2
|
SNP
|
rs1990760,
|
Disease risk
|
Positive
|
|
KCNH7
|
Homo sapiens
|
2q24.2
|
SNP
|
rs2068330
|
Disease risk
|
Positive
|
|
CIITA
|
Homo sapiens
|
16p13.13
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
PRF1
|
Homo sapiens
|
10q22.1
|
SNP
|
rs885822
|
Phenotypic risk
|
Positive
|
|
PRF1
|
Homo sapiens
|
10q22.1
|
SNP
|
rs10999426
|
Phenotypic risk
|
Positive
|
|
PRF1
|
Homo sapiens
|
10q22.1
|
SNP
|
rs3758562
|
Phenotypic risk
|
Positive
|
|
GALR2
|
Homo sapiens
|
17q25.1
|
SNP
|
rs61745847
|
up-regulation
|
Phenotypic risk
|
|
LEP
|
Homo sapiens
|
7q32.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
LEPR
|
Homo sapiens
|
1p31.3
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IL6
|
Homo sapiens
|
7p15.3
|
SNP
|
rs1800795
|
Disease risk
|
Positive
|
|
IL-12
|
Homo sapiens
|
5q33.3
|
SNP
|
rs3212227
|
Disease risk
|
Positive
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
SNP
|
rs3761547
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
LEP
|
Homo sapiens
|
7q32.1
|
SNP
|
rs7799039
|
Disease risk
|
Positive
|
|
LEPR
|
Homo sapiens
|
1p31.3
|
SNP
|
rs1137101
|
Disease risk
|
Positive
|
|
PPARGC1A
|
Homo sapiens
|
4p15.2
|
SNP
|
rs8192678
|
Disease risk
|
Positive
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
PLAU
|
Homo sapiens
|
10q22.2
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
SERPINB2
|
Homo sapiens
|
18q21.33-q22.1
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
IL7
|
Homo sapiens
|
8q21.13
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
MMEL1
|
Homo sapiens
|
1p36.32
|
SNP
|
rs3748816
|
Disease risk
|
Positive
|
|
IRF5
|
Homo sapiens
|
7q32.1
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
Allele
|
NA
|
Treatment risk
|
Positive
|
|
IL10
|
Homo sapiens
|
1q32.1
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
IL-12
|
Homo sapiens
|
5q33.3
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
MMP2
|
Homo sapiens
|
16q12.2
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IL1RL1
|
Homo sapiens
|
2q12.1
|
SNP
|
rs1041973
|
Disease risk
|
Positive
|
|
IL1RAP
|
Homo sapiens
|
3q28
|
SNP
|
rs4624606
|
Disease risk
|
Negative
|
|
IL6
|
Homo sapiens
|
7p15.3
|
SNP
|
rs1800795
|
Disease risk
|
Negative
|
|
HTRA1
|
Homo sapiens
|
10q26.13
|
SNP
|
rs11200638
|
Disease risk
|
Negative
|
|
GFI1
|
Homo sapiens
|
1p22.1
|
SNP
|
rs11804321
|
Disease risk
|
Positive
|
|
GFI1
|
Homo sapiens
|
1p22.1
|
SNP
|
rs11808092
|
Disease risk
|
Positive
|
|
GFI1
|
Homo sapiens
|
1p22.1
|
SNP
|
rs6680578
|
Disease risk
|
Positive
|
|
NFKB1
|
Homo sapiens
|
4q24
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
RELA
|
Homo sapiens
|
11q13.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs2903692
|
Disease risk
|
Positive
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs6498169
|
Disease risk
|
Positive
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs6498169
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
TGFBR2
|
Homo sapiens
|
3p24.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IRF5
|
Homo sapiens
|
7q32.1
|
SNP
|
rs2004640
|
Treatment risk
|
Negative
|
|
IRF5
|
Homo sapiens
|
7q32.1
|
SNP
|
rs3807306
|
Treatment risk
|
Negative
|
|
IRF5
|
Homo sapiens
|
7q32.1
|
SNP
|
rs4728142
|
Treatment risk
|
Negative
|
|
IRF8
|
Homo sapiens
|
16q24.1
|
SNP
|
rs13333054
|
Treatment risk
|
Negative
|
|
IRF8
|
Homo sapiens
|
16q24.1
|
SNP
|
rs17445836
|
Treatment risk
|
Negative
|
|
GPC5
|
Homo sapiens
|
13q31.3
|
SNP
|
rs10492503
|
Treatment risk
|
Negative
|
|
CTLA-4
|
Homo sapiens
|
2q33.2
|
SNP
|
NA
|
Disease risk
|
Negative
|
|
CXCL10
|
Homo sapiens
|
4q21.1
|
SNP
|
rs3921
|
Disease risk
|
Negative
|
|
CXCL10
|
Homo sapiens
|
4q21.1
|
SNP
|
rs8878
|
Disease risk
|
Negative
|
|
CXCL10
|
Homo sapiens
|
4q21.1
|
SNP
|
rs3921
|
Treatment risk
|
Positive
|
|
CXCL10
|
Homo sapiens
|
4q21.1
|
SNP
|
rs8878
|
Treatment risk
|
Positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs767455
|
Disease risk
|
Negative
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs4149584
|
Disease risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
CCL7
|
Homo sapiens
|
17q12
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DMB
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DMA
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
IL2
|
Homo sapiens
|
4q27
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
PRNP
|
Homo sapiens
|
20p13
|
SNP
|
NA
|
Disease risk
|
Negative
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
TRB
|
Homo sapiens
|
7q34
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
NOD2
|
Homo sapiens
|
16q12.1
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-C
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
GRM7
|
Homo sapiens
|
3p26.1
|
SNP
|
rs779867
|
Disease risk
|
Positive
|
|
GRM7
|
Homo sapiens
|
3p26.1
|
SNP
|
rs6782011
|
Disease risk
|
Negative
|
|
GRM7
|
Homo sapiens
|
3p26.1
|
SNP
|
rs779867
|
Disease risk
|
Negative
|
|
GRM7
|
Homo sapiens
|
3p26.1
|
SNP
|
rs6782011
|
Disease risk
|
Negative
|
|
LTA
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
CD226
|
Homo sapiens
|
18q22.2
|
SNP
|
rs763361
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DRA
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQA2
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
amino acid polymorphisms
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs703842
|
Disease risk
|
Positive
|
|
TGFB1
|
Homo sapiens
|
19q13.2
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IGH
|
Homo sapiens
|
14q32.33
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
SNP
|
rs333
|
Disease risk
|
Negative
|
|
IL4
|
Homo sapiens
|
5q31.1
|
VNTR (variable number tandem repeat)
|
3 VNTR (variable number tandem repeat)
|
Disease risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
CYP7A1
|
Homo sapiens
|
8q12.1
|
SNP
|
rs3808607
|
Disease risk
|
Negative
|
|
CYP46A1
|
Homo sapiens
|
14q32.2
|
SNP
|
rs754203
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
N/A
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
PTPRC
|
Homo sapiens
|
1q31.3-q32.1
|
SNP
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
amino acid polymorphisms
|
NA
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
CNP
|
Homo sapiens
|
17q21.2
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
NRG1
|
Homo sapiens
|
8p12
|
SNP
|
rs77493513
|
Disease risk
|
Positive
|
|
MIF
|
Homo sapiens
|
22q11.23
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IL6
|
Homo sapiens
|
7p15.3
|
Allele
|
NA
|
Treatment risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DPA1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
CFB
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3135388*A
|
Disease risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
TRA
|
Homo sapiens
|
14q11.2
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IL2
|
Homo sapiens
|
4q27
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
MIR196A2
|
Homo sapiens
|
12q13.13
|
SNP
|
rs1 1614913
|
Disease risk
|
Positive
|
|
TNFSF13B
|
Homo sapiens
|
13q33.3
|
SNP
|
rs7318477
|
Disease risk
|
Positive
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
IL1B
|
Homo sapiens
|
IL-1; IL1F2; IL1beta; IL1-BETA
|
SNP
|
rs16944
|
Disease risk
|
Negative
|
|
ICAM1
|
Homo sapiens
|
19p13.2
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
ICAM1
|
Homo sapiens
|
19p13.2
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
ICAM1
|
Homo sapiens
|
19p13.2
|
SNP
|
rs5498
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3135388
|
Disease risk
|
Positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
EIF2B1
|
Homo sapiens
|
12q24.31
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
ADA
|
Homo sapiens
|
20q13.12
|
SNP
|
rs244072
|
Disease risk
|
Positive
|
|
SPP1
|
Homo sapiens
|
4q22.1
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
SPP1
|
Homo sapiens
|
4q22.1
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs2300747G
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HAVCR2
|
Homo sapiens
|
N/A
|
SNP
|
rs1036199
|
Disease risk
|
Positive
|
|
HAVCR1
|
Homo sapiens
|
N/A
|
SNP
|
rs7702919
|
Disease risk
|
Negative
|
|
RGS7
|
Homo sapiens
|
N/A
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
TRB
|
Homo sapiens
|
7q34
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
LOC102724971
|
Homo sapiens
|
15q11.2
|
Allele
|
NA
|
Phenotypic risk
|
Positive
|
|
CYTH4
|
Homo sapiens
|
22q13.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CCR2
|
Homo sapiens
|
3p21.31
|
SNP
|
rs1799864
|
Disease risk
|
Positive
|
|
IL32
|
Homo sapiens
|
16p13.3
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CD24
|
Homo sapiens
|
6q21
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
BDNF
|
Homo sapiens
|
11p14.1
|
SNP
|
rs56164415
|
Disease risk
|
Negative
|
|
HSPA4
|
Homo sapiens
|
5q31.1
|
SNP
|
rs2227956
|
Disease risk
|
Positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
ADAMTS14
|
Homo sapiens
|
10q22.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
MBP
|
Homo sapiens
|
18q23
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IL7
|
Homo sapiens
|
8q21.13
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
IL-1B
|
Homo sapiens
|
2q14.1
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
IL1RN
|
Homo sapiens
|
2q14.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CHI3L1
|
Homo sapiens
|
1q32.1
|
SNP
|
rs4950928
|
Disease risk
|
Positive
|
|
GSTT1
|
Homo sapiens
|
22q11.23
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
GSTM1
|
Homo sapiens
|
1p13.3
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
CD24
|
Homo sapiens
|
6q21
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
NOS2A
|
Homo sapiens
|
17q11.2
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
OAS1
|
Homo sapiens
|
12q24.13
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs1883832
|
Disease risk
|
Positive
|
|
RAC2
|
Homo sapiens
|
22q13.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-A
|
Homo sapiens
|
6p22.1
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
Allele
|
NA
|
Disease risk
|
Positive
|
|
FCRL3
|
Homo sapiens
|
1q23.1
|
SNP
|
rs7528684
|
Disease risk
|
Positive
|
|
FCRL3
|
Homo sapiens
|
1q23.1
|
SNP
|
rs7522061
|
Disease risk
|
Positive
|
|
FCRL3
|
Homo sapiens
|
1q23.1
|
SNP
|
rs11264799
|
Disease risk
|
Negative
|
|
LMNB1
|
Homo sapiens
|
5q23.2
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
MBP
|
Homo sapiens
|
18q23
|
Allele
|
NA
|
Disease risk
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2228570
|
Disease risk
|
Positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs7975232
|
N/A
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs1544410
|
N/A
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs11568820
|
N/A
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs2228570
|
N/A
|
Negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236
|
N/A
|
Negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs11567686
|
Phenotypic risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs11567685
|
Phenotypic risk
|
Positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs7718919
|
Phenotypic risk
|
Positive
|
|
BDNF
|
Homo sapiens
|
11p14.1
|
SNP
|
rs6265
|
Disease risk
|
positive
|
|
NLRP3
|
Homo sapiens
|
1q44
|
SNP
|
rs3806265
|
Disease risk
|
positive
|
|
NLRP3
|
Homo sapiens
|
1q44
|
SNP
|
rs10754558
|
Disease risk
|
positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
positive
|
|
GSTP1
|
Homo sapiens
|
11q13.2
|
SNP
|
rs1695
|
N/A
|
negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236
|
Disease risk
|
positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs7975232
|
Disease risk
|
positive
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
SNP
|
rs3775291
|
N/A
|
negative
|
|
TLR3
|
Homo sapiens
|
4q35.1
|
insertion-deletion TLR3 [-/A](8)
|
N/A
|
N/A
|
negative
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
a 14 bp insertion / deletion in the untranslated exon 8
|
N/A
|
N/A
|
negative
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
The -725 C/G exchange in the HLA-G promoter region
|
N/A
|
N/A
|
negative
|
|
HLA-G
|
Homo sapiens
|
6p22.1
|
HLA-G*0105N, a deletion that results in an irregular stopcodon in exon 3
|
N/A
|
N/A
|
negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
SNP
|
N/A
|
N/A
|
negative
|
|
CD80
|
Homo sapiens
|
3q13.33
|
transitions,deletion
|
N/A
|
N/A
|
negative
|
|
ERV3-1
|
Homo sapiens
|
7q11.21
|
six single base pair variations and a drop-out of a nucleotide
|
N/A
|
N/A
|
negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
N/A
|
N/A
|
negative
|
|
TRB
|
Homo sapiens
|
7q34
|
polymorphism
|
N/A
|
N/A
|
negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
polymorphism
|
N/A
|
N/A
|
negative
|
|
C3
|
Homo sapiens
|
19p13.3
|
polymorphism
|
N/A
|
Disease risk
|
positive
|
|
P2RX7
|
Homo sapiens
|
12q24.31
|
SNP
|
rs1718119
|
Disease risk
|
positive
|
|
P2RX7
|
Homo sapiens
|
12q24.31
|
SNP
|
rs22390912
|
Disease risk
|
positive
|
|
ANKRD55
|
Homo sapiens
|
5q11.2
|
SNP
|
rs6859219
|
Disease risk
|
positive
|
|
MMEL1
|
Homo sapiens
|
1p36.32
|
SNP
|
rs3748816
|
N/A
|
negative
|
|
MANBA
|
Homo sapiens
|
4q24
|
SNP
|
rs7665090
|
Disease risk
|
positive
|
|
L3MBTL3
|
Homo sapiens
|
6q23.1
|
SNP
|
rs7740107
|
Disease risk
|
positive
|
|
TNF
|
Homo sapiens
|
6p21.33
|
SNP
|
rs1800629 G/A
|
Disease risk
|
positive
|
|
IL18
|
Homo sapiens
|
11q23.1
|
SNP
|
rs1946518 C/A
|
Disease risk
|
positive
|
|
IL16
|
Homo sapiens
|
15q25.1
|
SNP
|
rs4072111 C/T
|
N/A
|
negative
|
|
IDO2
|
Homo sapiens
|
8p11.21
|
SNP
|
rs10109853
|
N/A
|
negative
|
|
IDO2
|
Homo sapiens
|
8p11.21
|
SNP
|
rs4503083
|
N/A
|
negative
|
|
RORA
|
Homo sapiens
|
15q22.2
|
SNP
|
rs11639048
|
Disease risk
|
positive
|
|
RORA
|
Homo sapiens
|
15q22.2
|
SNP
|
rs4774388
|
Disease risk
|
positive
|
|
CBS
|
Homo sapiens
|
21q22.3
|
c.844_855ins68bp
|
N/A
|
Disease risk
|
positive
|
|
RFC1
|
Homo sapiens
|
4p14
|
c.80G>A
|
N/A
|
Disease risk
|
positive
|
|
GRIN1
|
Homo sapiens
|
9q34.3
|
SNP
|
rs4880213
|
Disease risk
|
positive
|
|
CASP8
|
Homo sapiens
|
2q33.1
|
SNP
|
rs2037815
|
Disease risk
|
positive
|
|
CASP8
|
Homo sapiens
|
2q33.1
|
SNP
|
rs12990906
|
Disease risk
|
positive
|
|
CASP8
|
Homo sapiens
|
2q33.1
|
SNP
|
rs13113
|
Disease risk
|
positive
|
|
MYO3B
|
Homo sapiens
|
2q31.1
|
SNP
|
N/A
|
N/A
|
negative
|
|
MYO3B
|
Homo sapiens
|
2q31.1
|
SNP
|
N/A
|
N/A
|
negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs10735810
|
N/A
|
negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
epsilon4
|
N/A
|
N/A
|
negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
DRB 1" 1501
|
N/A
|
Disease risk
|
positive
|
|
FOXO3
|
Homo sapiens
|
6q21
|
SNP
|
rs2253310
|
Disease risk
|
positive
|
|
FOXO3
|
Homo sapiens
|
6q21
|
SNP
|
rs4966936
|
Disease risk
|
positive
|
|
FOXO1
|
Homo sapiens
|
13q14.11
|
SNP
|
rs3900833
|
Disease risk
|
positive
|
|
IL12B
|
Homo sapiens
|
5q33.3
|
SNP
|
rs17860508
|
Disease risk
|
positive
|
|
IL12B
|
Homo sapiens
|
5q33.3
|
SNP
|
rs3212227
|
Disease risk
|
positive
|
|
EVI5
|
Homo sapiens
|
1p22.1
|
SNP
|
rs6680578
|
N/A
|
negative
|
|
EVI5
|
Homo sapiens
|
1p22.1
|
SNP
|
rs11810217
|
N/A
|
negative
|
|
PDCD1
|
Homo sapiens
|
2q37.3
|
SNP
|
rs11568821
|
Disease risk
|
positive
|
|
PDCD1
|
Homo sapiens
|
2q37.3
|
SNP
|
rs2227981
|
Disease risk
|
positive
|
|
PDCD1
|
Homo sapiens
|
2q37.3
|
SNP
|
rs2227982
|
Disease risk
|
positive
|
|
ERAP1
|
Homo sapiens
|
5q15
|
SNP
|
rs30187
|
Disease risk
|
positive
|
|
GRN
|
Homo sapiens
|
17q21.31
|
SNP
|
rs2879096
|
Disease risk
|
positive
|
|
CIITA
|
Homo sapiens
|
16p13.13
|
SNP
|
rs4774
|
Disease risk
|
positive
|
|
SPARCL1
|
Homo sapiens
|
4q22.1
|
SNP
|
rs1049539
|
N/A
|
negative
|
|
SPARCL1
|
Homo sapiens
|
4q22.1
|
SNP
|
rs1049544
|
N/A
|
negative
|
|
SPARCL1
|
Homo sapiens
|
4q22.1
|
SNP
|
rs1130643
|
N/A
|
negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
DRB1*15:01 allele
|
N/A
|
Disease risk
|
positive
|
|
PLCG2
|
Homo sapiens
|
16q23.3
|
SNP
|
rs72824905
|
Disease risk
|
positive
|
|
HTR2A
|
Homo sapiens
|
13q14.2
|
DNA methylation
|
N/A
|
Disease risk
|
positive
|
|
CD33
|
Homo sapiens
|
19q13.41
|
SNP
|
rs3865444
|
Disease risk
|
positive
|
|
CD58
|
Homo sapiens
|
1p13.1
|
SNP
|
rs1414273
|
Disease risk
|
positive
|
|
AHI1
|
Homo sapiens
|
6q23.3
|
SNP
|
rs11154801
|
Disease risk
|
positive
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs7975232
|
N/A
|
negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
SNP
|
rs731236
|
Disease risk
|
positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs1800693
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
allele
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
HLA-DRB1 *0801 allele
|
N/A
|
Disease risk
|
positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
epsilon-4 allele
|
N/A
|
N/A
|
negative
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
deletion
|
N/A
|
Disease risk
|
positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
SNP
|
rs3087243
|
Disease risk
|
positive
|
|
CCR5
|
Homo sapiens
|
3p21.31
|
A 32-bp deletion in the CCR5
|
N/A
|
Disease risk
|
positive
|
|
MAG
|
Homo sapiens
|
19q13.12
|
SNP
|
N/A
|
N/A
|
negative
|
|
SH2D2A
|
Homo sapiens
|
1q23.1
|
SH2D2A GA repeat
|
N/A
|
N/A
|
negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
HLA-DR15
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
DRB1*1501
|
N/A
|
Disease risk
|
positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
DQA1*0102
|
N/A
|
Disease risk
|
positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
DQB1*0602
|
N/A
|
Disease risk
|
positive
|
|
HRES1
|
Homo sapiens
|
1q42
|
allelic
|
N/A
|
Disease risk
|
positive
|
|
TAP1
|
Homo sapiens
|
6p21.32
|
dimorphisms
|
N/A
|
Disease risk
|
positive
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
dimorphisms
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
DRB5 * 0101
|
N/A
|
Disease risk
|
positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
DQB1*0602
|
N/A
|
Disease risk
|
positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
DQA1*0102
|
N/A
|
Disease risk
|
positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
HLA-DP β
|
N/A
|
N/A
|
negative
|
|
LRP2
|
Homo sapiens
|
2q31.1
|
SNP
|
rs12988804
|
Disease risk
|
positive
|
|
SIRPG
|
Homo sapiens
|
20p13
|
SNP
|
rs2281808
|
Disease risk
|
positive
|
|
C3
|
Homo sapiens
|
19p13.3
|
SNP
|
rs2230199
|
Disease risk
|
positive
|
|
MIR155
|
Homo sapiens
|
21q21.3
|
SNP
|
rs767649
|
N/A
|
negative
|
|
MIR196A2
|
Homo sapiens
|
12q13.13
|
SNP
|
rs11614913
|
N/A
|
negative
|
|
VDR
|
Homo sapiens
|
12q13.11
|
FokI ff
|
N/A
|
Disease risk
|
positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs201084372
|
Disease risk
|
positive
|
|
IL12B
|
Homo sapiens
|
5q33.3
|
SNP
|
rs6887695
|
Disease risk
|
positive
|
|
CSGALNACT1
|
Homo sapiens
|
8p21.3
|
cSNP
|
rs140161612
|
N/A
|
negative
|
|
ACE
|
Homo sapiens
|
17q23.3
|
ACE homozygotes, II
|
N/A
|
Disease risk
|
positive
|
|
ACE
|
Homo sapiens
|
17q23.3
|
ACE homozygotes,DD
|
N/A
|
Disease risk
|
positive
|
|
ACE
|
Homo sapiens
|
17q23.3
|
AT1R 1166A/C
|
N/A
|
N/A
|
negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
positive
|
|
CIITA
|
Homo sapiens
|
16p13.13
|
SNP
|
rs4774 * C
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
HLA-DRB1*15:01
|
N/A
|
Disease risk
|
positive
|
|
WT1
|
Homo sapiens
|
11p13
|
SNP
|
rs10767935
|
Disease risk
|
positive
|
|
WT1
|
Homo sapiens
|
11p13
|
SNP
|
rs5030244
|
Disease risk
|
positive
|
|
NQO1
|
Homo sapiens
|
16q22.1
|
SNP
|
rs1800566
|
N/A
|
negative
|
|
CD226
|
Homo sapiens
|
18q22.2
|
SNP
|
rs1788229
|
N/A
|
negative
|
|
CD226
|
Homo sapiens
|
18q22.2
|
SNP
|
rs763361
|
N/A
|
negative
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
DQB1*0303
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
HLA-DRB1 * 04 / * 07
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
HLA-DRB1*09 (DR53)
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
DRB1*15
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
*16 (DR51)
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
*08 (DR8)
|
N/A
|
Disease risk
|
positive
|
|
STAT3
|
Homo sapiens
|
17q21.2
|
SNP
|
rs744166
|
Disease risk
|
positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
CT60A/G
|
N/A
|
Disease risk
|
positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
Jo31G/T
|
N/A
|
Disease risk
|
positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
CTLA-4-319C/T
|
N/A
|
Disease risk
|
positive
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
(AT)n repeat
|
N/A
|
Disease risk
|
positive
|
|
BTG1
|
Homo sapiens
|
12q21.33
|
SNP
|
rs731652
|
Disease risk
|
positive
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
R92Q
|
N/A
|
Disease risk
|
positive
|
|
DLG5
|
Homo sapiens
|
10q22.3
|
SNP
|
rs1248696
|
N/A
|
negative
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs2076530
|
N/A
|
negative
|
|
UCP2
|
Homo sapiens
|
11q13.4
|
UCP2-866G
|
N/A
|
Disease risk
|
positive
|
|
PTPRC
|
Homo sapiens
|
1q31.3-q32.1
|
C77G
|
N/A
|
N/A
|
negative
|
|
IFNGR2
|
Homo sapiens
|
21q22.11
|
IFNGR2*Arg64
|
N/A
|
Disease risk
|
positive
|
|
APOE
|
Homo sapiens
|
19q13.32
|
epsilon4
|
N/A
|
Disease risk
|
positive
|
|
FCGR2A
|
Homo sapiens
|
1q23.3
|
allele
|
N/A
|
N/A
|
negative
|
|
FCGR3B
|
Homo sapiens
|
1q23.3
|
allele
|
N/A
|
N/A
|
negative
|
|
CTLA4
|
Homo sapiens
|
2q33.2
|
intragenic polymorphisms
|
N/A
|
Disease risk
|
positive
|
|
TAP2
|
Homo sapiens
|
6p21.32
|
locus
|
N/A
|
N/A
|
negative
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs987107
|
Disease risk
|
positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs3194051
|
Disease risk
|
positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs1494571
|
Disease risk
|
positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs1883832
|
Disease risk
|
positive
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs6074022
|
Disease risk
|
positive
|
|
CNR2
|
Homo sapiens
|
1p36.11
|
SNP
|
rs35761398
|
Disease risk
|
positive
|
|
GTF2I
|
Homo sapiens
|
7q11.23
|
SNP
|
rs117026326
|
N/A
|
negative
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs12722489
|
Disease risk
|
positive
|
|
CXCR5
|
Homo sapiens
|
11q23.3
|
SNP
|
rs3922
|
N/A
|
negative
|
|
FTO
|
Homo sapiens
|
16q12.2
|
SNP
|
rs9939609
|
Disease risk
|
positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs11567685
|
Disease risk
|
positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
N/A
|
negative
|
|
IL18
|
Homo sapiens
|
11q23.1
|
SNP
|
rs187238
|
Disease risk
|
positive
|
|
KIR2DL1
|
Homo sapiens
|
19q13.42
|
N/A
|
N/A
|
Disease risk
|
positive
|
|
HLA-B
|
Homo sapiens
|
6p21.33
|
HLA-Bw4
|
N/A
|
Disease risk
|
positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs2104286
|
Disease risk
|
positive
|
|
IL2RA
|
Homo sapiens
|
10p15.1
|
SNP
|
rs11594656
|
Disease risk
|
positive
|
|
LILRA3
|
Homo sapiens
|
19q13.4
|
deletion
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
SNP
|
rs3135388
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
HLA-DRB1(*)0406
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
DRB1(*)1302, DRB1(*)120201 and DPB1(*)2101
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
DRB1(*)120201 and DPB1(*)2101
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
DPB1(*)2101
|
N/A
|
Disease risk
|
positive
|
|
UCP2
|
Homo sapiens
|
11q13.4
|
SNP
|
rs660339
|
Disease risk
|
positive
|
|
CD24
|
Homo sapiens
|
6q21
|
Ala/Val
|
N/A
|
N/A
|
negative
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
5'GT repeat
|
N/A
|
N/A
|
negative
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
D543N
|
N/A
|
N/A
|
negative
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
1729 + 55del4
|
N/A
|
N/A
|
negative
|
|
SLC11A1
|
Homo sapiens
|
2q35
|
1729 + 271del4
|
N/A
|
N/A
|
negative
|
|
APOE
|
Homo sapiens
|
19q13.32
|
epsilon4
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
HLA-DRB1*15
|
N/A
|
N/A
|
negative
|
|
ICAM1
|
Homo sapiens
|
19p13.2
|
Exon 4 and exon 6
|
N/A
|
N/A
|
negative
|
|
MBP
|
Homo sapiens
|
18q23
|
1445 bp
|
N/A
|
N/A
|
negative
|
|
Ace
|
Homo sapiens
|
11 E1; 11 68.84 cM
|
SNP
|
rs1799752
|
Disease risk
|
positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs11567685
|
Disease risk
|
positive
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
positive
|
|
CD6
|
Homo sapiens
|
11q12.2
|
SNP
|
rs11230563
|
Disease risk
|
positive
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs12708716
|
Disease risk
|
positive
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs6498169
|
Disease risk
|
positive
|
|
EVI5
|
Homo sapiens
|
1p22.1
|
SNP
|
rs10735781
|
Disease risk
|
positive
|
|
EVI5
|
Homo sapiens
|
1p22.1
|
SNP
|
rs6680578
|
Disease risk
|
positive
|
|
GPC5
|
Homo sapiens
|
13q31.3
|
SNP
|
rs553717
|
Disease risk
|
positive
|
|
TYK2
|
Homo sapiens
|
19p13.2
|
SNP
|
rs34536443
|
Disease risk
|
positive
|
|
EBF1
|
Homo sapiens
|
5q33.3
|
SNP
|
rs1368297
|
Disease risk
|
positive
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
N/A
|
HLA-DPB1*0501
|
Disease risk
|
positive
|
|
CCL2
|
Homo sapiens
|
17q12
|
SNP
|
rs1024611
|
Disease risk
|
we did not find any association, which was consistent with other studies in Caucasian populations. In conclusion, our results suggest that CCL2 variants may not contribute to the pathogenesis of IDD
|
|
CCL2
|
Homo sapiens
|
17q12
|
SNP
|
rs2857656
|
Disease risk
|
we did not find any association, which was consistent with other studies in Caucasian populations. In conclusion, our results suggest that CCL2 variants may not contribute to the pathogenesis of IDD
|
|
CCL2
|
Homo sapiens
|
17q12
|
SNP
|
rs28730833
|
Disease risk
|
we did not find any association, which was consistent with other studies in Caucasian populations. In conclusion, our results suggest that CCL2 variants may not contribute to the pathogenesis of IDD
|
|
CCL2
|
Homo sapiens
|
17q12
|
SNP
|
rs3917887
|
Disease risk
|
we did not find any association, which was consistent with other studies in Caucasian populations. In conclusion, our results suggest that CCL2 variants may not contribute to the pathogenesis of IDD
|
|
CCL2
|
Homo sapiens
|
17q12
|
SNP
|
rs2857657
|
Disease risk
|
we did not find any association, which was consistent with other studies in Caucasian populations. In conclusion, our results suggest that CCL2 variants may not contribute to the pathogenesis of IDD
|
|
CCL2
|
Homo sapiens
|
17q12
|
SNP
|
rs4586
|
Disease risk
|
we did not find any association, which was consistent with other studies in Caucasian populations. In conclusion, our results suggest that CCL2 variants may not contribute to the pathogenesis of IDD
|
|
CCL2
|
Homo sapiens
|
17q12
|
SNP
|
rs13900
|
Disease risk
|
we did not find any association, which was consistent with other studies in Caucasian populations. In conclusion, our results suggest that CCL2 variants may not contribute to the pathogenesis of IDD
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs4149584
|
Disease risk
|
our results provide support for a sex†and HLAâ€DRB1*15:01â€independent association of TNFRSF1A rs1800693 SNP with MS susceptibility, but not with age at disease onset, severity or rate of disability accumulation
|
|
TNFRSF1A
|
Homo sapiens
|
12p13.31
|
SNP
|
rs1800693
|
Disease risk
|
our results provide support for a sex†and HLAâ€DRB1*15:01â€independent association of TNFRSF1A rs1800693 SNP with MS susceptibility, but not with age at disease onset, severity or rate of disability accumulation
|
|
GC
|
Homo sapiens
|
4q13.3
|
gene polymorphisms
|
N/A
|
Disease risk
|
While MP therapy during pregnancy is considered relatively save for the fetus, it may be detrimental for later cognitive and neuropsychiatric function. The underlying mechanism is thought to be an epigenetically mediated desensitization of GC receptors, the subsequent increase in stress sensitivity, and a GC-mediated impairment of brain development.
|
|
TGFB3
|
Homo sapiens
|
14q24.3
|
gene polymorphisms
|
N/A
|
Disease risk
|
TGFP3, the only gene highlighted by this study, deserves further analysis
|
|
FGF2
|
Homo sapiens
|
4q28.1
|
gene polymorphisms
|
N/A
|
Disease risk
|
TGFP3, the only gene highlighted by this study, deserves further analysis
|
|
FGFR2
|
Homo sapiens
|
10q26.13
|
gene polymorphisms
|
N/A
|
Disease risk
|
TGFP3, the only gene highlighted by this study, deserves further analysis
|
|
FGFR3
|
Homo sapiens
|
4p16.3
|
gene polymorphisms
|
N/A
|
Disease risk
|
TGFP3, the only gene highlighted by this study, deserves further analysis
|
|
PDGFA
|
Homo sapiens
|
7p22.3
|
gene polymorphisms
|
N/A
|
Disease risk
|
TGFP3, the only gene highlighted by this study, deserves further analysis
|
|
IGF1R
|
Homo sapiens
|
15q26.3
|
gene polymorphisms
|
N/A
|
Disease risk
|
TGFP3, the only gene highlighted by this study, deserves further analysis
|
|
TRK-C
|
Homo sapiens
|
15q25.3
|
gene polymorphisms
|
N/A
|
Disease risk
|
TGFP3, the only gene highlighted by this study, deserves further analysis
|
|
NRG1
|
Homo sapiens
|
8p12
|
gene polymorphisms
|
N/A
|
Disease risk
|
TGFP3, the only gene highlighted by this study, deserves further analysis
|
|
EGFR
|
Homo sapiens
|
7p11.2
|
gene polymorphisms
|
N/A
|
Disease risk
|
TGFP3, the only gene highlighted by this study, deserves further analysis
|
|
ERBB2
|
Homo sapiens
|
17q12
|
gene polymorphisms
|
N/A
|
Disease risk
|
TGFP3, the only gene highlighted by this study, deserves further analysis
|
|
NR5A1
|
Homo sapiens
|
9q33.3
|
gene polymorphisms
|
N/A
|
Disease risk
|
TGFP3, the only gene highlighted by this study, deserves further analysis
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
gene polymorphisms
|
N/A
|
Disease risk
|
Thus, the contribution of HLA class II to the pathogenesis of MS is not mediated by allele-overlapping antigen binding sites, but is confined to the disease associated HLA allele
|
|
CD4
|
Homo sapiens
|
12p13.31
|
SNP
|
rs7957426
|
Disease risk
|
Three SNPs (rs3782736, rs7957426, rs10774450) showed association at the 5% significance level
|
|
CD4
|
Homo sapiens
|
12p13.31
|
SNP
|
rs10774450
|
Disease risk
|
Three SNPs (rs3782736, rs7957426, rs10774450) showed association at the 5% significance level
|
|
CD4
|
Homo sapiens
|
12p13.31
|
SNP
|
rs3782736
|
Disease risk
|
Three SNPs (rs3782736, rs7957426, rs10774450) showed association at the 5% significance level
|
|
CCL14
|
Homo sapiens
|
17q12
|
SNP
|
rs854680
|
Disease risk
|
this study reveals strong associations with a marker and a haplotype encompassing the CCL14 gene, which suggests that a lupus relevant variant may lie within or in the proximity of this haplotype
|
|
CCL14
|
Homo sapiens
|
17q12
|
SNP
|
rs16971802
|
Disease risk
|
this study reveals strong associations with a marker and a haplotype encompassing the CCL14 gene, which suggests that a lupus relevant variant may lie within or in the proximity of this haplotype
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
resulting in stronger association with similar OR (P 1.9 β 10E29). These findings in our sample support previous reported association studies between IL7RA rs6897932 and MS
|
|
GPC1
|
Homo sapiens
|
2q37.3
|
SNP
|
rs9523787
|
Disease risk
|
An intronic SNP in the Glypican-5 gene (rs9523787) showed association with MS (pcorr= 0.006)
|
|
GPC1
|
Homo sapiens
|
2q37.3
|
SNP
|
rs7333912
|
Disease risk
|
An intronic SNP in the Glypican-5 gene (rs9523787) showed association with MS (pcorr= 0.006)
|
|
GPC1
|
Homo sapiens
|
2q37.3
|
SNP
|
rs17267815
|
Disease risk
|
An intronic SNP in the Glypican-5 gene (rs9523787) showed association with MS (pcorr= 0.006)
|
|
GPC1
|
Homo sapiens
|
2q37.3
|
SNP
|
rs12876985
|
Disease risk
|
An intronic SNP in the Glypican-5 gene (rs9523787) showed association with MS (pcorr= 0.006)
|
|
IRF5
|
Homo sapiens
|
7q32.1
|
SNP
|
rs4728142
|
Disease risk
|
Additionally, trends for association were observed between rs3807306T and infection with HHV-6 [p 0.05, OR (95% CI) 1.56 (1.00–2.44)] and response to IFN-b therapy [P 0.09, OR (95% CI) 1.39 (0.95–2.05)].
|
|
IRF5
|
Homo sapiens
|
7q32.1
|
SNP
|
rs3807306
|
Disease risk
|
Additionally, trends for association were observed between rs3807306T and infection with HHV-6 [p 0.05, OR (95% CI) 1.56 (1.00–2.44)] and response to IFN-b therapy [P 0.09, OR (95% CI) 1.39 (0.95–2.05)].
|
|
PCK1
|
Homo sapiens
|
20q13.31
|
SNP
|
rs8192708G
|
Disease risk
|
MS subjects were genotyped for five single nucleotide polymorphisms (SNPs) associated with susceptibility to AD: PICALM, CR1, CLU, PCK1, and ZNF224. We assessed brain volume using Brain Parenchymal Fraction (BPF) measurements obtained from Magnetic Resonance Imaging (MRI) data and cognitive function using the Symbol Digit Modalities Test (SDMT). Genotypes were correlated with cross-sectional BPF and SDMT scores using linear regression after adjusting for sex, age at symptom onset, and disease duration. 722 MS patients with a mean (6SD) age at enrollment of 41 (610) years were followed for 44 (628) months. The AD risk-associated allele of a non-synonymous SNP in the PCK1 locus (rs8192708G ) is associated with a smaller average brain volume (P = 0.0047) at the baseline MRI, but it does not impact our baseline estimate of cognition. PCK1 is additionally associated with higher baseline T2-hyperintense lesion volume (P = 0.0088). Finally, we provide technical validation of our observation in a subset of 641 subjects that have more than one MRI study, demonstrating the same association between PCK1 and smaller average brain volume (P = 0.0089) at the last MRI visit
|
|
PICALM
|
Homo sapiens
|
11q14.2
|
SNP
|
rs3851179
|
Disease risk
|
MS subjects were genotyped for five single nucleotide polymorphisms (SNPs) associated with susceptibility to AD: PICALM, CR1, CLU, PCK1, and ZNF224. We assessed brain volume using Brain Parenchymal Fraction (BPF) measurements obtained from Magnetic Resonance Imaging (MRI) data and cognitive function using the Symbol Digit Modalities Test (SDMT). Genotypes were correlated with cross-sectional BPF and SDMT scores using linear regression after adjusting for sex, age at symptom onset, and disease duration. 722 MS patients with a mean (6SD) age at enrollment of 41 (610) years were followed for 44 (628) months. The AD risk-associated allele of a non-synonymous SNP in the PCK1 locus (rs8192708G ) is associated with a smaller average brain volume (P = 0.0047) at the baseline MRI, but it does not impact our baseline estimate of cognition. PCK1 is additionally associated with higher baseline T2-hyperintense lesion volume (P = 0.0088). Finally, we provide technical validation of our observation in a subset of 641 subjects that have more than one MRI study, demonstrating the same association between PCK1 and smaller average brain volume (P = 0.0089) at the last MRI visit
|
|
CR1
|
Homo sapiens
|
1q32.2
|
SNP
|
rs6656401
|
Disease risk
|
MS subjects were genotyped for five single nucleotide polymorphisms (SNPs) associated with susceptibility to AD: PICALM, CR1, CLU, PCK1, and ZNF224. We assessed brain volume using Brain Parenchymal Fraction (BPF) measurements obtained from Magnetic Resonance Imaging (MRI) data and cognitive function using the Symbol Digit Modalities Test (SDMT). Genotypes were correlated with cross-sectional BPF and SDMT scores using linear regression after adjusting for sex, age at symptom onset, and disease duration. 722 MS patients with a mean (6SD) age at enrollment of 41 (610) years were followed for 44 (628) months. The AD risk-associated allele of a non-synonymous SNP in the PCK1 locus (rs8192708G ) is associated with a smaller average brain volume (P = 0.0047) at the baseline MRI, but it does not impact our baseline estimate of cognition. PCK1 is additionally associated with higher baseline T2-hyperintense lesion volume (P = 0.0088). Finally, we provide technical validation of our observation in a subset of 641 subjects that have more than one MRI study, demonstrating the same association between PCK1 and smaller average brain volume (P = 0.0089) at the last MRI visit
|
|
CLU
|
Homo sapiens
|
8p21.1
|
SNP
|
rs11136000
|
Disease risk
|
MS subjects were genotyped for five single nucleotide polymorphisms (SNPs) associated with susceptibility to AD: PICALM, CR1, CLU, PCK1, and ZNF224. We assessed brain volume using Brain Parenchymal Fraction (BPF) measurements obtained from Magnetic Resonance Imaging (MRI) data and cognitive function using the Symbol Digit Modalities Test (SDMT). Genotypes were correlated with cross-sectional BPF and SDMT scores using linear regression after adjusting for sex, age at symptom onset, and disease duration. 722 MS patients with a mean (6SD) age at enrollment of 41 (610) years were followed for 44 (628) months. The AD risk-associated allele of a non-synonymous SNP in the PCK1 locus (rs8192708G ) is associated with a smaller average brain volume (P = 0.0047) at the baseline MRI, but it does not impact our baseline estimate of cognition. PCK1 is additionally associated with higher baseline T2-hyperintense lesion volume (P = 0.0088). Finally, we provide technical validation of our observation in a subset of 641 subjects that have more than one MRI study, demonstrating the same association between PCK1 and smaller average brain volume (P = 0.0089) at the last MRI visit
|
|
ZNF224
|
Homo sapiens
|
19q13.31
|
SNP
|
rs3746319
|
Disease risk
|
MS subjects were genotyped for five single nucleotide polymorphisms (SNPs) associated with susceptibility to AD: PICALM, CR1, CLU, PCK1, and ZNF224. We assessed brain volume using Brain Parenchymal Fraction (BPF) measurements obtained from Magnetic Resonance Imaging (MRI) data and cognitive function using the Symbol Digit Modalities Test (SDMT). Genotypes were correlated with cross-sectional BPF and SDMT scores using linear regression after adjusting for sex, age at symptom onset, and disease duration. 722 MS patients with a mean (6SD) age at enrollment of 41 (610) years were followed for 44 (628) months. The AD risk-associated allele of a non-synonymous SNP in the PCK1 locus (rs8192708G ) is associated with a smaller average brain volume (P = 0.0047) at the baseline MRI, but it does not impact our baseline estimate of cognition. PCK1 is additionally associated with higher baseline T2-hyperintense lesion volume (P = 0.0088). Finally, we provide technical validation of our observation in a subset of 641 subjects that have more than one MRI study, demonstrating the same association between PCK1 and smaller average brain volume (P = 0.0089) at the last MRI visit
|
|
MERTK
|
Homo sapiens
|
2q13
|
SNP
|
rs867311
|
Disease risk
|
All 12 replicated SNPs were in strong linkage disequilibrium with each other. In combination, these data suggest the MERTK gene is a novel risk gene for MS susceptibility
|
|
MERTK
|
Homo sapiens
|
2q13
|
SNP
|
rs12477716
|
Disease risk
|
All 12 replicated SNPs were in strong linkage disequilibrium with each other. In combination, these data suggest the MERTK gene is a novel risk gene for MS susceptibility
|
|
MERTK
|
Homo sapiens
|
2q13
|
SNP
|
rs17835605
|
Disease risk
|
All 12 replicated SNPs were in strong linkage disequilibrium with each other. In combination, these data suggest the MERTK gene is a novel risk gene for MS susceptibility
|
|
MERTK
|
Homo sapiens
|
2q13
|
SNP
|
rs4278932
|
Disease risk
|
All 12 replicated SNPs were in strong linkage disequilibrium with each other. In combination, these data suggest the MERTK gene is a novel risk gene for MS susceptibility
|
|
MERTK
|
Homo sapiens
|
2q13
|
SNP
|
rs4528767
|
Disease risk
|
All 12 replicated SNPs were in strong linkage disequilibrium with each other. In combination, these data suggest the MERTK gene is a novel risk gene for MS susceptibility
|
|
MERTK
|
Homo sapiens
|
2q13
|
SNP
|
rs17174870
|
Disease risk
|
All 12 replicated SNPs were in strong linkage disequilibrium with each other. In combination, these data suggest the MERTK gene is a novel risk gene for MS susceptibility
|
|
MERTK
|
Homo sapiens
|
2q13
|
SNP
|
rs1516629
|
Disease risk
|
All 12 replicated SNPs were in strong linkage disequilibrium with each other. In combination, these data suggest the MERTK gene is a novel risk gene for MS susceptibility
|
|
IRF5
|
Homo sapiens
|
7q32.1
|
SNP
|
rs2004640-TT
|
Disease risk
|
The clinical relevance of the rs2004640-TT genotype was validated in an independent cohort wherein a shorter time to first relapse was found (P 0.037). These findings suggest a role for IRF5 gene variation in the pharmacological and clinical outcome of IFNb therapy that might have relevance as biomarker to predict the response to IFNb in multiple sclerosis
|
|
IRF5
|
Homo sapiens
|
7q32.1
|
SNP
|
rs47281420-AA
|
Disease risk
|
The clinical relevance of the rs2004640-TT genotype was validated in an independent cohort wherein a shorter time to first relapse was found (P 0.037). These findings suggest a role for IRF5 gene variation in the pharmacological and clinical outcome of IFNb therapy that might have relevance as biomarker to predict the response to IFNb in multiple sclerosis
|
|
IRF5
|
Homo sapiens
|
7q32.1
|
SNP
|
rs4728142-AA
|
Disease risk
|
The clinical relevance of the rs2004640-TT genotype was validated in an independent cohort wherein a shorter time to first relapse was found (P 0.037). These findings suggest a role for IRF5 gene variation in the pharmacological and clinical outcome of IFNb therapy that might have relevance as biomarker to predict the response to IFNb in multiple sclerosis
|
|
USP18
|
Homo sapiens
|
22q11.21
|
SNP
|
rs2542109
|
Disease risk
|
Altogether, these results point to a role of USP18 in MS pathogenesis and the therapeutic response to IFNb.
|
|
USP18
|
Homo sapiens
|
22q11.21
|
SNP
|
rs9618216
|
Disease risk
|
Altogether, these results point to a role of USP18 in MS pathogenesis and the therapeutic response to IFNb.
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
SNP
|
rs6073751
|
Disease risk
|
We determined the first five axes of variation resulting from a multidimensional scaling analysis (MDS) of the identity by state (IBS) matrix. These were used as covariates in the analysis, thereby taking population stratification into account. SNPs with a minor allele frequency (MAF) b0.01, a call rate b98%, or a significant deviation from Hardy–Weinberg-Equilibrium
|
|
MMP9
|
Homo sapiens
|
20q13.12
|
SNP
|
rs3918242
|
Disease risk
|
We determined the first five axes of variation resulting from a multidimensional scaling analysis (MDS) of the identity by state (IBS) matrix. These were used as covariates in the analysis, thereby taking population stratification into account. SNPs with a minor allele frequency (MAF) b0.01, a call rate b98%, or a significant deviation from Hardy–Weinberg-Equilibrium
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
SNP
|
rs1801133
|
Disease risk
|
In our study, we observed that the frequency of the T/T genotype for the MTHFR C[677]T polymorphism was significantly higher in patients than in controls (p = 0.04, OR: 3.16, 95% CI: 1.23-8.17).Though for the MTHFR A[1298]C polymorphism, the A/A genotype was more frequent in controls than in patients (41.3% vs. 32.5%, p = 0.04). Similarly to previous studies, we found a possible link between an increased risk of MS and the MTHFR C[677]T polymorphism and a decreased risk (protective effects) of MS and the MTHFR A[1298]C polymorphism
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
SNP
|
rs1801131
|
Disease risk
|
In our study, we observed that the frequency of the T/T genotype for the MTHFR C[677]T polymorphism was significantly higher in patients than in controls (p = 0.04, OR: 3.16, 95% CI: 1.23-8.17).Though for the MTHFR A[1298]C polymorphism, the A/A genotype was more frequent in controls than in patients (41.3% vs. 32.5%, p = 0.04). Similarly to previous studies, we found a possible link between an increased risk of MS and the MTHFR C[677]T polymorphism and a decreased risk (protective effects) of MS and the MTHFR A[1298]C polymorphism
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
SNP
|
rs1805087
|
Disease risk
|
In our study, we observed that the frequency of the T/T genotype for the MTHFR C[677]T polymorphism was significantly higher in patients than in controls (p = 0.04, OR: 3.16, 95% CI: 1.23-8.17).Though for the MTHFR A[1298]C polymorphism, the A/A genotype was more frequent in controls than in patients (41.3% vs. 32.5%, p = 0.04). Similarly to previous studies, we found a possible link between an increased risk of MS and the MTHFR C[677]T polymorphism and a decreased risk (protective effects) of MS and the MTHFR A[1298]C polymorphism
|
|
MTHFR
|
Homo sapiens
|
1p36.22
|
SNP
|
rs1801394
|
Disease risk
|
In our study, we observed that the frequency of the T/T genotype for the MTHFR C[677]T polymorphism was significantly higher in patients than in controls (p = 0.04, OR: 3.16, 95% CI: 1.23-8.17).Though for the MTHFR A[1298]C polymorphism, the A/A genotype was more frequent in controls than in patients (41.3% vs. 32.5%, p = 0.04). Similarly to previous studies, we found a possible link between an increased risk of MS and the MTHFR C[677]T polymorphism and a decreased risk (protective effects) of MS and the MTHFR A[1298]C polymorphism
|
|
MBP
|
Homo sapiens
|
18q23
|
SNP
|
rs12959006
|
Disease risk
|
Lymphocyte activation measured by CD69 expression was also analyzed according to sex and rs12959006 genotype. The rs12959006 polymorphism contributed significantly to a higher number of relapses at 5 years after onset only in male patients (rs12959006TT β = 0.74 [0.36–1.09]; p = 7 × 105 ). Titers of anti-HHV6 IgG antibodies showed also a mild association with relapses, both in male and female patients (β = 0.01 [0.01–0.02]; p = 3.7 × 108 ). Both the genetic variation in MBP and HHV-6 infection aid in predicting a higher number of relapses during the first years of MS. The association described in MBP rs12959006T is exclusive to male patients
|
|
PTPRC
|
Homo sapiens
|
1q31.3-q32.1
|
SNP
|
polymorphism
|
Disease risk
|
We further show that populations living in the Pamir mountains of Central Asia have a very high prevalence of the C77G variant
|
|
APOE
|
Homo sapiens
|
19q13.32
|
gene polymorphisms
|
N/A
|
Disease risk
|
The frequency of E4 allele as a genetic risk factor for some multifactorial diseases in the population of Southern Iran is in the lowest reported amounts in the world. Iranian population has Caucasoid origin but differs from some Caucasian populations in Europe and America
|
|
TOR1A
|
Homo sapiens
|
9q34.11
|
SNP
|
rs2395182,
|
Disease risk
|
Our results show that this tag SNP method is very accurate and provides an excellent basis for population screening for CD
|
|
TOR1A
|
Homo sapiens
|
9q34.11
|
SNP
|
rs7775228
|
Disease risk
|
Our results show that this tag SNP method is very accurate and provides an excellent basis for population screening for CD
|
|
TOR1A
|
Homo sapiens
|
9q34.11
|
SNP
|
rs2187668
|
Disease risk
|
Our results show that this tag SNP method is very accurate and provides an excellent basis for population screening for CD
|
|
TOR1A
|
Homo sapiens
|
9q34.11
|
SNP
|
rs4639334
|
Disease risk
|
Our results show that this tag SNP method is very accurate and provides an excellent basis for population screening for CD
|
|
TOR1A
|
Homo sapiens
|
9q34.11
|
SNP
|
rs7454108
|
Disease risk
|
Our results show that this tag SNP method is very accurate and provides an excellent basis for population screening for CD
|
|
TOR1A
|
Homo sapiens
|
9q34.11
|
SNP
|
rs4713586
|
Disease risk
|
Our results show that this tag SNP method is very accurate and provides an excellent basis for population screening for CD
|
|
CIITA
|
Homo sapiens
|
16p13.13
|
SNP
|
rs3087456
|
Disease risk
|
We thus conclude that previous findings with regard to the role of the CIITA -168AG SNP in autoimmunity may have to be reconsidered
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
This suggests that rs6897932 is not associated with general inflammation, and the reported associations between the T-allele in rs6897932 with several autoimmune diseases may be mediated through effects on a restricted part of the immune system
|
|
AQP4
|
Homo sapiens
|
18q11.2
|
SNP
|
rs1839318
|
Disease risk
|
Although it is possible that the mutations contributed to an increased risk of inflammatory central nervous system disease in these individuals, it is unlikely that mutations are a significant contributor to most patients with NMO spectrum disorders in China
|
|
AQP4
|
Homo sapiens
|
18q11.2
|
SNP
|
rs72557968
|
Disease risk
|
Although it is possible that the mutations contributed to an increased risk of inflammatory central nervous system disease in these individuals, it is unlikely that mutations are a significant contributor to most patients with NMO spectrum disorders in China
|
|
STAT4
|
Homo sapiens
|
2q32.2-q32.3
|
SNP
|
rs7574865
|
Disease risk
|
The results of multiple test comparisons were corrected using the Benjamini and Hochberg false discovery rate (FDR–BH). After correcting for multiple test comparisons, the minor alleles of four STAT4 SNPs exhibited significant association with increased risk of NMOSD (rs7574865 T, odds ratio [OR] = 1.66, 95% confidence interval [CI] 1.32–2.08, Pcorr = 0.000; rs10181656 G, OR = 1.62, 95% CI 1.29–2.03, Pcorr = 0.000; rs10168266 T, OR = 1.59, 95% CI 1.27–2.00, Pcorr = 0.001; and rs13426947 A, OR = 1.51, 95% CI 1.21–1.90, Pcorr = 0.004). Identical results were observed in the dominant, recessive, and additive models. In contrast, the G allele of rs7601754 displayed a protective effect against NMOSD (OR = 0.53, 95% CI 0.36–0.76, Pcorr = 0.006). Our study indicates that STAT4 polymorphisms are associated with the risk of NMOSD, which provides novel insights into the underlying mechanisms of this disease
|
|
STAT4
|
Homo sapiens
|
2q32.2-q32.3
|
SNP
|
rs10181656
|
Disease risk
|
The results of multiple test comparisons were corrected using the Benjamini and Hochberg false discovery rate (FDR–BH). After correcting for multiple test comparisons, the minor alleles of four STAT4 SNPs exhibited significant association with increased risk of NMOSD (rs7574865 T, odds ratio [OR] = 1.66, 95% confidence interval [CI] 1.32–2.08, Pcorr = 0.000; rs10181656 G, OR = 1.62, 95% CI 1.29–2.03, Pcorr = 0.000; rs10168266 T, OR = 1.59, 95% CI 1.27–2.00, Pcorr = 0.001; and rs13426947 A, OR = 1.51, 95% CI 1.21–1.90, Pcorr = 0.004). Identical results were observed in the dominant, recessive, and additive models. In contrast, the G allele of rs7601754 displayed a protective effect against NMOSD (OR = 0.53, 95% CI 0.36–0.76, Pcorr = 0.006). Our study indicates that STAT4 polymorphisms are associated with the risk of NMOSD, which provides novel insights into the underlying mechanisms of this disease
|
|
STAT4
|
Homo sapiens
|
2q32.2-q32.3
|
SNP
|
rs7601754
|
Disease risk
|
The results of multiple test comparisons were corrected using the Benjamini and Hochberg false discovery rate (FDR–BH). After correcting for multiple test comparisons, the minor alleles of four STAT4 SNPs exhibited significant association with increased risk of NMOSD (rs7574865 T, odds ratio [OR] = 1.66, 95% confidence interval [CI] 1.32–2.08, Pcorr = 0.000; rs10181656 G, OR = 1.62, 95% CI 1.29–2.03, Pcorr = 0.000; rs10168266 T, OR = 1.59, 95% CI 1.27–2.00, Pcorr = 0.001; and rs13426947 A, OR = 1.51, 95% CI 1.21–1.90, Pcorr = 0.004). Identical results were observed in the dominant, recessive, and additive models. In contrast, the G allele of rs7601754 displayed a protective effect against NMOSD (OR = 0.53, 95% CI 0.36–0.76, Pcorr = 0.006). Our study indicates that STAT4 polymorphisms are associated with the risk of NMOSD, which provides novel insights into the underlying mechanisms of this disease
|
|
STAT4
|
Homo sapiens
|
2q32.2-q32.3
|
SNP
|
rs10168266
|
Disease risk
|
The results of multiple test comparisons were corrected using the Benjamini and Hochberg false discovery rate (FDR–BH). After correcting for multiple test comparisons, the minor alleles of four STAT4 SNPs exhibited significant association with increased risk of NMOSD (rs7574865 T, odds ratio [OR] = 1.66, 95% confidence interval [CI] 1.32–2.08, Pcorr = 0.000; rs10181656 G, OR = 1.62, 95% CI 1.29–2.03, Pcorr = 0.000; rs10168266 T, OR = 1.59, 95% CI 1.27–2.00, Pcorr = 0.001; and rs13426947 A, OR = 1.51, 95% CI 1.21–1.90, Pcorr = 0.004). Identical results were observed in the dominant, recessive, and additive models. In contrast, the G allele of rs7601754 displayed a protective effect against NMOSD (OR = 0.53, 95% CI 0.36–0.76, Pcorr = 0.006). Our study indicates that STAT4 polymorphisms are associated with the risk of NMOSD, which provides novel insights into the underlying mechanisms of this disease
|
|
STAT4
|
Homo sapiens
|
2q32.2-q32.3
|
SNP
|
rs13426947
|
Disease risk
|
The results of multiple test comparisons were corrected using the Benjamini and Hochberg false discovery rate (FDR–BH). After correcting for multiple test comparisons, the minor alleles of four STAT4 SNPs exhibited significant association with increased risk of NMOSD (rs7574865 T, odds ratio [OR] = 1.66, 95% confidence interval [CI] 1.32–2.08, Pcorr = 0.000; rs10181656 G, OR = 1.62, 95% CI 1.29–2.03, Pcorr = 0.000; rs10168266 T, OR = 1.59, 95% CI 1.27–2.00, Pcorr = 0.001; and rs13426947 A, OR = 1.51, 95% CI 1.21–1.90, Pcorr = 0.004). Identical results were observed in the dominant, recessive, and additive models. In contrast, the G allele of rs7601754 displayed a protective effect against NMOSD (OR = 0.53, 95% CI 0.36–0.76, Pcorr = 0.006). Our study indicates that STAT4 polymorphisms are associated with the risk of NMOSD, which provides novel insights into the underlying mechanisms of this disease
|
|
MGMT
|
Homo sapiens
|
10q26.3
|
gene polymorphisms
|
N/A
|
Disease risk
|
Hence, we show for the first time that MGMT hypermethylation occurs in chronic diseases that are not strictly associated to distinct pathogens, oncogenic viruses or neoplasms but that lead to damage of the myelin sheath in various ways. While this gives new insights into epigenetic and pathophysiological processes involved in de- and remyelination, which might offer new therapeutic opportunities for demyelinating diseases in the future, it also reduces the specificity of MGMT hypermethylation as a tumor biomarker.
|
|
USP18
|
Homo sapiens
|
22q11.21
|
SNP
|
rs2252257
|
Disease risk
|
Most clinical characteristics of familial NMOSD were indistinguishable from sporadic NMOSD except for the worst episodes severity. USP18 with impaired intronic regulatory function contributed to the pathogenesis of NMOSD
|
|
USP18
|
Homo sapiens
|
22q11.21
|
SNP
|
rs361553
|
Disease risk
|
Most clinical characteristics of familial NMOSD were indistinguishable from sporadic NMOSD except for the worst episodes severity. USP18 with impaired intronic regulatory function contributed to the pathogenesis of NMOSD
|
|
USP18
|
Homo sapiens
|
22q11.21
|
SNP
|
rs5746523
|
Disease risk
|
Most clinical characteristics of familial NMOSD were indistinguishable from sporadic NMOSD except for the worst episodes severity. USP18 with impaired intronic regulatory function contributed to the pathogenesis of NMOSD
|
|
FOXP3
|
Homo sapiens
|
Xp11.23
|
N/A
|
N/A
|
Disease risk
|
CD4+ Foxp3+ T cells were increased in SLE patients compared with organ-specific autoimmune disease controls or healthy controls. Circulating CD4+ Foxp3+ T cells were correlated with the disease activity of SLE. The increased CD4+ Foxp3+ T cells in active SLE patients were mainly derived from thymus-derived Treg (tTreg) cells, as determined by a demethylated TSDR status, and represented a unique phenotype, upregulated expression of CD49d, CD161, and IL-17A, with immunosuppressive ability comparable to that of healthy controls. Finally, CD4+ Foxp3+ IL-17A+ cells were infiltrated into the renal biopsy specimens of patients with active lupus nephritis.
|
|
AR
|
Homo sapiens
|
Xq12
|
DNA methylation
|
DNA methylation
|
Disease risk
|
We found a strong correlation between dichorionic fetal anatomy and differences in X chromosome inactivation patterns between members of an MZ twin pair. In contrast, all monochorionic twin pairs had closely correlated patterns of X chromosome inactivation. X chromosome inactivation patterns did not distinguish between MZ twin pairs who were concordant or discordant for autoimmune disease
|
|
S1PR1
|
Homo sapiens
|
1p21.2
|
DNA methylation
|
DNA methylation
|
Disease risk
|
This study suggests that individual genetic variations of S1P 1 can infl uence receptor function and, therefore, infer differential disease risks and interaction with S1P 1 -targeted therapeutics
|
|
FCRL3
|
Homo sapiens
|
1q23.1
|
SNP
|
rs7528684
|
Disease risk
|
Distribution of Genotype Frequency and the Risk of NMO The case-control analysis demonstrated that rs7528684 (FCRL3_3), rs945635 (FCRL3_5), rs3761959 (FCRL3_6), and rs2282284 (FCRL3_8) showed significant associations with risk of NMO, whereas other 3 SNPs were not. To be specific, the FCRL3_3C, FCRL3_5C, FCRL3_6A, FCRL3_8G allelic frequencies were significantly higher in the case group than those in the control group (OR 1.50, 95% CI: 1.11–2.03, P 0.008; OR 1.44, 95% CI: 1.07–1.94, P 0.015; OR 1.45, 95% CI: 1.08–1.95, P 0.014; OR 2.01, 95% CI: 1.13–3.60, P 0.016). Moreover, their recessive models (except rs3761959) and homozygous models also revealed the remarkable associations between the genetic variants and the risk of NMO. However, the dominant models or the allelic models failed to show any significant correlations between the rest 3 SNPs and the risk of NMO. In addition, haplotype analysis showed that FCRL3_3C, FCRL3_6A, and FCRL3_8G were in a strong linkage disequilibrium (LD), except FCRL3_5
|
|
FCRL3
|
Homo sapiens
|
1q23.1
|
SNP
|
rs11264799
|
Disease risk
|
Distribution of Genotype Frequency and the Risk of NMO The case-control analysis demonstrated that rs7528684 (FCRL3_3), rs945635 (FCRL3_5), rs3761959 (FCRL3_6), and rs2282284 (FCRL3_8) showed significant associations with risk of NMO, whereas other 3 SNPs were not. To be specific, the FCRL3_3C, FCRL3_5C, FCRL3_6A, FCRL3_8G allelic frequencies were significantly higher in the case group than those in the control group (OR 1.50, 95% CI: 1.11–2.03, P 0.008; OR 1.44, 95% CI: 1.07–1.94, P 0.015; OR 1.45, 95% CI: 1.08–1.95, P 0.014; OR 2.01, 95% CI: 1.13–3.60, P 0.016). Moreover, their recessive models (except rs3761959) and homozygous models also revealed the remarkable associations between the genetic variants and the risk of NMO. However, the dominant models or the allelic models failed to show any significant correlations between the rest 3 SNPs and the risk of NMO. In addition, haplotype analysis showed that FCRL3_3C, FCRL3_6A, and FCRL3_8G were in a strong linkage disequilibrium (LD), except FCRL3_5
|
|
FCRL3
|
Homo sapiens
|
1q23.1
|
SNP
|
rs945635
|
Disease risk
|
Distribution of Genotype Frequency and the Risk of NMO The case-control analysis demonstrated that rs7528684 (FCRL3_3), rs945635 (FCRL3_5), rs3761959 (FCRL3_6), and rs2282284 (FCRL3_8) showed significant associations with risk of NMO, whereas other 3 SNPs were not. To be specific, the FCRL3_3C, FCRL3_5C, FCRL3_6A, FCRL3_8G allelic frequencies were significantly higher in the case group than those in the control group (OR 1.50, 95% CI: 1.11–2.03, P 0.008; OR 1.44, 95% CI: 1.07–1.94, P 0.015; OR 1.45, 95% CI: 1.08–1.95, P 0.014; OR 2.01, 95% CI: 1.13–3.60, P 0.016). Moreover, their recessive models (except rs3761959) and homozygous models also revealed the remarkable associations between the genetic variants and the risk of NMO. However, the dominant models or the allelic models failed to show any significant correlations between the rest 3 SNPs and the risk of NMO. In addition, haplotype analysis showed that FCRL3_3C, FCRL3_6A, and FCRL3_8G were in a strong linkage disequilibrium (LD), except FCRL3_5
|
|
FCRL3
|
Homo sapiens
|
1q23.1
|
SNP
|
rs3761959
|
Disease risk
|
Distribution of Genotype Frequency and the Risk of NMO The case-control analysis demonstrated that rs7528684 (FCRL3_3), rs945635 (FCRL3_5), rs3761959 (FCRL3_6), and rs2282284 (FCRL3_8) showed significant associations with risk of NMO, whereas other 3 SNPs were not. To be specific, the FCRL3_3C, FCRL3_5C, FCRL3_6A, FCRL3_8G allelic frequencies were significantly higher in the case group than those in the control group (OR 1.50, 95% CI: 1.11–2.03, P 0.008; OR 1.44, 95% CI: 1.07–1.94, P 0.015; OR 1.45, 95% CI: 1.08–1.95, P 0.014; OR 2.01, 95% CI: 1.13–3.60, P 0.016). Moreover, their recessive models (except rs3761959) and homozygous models also revealed the remarkable associations between the genetic variants and the risk of NMO. However, the dominant models or the allelic models failed to show any significant correlations between the rest 3 SNPs and the risk of NMO. In addition, haplotype analysis showed that FCRL3_3C, FCRL3_6A, and FCRL3_8G were in a strong linkage disequilibrium (LD), except FCRL3_5
|
|
FCRL3
|
Homo sapiens
|
1q23.1
|
SNP
|
rs2210913
|
Disease risk
|
Distribution of Genotype Frequency and the Risk of NMO The case-control analysis demonstrated that rs7528684 (FCRL3_3), rs945635 (FCRL3_5), rs3761959 (FCRL3_6), and rs2282284 (FCRL3_8) showed significant associations with risk of NMO, whereas other 3 SNPs were not. To be specific, the FCRL3_3C, FCRL3_5C, FCRL3_6A, FCRL3_8G allelic frequencies were significantly higher in the case group than those in the control group (OR 1.50, 95% CI: 1.11–2.03, P 0.008; OR 1.44, 95% CI: 1.07–1.94, P 0.015; OR 1.45, 95% CI: 1.08–1.95, P 0.014; OR 2.01, 95% CI: 1.13–3.60, P 0.016). Moreover, their recessive models (except rs3761959) and homozygous models also revealed the remarkable associations between the genetic variants and the risk of NMO. However, the dominant models or the allelic models failed to show any significant correlations between the rest 3 SNPs and the risk of NMO. In addition, haplotype analysis showed that FCRL3_3C, FCRL3_6A, and FCRL3_8G were in a strong linkage disequilibrium (LD), except FCRL3_5
|
|
FCRL3
|
Homo sapiens
|
1q23.1
|
SNP
|
rs2282284
|
Disease risk
|
Distribution of Genotype Frequency and the Risk of NMO The case-control analysis demonstrated that rs7528684 (FCRL3_3), rs945635 (FCRL3_5), rs3761959 (FCRL3_6), and rs2282284 (FCRL3_8) showed significant associations with risk of NMO, whereas other 3 SNPs were not. To be specific, the FCRL3_3C, FCRL3_5C, FCRL3_6A, FCRL3_8G allelic frequencies were significantly higher in the case group than those in the control group (OR 1.50, 95% CI: 1.11–2.03, P 0.008; OR 1.44, 95% CI: 1.07–1.94, P 0.015; OR 1.45, 95% CI: 1.08–1.95, P 0.014; OR 2.01, 95% CI: 1.13–3.60, P 0.016). Moreover, their recessive models (except rs3761959) and homozygous models also revealed the remarkable associations between the genetic variants and the risk of NMO. However, the dominant models or the allelic models failed to show any significant correlations between the rest 3 SNPs and the risk of NMO. In addition, haplotype analysis showed that FCRL3_3C, FCRL3_6A, and FCRL3_8G were in a strong linkage disequilibrium (LD), except FCRL3_5
|
|
FCRL3
|
Homo sapiens
|
1q23.1
|
SNP
|
rs2282283
|
Disease risk
|
Distribution of Genotype Frequency and the Risk of NMO The case-control analysis demonstrated that rs7528684 (FCRL3_3), rs945635 (FCRL3_5), rs3761959 (FCRL3_6), and rs2282284 (FCRL3_8) showed significant associations with risk of NMO, whereas other 3 SNPs were not. To be specific, the FCRL3_3C, FCRL3_5C, FCRL3_6A, FCRL3_8G allelic frequencies were significantly higher in the case group than those in the control group (OR 1.50, 95% CI: 1.11–2.03, P 0.008; OR 1.44, 95% CI: 1.07–1.94, P 0.015; OR 1.45, 95% CI: 1.08–1.95, P 0.014; OR 2.01, 95% CI: 1.13–3.60, P 0.016). Moreover, their recessive models (except rs3761959) and homozygous models also revealed the remarkable associations between the genetic variants and the risk of NMO. However, the dominant models or the allelic models failed to show any significant correlations between the rest 3 SNPs and the risk of NMO. In addition, haplotype analysis showed that FCRL3_3C, FCRL3_6A, and FCRL3_8G were in a strong linkage disequilibrium (LD), except FCRL3_5
|
|
CYP4F2
|
Homo sapiens
|
19p13.12
|
SNP
|
rs1558139
|
Disease risk
|
We revealed CYP4F2 rs1558139 AA genotype association with ON and MS in male. According to statistical analysis, the higher IL-17A levels were determined to be associated with inflammation processes while ON. These findings suggest new biological markers for the diagnostics of ON, but further studies with a larger number of patients, however, are necessary in order to better understand of ON development.
|
|
TNFSF13B
|
Homo sapiens
|
13q33.3
|
SNP
|
rs374039502
|
Disease risk
|
In conclusion, in the present study we have failed to identify an association between the TNFSF13B functional variant previously associated with autoimmunity and two immunerelated diseases, GCA and SSc. Thus, this genetic variant does not seem to be responsible for the increased levels of BAFF found in these disorders
|
|
CETP
|
Homo sapiens
|
16q13
|
SNP
|
rs5882
|
Disease risk
|
Our study determined that the G/A genotype of CETPrs708272 was associated with two-folddecreased odds of ON development under the codominant (OR = 0.495;95%CI:0.256–0.959) and overdominant (OR = 0.501;95%CI:0.280–0.895) models. Also, each allele C at VEGFArs833068 was associated with 1.7-fold increased odds of ON development under the additive model (OR = 1.733;95% CI:1.148–2.615). Furthermore, IL6 rs1800795 G/G genotype was associated with increased odds of ON development under the codominant (OR = 2.869;95%CI:1.280–6.434) and recessive (OR = 2.315;95% CI:1.251–4.285) models
|
|
CETP
|
Homo sapiens
|
16q13
|
SNP
|
rs708272
|
Disease risk
|
Our study determined that the G/A genotype of CETPrs708272 was associated with two-folddecreased odds of ON development under the codominant (OR = 0.495;95%CI:0.256–0.959) and overdominant (OR = 0.501;95%CI:0.280–0.895) models. Also, each allele C at VEGFArs833068 was associated with 1.7-fold increased odds of ON development under the additive model (OR = 1.733;95% CI:1.148–2.615). Furthermore, IL6 rs1800795 G/G genotype was associated with increased odds of ON development under the codominant (OR = 2.869;95%CI:1.280–6.434) and recessive (OR = 2.315;95% CI:1.251–4.285) models
|
|
SIRT1
|
Homo sapiens
|
10q21.3
|
SNP
|
rs12778366
|
Disease risk
|
Our study determined that the G/A genotype of CETPrs708272 was associated with two-folddecreased odds of ON development under the codominant (OR = 0.495;95%CI:0.256–0.959) and overdominant (OR = 0.501;95%CI:0.280–0.895) models. Also, each allele C at VEGFArs833068 was associated with 1.7-fold increased odds of ON development under the additive model (OR = 1.733;95% CI:1.148–2.615). Furthermore, IL6 rs1800795 G/G genotype was associated with increased odds of ON development under the codominant (OR = 2.869;95%CI:1.280–6.434) and recessive (OR = 2.315;95% CI:1.251–4.285) models
|
|
FGFR2
|
Homo sapiens
|
10q26.13
|
SNP
|
rs2981582
|
Disease risk
|
Our study determined that the G/A genotype of CETPrs708272 was associated with two-folddecreased odds of ON development under the codominant (OR = 0.495;95%CI:0.256–0.959) and overdominant (OR = 0.501;95%CI:0.280–0.895) models. Also, each allele C at VEGFArs833068 was associated with 1.7-fold increased odds of ON development under the additive model (OR = 1.733;95% CI:1.148–2.615). Furthermore, IL6 rs1800795 G/G genotype was associated with increased odds of ON development under the codominant (OR = 2.869;95%CI:1.280–6.434) and recessive (OR = 2.315;95% CI:1.251–4.285) models
|
|
STAT3
|
Homo sapiens
|
17q21.2
|
SNP
|
rs744166
|
Disease risk
|
Our study determined that the G/A genotype of CETPrs708272 was associated with two-folddecreased odds of ON development under the codominant (OR = 0.495;95%CI:0.256–0.959) and overdominant (OR = 0.501;95%CI:0.280–0.895) models. Also, each allele C at VEGFArs833068 was associated with 1.7-fold increased odds of ON development under the additive model (OR = 1.733;95% CI:1.148–2.615). Furthermore, IL6 rs1800795 G/G genotype was associated with increased odds of ON development under the codominant (OR = 2.869;95%CI:1.280–6.434) and recessive (OR = 2.315;95% CI:1.251–4.285) models
|
|
VEGFA
|
Homo sapiens
|
6p21.1
|
SNP
|
rs833068
|
Disease risk
|
Our study determined that the G/A genotype of CETPrs708272 was associated with two-folddecreased odds of ON development under the codominant (OR = 0.495;95%CI:0.256–0.959) and overdominant (OR = 0.501;95%CI:0.280–0.895) models. Also, each allele C at VEGFArs833068 was associated with 1.7-fold increased odds of ON development under the additive model (OR = 1.733;95% CI:1.148–2.615). Furthermore, IL6 rs1800795 G/G genotype was associated with increased odds of ON development under the codominant (OR = 2.869;95%CI:1.280–6.434) and recessive (OR = 2.315;95% CI:1.251–4.285) models
|
|
IL6
|
Homo sapiens
|
7p15.3
|
SNP
|
rs1800795
|
Disease risk
|
Our study determined that the G/A genotype of CETPrs708272 was associated with two-folddecreased odds of ON development under the codominant (OR = 0.495;95%CI:0.256–0.959) and overdominant (OR = 0.501;95%CI:0.280–0.895) models. Also, each allele C at VEGFArs833068 was associated with 1.7-fold increased odds of ON development under the additive model (OR = 1.733;95% CI:1.148–2.615). Furthermore, IL6 rs1800795 G/G genotype was associated with increased odds of ON development under the codominant (OR = 2.869;95%CI:1.280–6.434) and recessive (OR = 2.315;95% CI:1.251–4.285) models
|
|
CD3G
|
Homo sapiens
|
11q23.3
|
N/A
|
rs3753058
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
CD44
|
Homo sapiens
|
11p13
|
N/A
|
rs1058200
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
CD44
|
Homo sapiens
|
11p13
|
N/A
|
rs1467558
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
CD5
|
Homo sapiens
|
11q12.2
|
N/A
|
rs637186
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
CD5
|
Homo sapiens
|
11q12.2
|
N/A
|
rs2241002
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
CD69
|
Homo sapiens
|
12p13.31
|
N/A
|
rs3176798
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
PLCG1
|
Homo sapiens
|
20q12
|
N/A
|
rs753381
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
PLCG1
|
Homo sapiens
|
20q12
|
N/A
|
rs8192707
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
PTPN12
|
Homo sapiens
|
7q11.23
|
N/A
|
rs9640663
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
PTPN12
|
Homo sapiens
|
7q11.23
|
N/A
|
rs3750050
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
PTPN3
|
Homo sapiens
|
9q31.3
|
N/A
|
rs101168060
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
PTPN6
|
Homo sapiens
|
12p13.31
|
N/A
|
rs2301262
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
SLAMF1
|
Homo sapiens
|
1q23.3
|
N/A
|
rs164288
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
SLAMF1
|
Homo sapiens
|
1q23.3
|
N/A
|
rs3796504
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
SLAMF1
|
Homo sapiens
|
1q23.3
|
N/A
|
rs2295612
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
PTPN22
|
Homo sapiens
|
1p13.2
|
N/A
|
rs2476601
|
Disease risk
|
Typing the 41 SNPs with functioning DCE assay (Fischer and Lerman, 1983) in the pooled Norwegian controls (n= 4000) demonstrated that 16 of these (39%) were heterozygous in the Norwegian population , four of these displaying a minor allele frequency of less than 1%
|
|
TGFB2
|
Homo sapiens
|
1q41
|
N/A
|
rs10495098
|
Disease risk
|
We have demonstrated a trend towards association of the 5’ region of TGFB2, including the promoter region and exon 1, with PD. When coupled with the recent observation that TGFb2 appears to have a role in the maintainance of striatal dopamine levels in rodents, this finding provides some support for the hypothesis that variation in the TGFB2 gene influences susceptibility to idiopathic PD. We suggest that the relevance of marker rs6658835 should be explored in other PD cohorts
|
|
TGFB2
|
Homo sapiens
|
1q41
|
N/A
|
rs6658835
|
Disease risk
|
We have demonstrated a trend towards association of the 5’ region of TGFB2, including the promoter region and exon 1, with PD. When coupled with the recent observation that TGFb2 appears to have a role in the maintainance of striatal dopamine levels in rodents, this finding provides some support for the hypothesis that variation in the TGFB2 gene influences susceptibility to idiopathic PD. We suggest that the relevance of marker rs6658835 should be explored in other PD cohorts
|
|
TGFB2
|
Homo sapiens
|
1q41
|
N/A
|
rs4846476
|
Disease risk
|
We have demonstrated a trend towards association of the 5’ region of TGFB2, including the promoter region and exon 1, with PD. When coupled with the recent observation that TGFb2 appears to have a role in the maintainance of striatal dopamine levels in rodents, this finding provides some support for the hypothesis that variation in the TGFB2 gene influences susceptibility to idiopathic PD. We suggest that the relevance of marker rs6658835 should be explored in other PD cohorts
|
|
IRF5
|
Homo sapiens
|
7q32.1
|
N/A
|
rs4728142
|
Disease risk
|
These findings add IRF5 to the short list of genes shown to be associated with MS in more than one population. Our study adds to the evidence that there might be genes or pathways that are common in multiple autoimmune diseases, and that the type I interferon system is likely to be involved in the development of these diseases
|
|
IRF5
|
Homo sapiens
|
7q32.1
|
N/A
|
rs3807306
|
Disease risk
|
These findings add IRF5 to the short list of genes shown to be associated with MS in more than one population. Our study adds to the evidence that there might be genes or pathways that are common in multiple autoimmune diseases, and that the type I interferon system is likely to be involved in the development of these diseases
|
|
PON1
|
Homo sapiens
|
7q21.3
|
N/A
|
polymorphismã€genotypes and allelic variants
|
Disease risk
|
The results of the present study suggest that PON1 polymorphism is not related with the risk for multiple sclerosis in our population
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
N/A
|
rs6897932
|
Disease risk
|
It is known that demographic as well as environmental factors have a substantial role in multiple sclerosis development, as well as population genetic background. The results of this study indicate that other types of genome variants should be required for the development and/or progression of multiple sclerosis, which may vary among populations
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
N/A
|
rs7579737
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
N/A
|
rs7558013
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
N/A
|
rs2241116
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
N/A
|
rs17027056
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
N/A
|
rs4851005
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
N/A
|
rs6706002
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
N/A
|
rs11465597
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
SNP
|
rs10515921
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
SNP
|
rs7603730
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
SNP
|
rs6750020
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
SNP
|
rs3213733
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
SNP
|
rs2041740
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL18R1
|
Homo sapiens
|
2q12.1
|
SNP
|
rs11903946
|
Disease risk
|
The absence of a genetic association in the IL18R1 gene itself suggests regulation from other parts of the genome, or as part of the inflammatory cascade in multiple sclerosis without a prime genetic cause.
|
|
IL7R
|
Homo sapiens
|
5p13.2
|
SNP
|
rs6897932
|
Disease risk
|
Although the power of this study was limited, our preliminary data suggest that disease susceptibility genes in MS in the Indian population may be similar to those of western populations
|
|
CLEC16A
|
Homo sapiens
|
16p13.13
|
SNP
|
rs 12708716
|
Disease risk
|
Although the power of this study was limited, our preliminary data suggest that disease susceptibility genes in MS in the Indian population may be similar to those of western populations
|
|
CD226
|
Homo sapiens
|
18q22.2
|
SNP
|
rs763361
|
Disease risk
|
Although the power of this study was limited, our preliminary data suggest that disease susceptibility genes in MS in the Indian population may be similar to those of western populations
|
|
CIITA
|
Homo sapiens
|
16p13.13
|
SNP
|
rs4774C
|
Disease risk
|
The results show that MS patients without HHV-6 active replication are better responders to interferon beta treatment than those with HHV-6 active replication
|
|
CIITA
|
Homo sapiens
|
16p13.13
|
SNP
|
rs3087456G
|
Disease risk
|
The results show that MS patients without HHV-6 active replication are better responders to interferon beta treatment than those with HHV-6 active replication
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs1883832C
|
Disease risk
|
Our analysis revealed that individuals possessing CT and TT genotypes (predisposing to MS) had decreased level of CD40 mRNA in comparison to those with CC. Moreover, we demonstrated the potential role of impaired CD40-CD40L interaction in developing of multiple sclerosis
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs11569343C
|
Disease risk
|
Our analysis revealed that individuals possessing CT and TT genotypes (predisposing to MS) had decreased level of CD40 mRNA in comparison to those with CC. Moreover, we demonstrated the potential role of impaired CD40-CD40L interaction in developing of multiple sclerosis
|
|
CD40
|
Homo sapiens
|
20q13.12
|
SNP
|
rs752118C
|
Disease risk
|
Our analysis revealed that individuals possessing CT and TT genotypes (predisposing to MS) had decreased level of CD40 mRNA in comparison to those with CC. Moreover, we demonstrated the potential role of impaired CD40-CD40L interaction in developing of multiple sclerosis
|
|
CD40LG
|
Homo sapiens
|
Xq26.3
|
SNP
|
rs3092923T
|
Disease risk
|
Our analysis revealed that individuals possessing CT and TT genotypes (predisposing to MS) had decreased level of CD40 mRNA in comparison to those with CC. Moreover, we demonstrated the potential role of impaired CD40-CD40L interaction in developing of multiple sclerosis
|
|
CD40LG
|
Homo sapiens
|
Xq26.3
|
SNP
|
rs3092952A
|
Disease risk
|
Our analysis revealed that individuals possessing CT and TT genotypes (predisposing to MS) had decreased level of CD40 mRNA in comparison to those with CC. Moreover, we demonstrated the potential role of impaired CD40-CD40L interaction in developing of multiple sclerosis
|
|
SOCS1
|
Homo sapiens
|
16p13.13
|
SNP
|
rs243324
|
Disease risk
|
we found that SOCS1 gene overexpressed in RR-MS patients
|
|
VAMP2
|
Homo sapiens
|
17p13.1
|
polymorphisms
|
N/A
|
Disease risk
|
It is the first time that VSEs have been analyzed, and we directly connect the genetic risk factors for MS risk with Vitamin D based on VSEs.
|
|
TREM2
|
Homo sapiens
|
6p21.1
|
SNP
|
rs75932628
|
Disease risk
|
This variant does not seem to play a determining role in the pathogenesis of MS, although further studies examining the presence of TREM2 mutations in other, phylogenetically different populations and the epigenetic regulation of this gene are needed in order to thoroughly investigate its role in MS.
|
|
MIR146A
|
Homo sapiens
|
5q33.3
|
SNP
|
rs2910164
|
N/A
|
this study determined that the C and T alleles of rs2910164 and rs1044165 are risk factors for MS in the Iranian population
|
|
MIR223
|
Homo sapiens
|
Xq12
|
SNP
|
rs1044165
|
N/A
|
this study determined that the C and T alleles of rs2910164 and rs1044165 are risk factors for MS in the Iranian population
|
|
IL1B
|
Homo sapiens
|
2q14.1
|
SNP
|
rs35829419
|
Disease risk
|
positive
|
|
HHEX
|
Homo sapiens
|
10q23.33
|
SNP
|
rs7923837
|
Disease risk
|
positive
|
|
WAS
|
Homo sapiens
|
Xp11.23
|
altering histone methylation
|
N/A
|
Treatment risk
|
positive
|
|
TAC1
|
Homo sapiens
|
7q21.3
|
SNP
|
rs1510303
|
Disease risk
|
positive
|
|
PRKCA
|
Homo sapiens
|
17q24.2
|
SNP
|
rs7220007
|
Disease risk
|
positive
|
|
Spp1
|
Homo sapiens
|
4q22.1
|
SNP
|
rs 4754
|
Disease risk
|
positive
|
|
ERG
|
Homo sapiens
|
21q22.2
|
DNA methylation
|
N/A
|
Disease risk
|
positive
|
|
HLA-DRB1
|
Homo sapiens
|
6p21.32
|
restriction fragment length polymorphism
|
N/A
|
Disease risk
|
positive
|
|
HLA-DQA1
|
Homo sapiens
|
6p21.32
|
restriction fragment length polymorphism
|
N/A
|
Disease risk
|
positive
|
|
HLA-DQB1
|
Homo sapiens
|
6p21.32
|
restriction fragment length polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
HLA-DPA1
|
Homo sapiens
|
6p21.32
|
restriction fragment length polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
restriction fragment length polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
TRBV20OR9-2
|
Homo sapiens
|
9p13.3
|
restriction fragment length polymorphism
|
N/A
|
Disease risk
|
Negative
|
|
HLA-DPB1
|
Homo sapiens
|
6p21.32
|
restriction fragment length polymorphism
|
N/A
|
Disease risk
|
Negative
|